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Abstract 
Drug metabolism is a major determinant of variability in response to medicines. Factors 
affecting the activity of drug-metabolising enzymes can be classified as intrinsic, such as 
genetics, or extrinsic, such as diet. The effects of genetics and diet on cytochrome P450 
(CYP) activity can be different between people of different geographic ancestry, and very 
few studies exist that explore these interactions simultaneously. Overall, this thesis 
examines how cruciferous vegetable-enriched diets, genetics and CYP activity interact to 
explain variability in drug response between Europeans and South Asians. 
The aims of this thesis were to: 
1. Review the relevant literature and form a theoretical framework supporting the 
hypotheses tested in this thesis; 
2. Conduct a systematic review with meta-analyses of trials investigating the impact of 
cruciferous vegetable dietary intervention trials on drug metabolism; 
3. Design, optimise and validate a UHPLC-MS/MS CYP-phenotyping cocktail assay in 
human plasma for CYP1A2, CYP2C19, CYP2C9, CYP2D6 and CYP3A4; 
4. Design, optimise and validate a UHPLC-MS/MS sulforaphane assay in human plasma; 
and 
5. On the back of hypotheses generated from the systematic review, design and 
conduct a controlled, 3-period crossover trial that aimed to: 
a. Investigate the short-term and medium-term effects of a broccoli-enriched 
diet on CYP1A2, CYP2C19, CYP2C9, CYP2D6 and CYP3A4 activities; 
b. Establish if the above effects vary between those of European and South 
Asian ancestry; 
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c. Confirm that CYP1A2 is induced in Europeans on a broccoli-enriched diet, 
with no or a reduced change in South Asians; and 
d. Explore the contribution of diet, genetics and geographic ancestry on 
variability in CYP1A2, CYP2C19, CYP2C9, CYP2D6 and CYP3A4 activities. 
In Chapter 2, n = 23 studies were identified that met the systematic inclusion criteria. Drug-
metabolising enzymes represented in the literature included CYPs, UGTs, GSTs, NAT and 
xanthine oxidase. The type of cruciferous vegetable interventions, choice of phenotyping 
metrics and choice of probe drugs were highly heterogeneous, except for CYP1A2 and GST-
α. Meta-analysis was possible for CYP1A2 and GST-α due to the number and nature of the 
studies that investigated these enzymes. Their activities were significantly increased by 15-
40% after a cruciferous vegetable interaction. Dose-response relationships were established 
between cruciferous vegetable consumption and CYP1A2, GST-α and UGT1A1 activities. 
Critical analysis revealed that only 48% of the studies included a panel of high-quality 
characteristics in their design. Results from this review were used to formulate testable 
hypotheses in Chapter 5. 
Chapter 3 outlines the design, optimisation and validation of a CYP-phenotyping cocktail 
assay that was needed to analyse samples from the crossover trial reported in Chapter 5. 
Samples were analysed using an Agilent 1290 infinity LC system in tandem with 6460A triple 
quadrupole mass spectrometers. Separation of the analytes was achieved with an Agilent 
Zorbax Eclipse XDB-C18 (4.6 x 50 mm, 1.8 μm) column fitted with a Zorbax Eclipse XDB-C18 
(4.6 x 5.0 mm, 1.8 μm) guard column. Standard curves for all analytes were linear over wide 
plasma concentration ranges (0.78-3000 ng/mL) and the methods met guideline-
recommended requirements for specificity, sensitivity (analyte LLOQs 0.78-23.4 ng/mL), 
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accuracy (intra-day RE % nominal concentration 90.7-110.2; inter-day RE % 87.0-110.5) and 
precision (intra-day analyte RSD % 0.46-11.4%; inter-day RSD % 1.36-11.2). Recovery and 
matrix effects were also investigated and concluded to be non-interfering. This improved 
CYP cocktail assay has been used successfully used to phenotype n = 21 participants of 
European and South Asian ancestry as reported in Chapter 5. 
Similarly, a UHPLC-MS/MS assay was designed, optimised and validated to measure 
sulforaphane (SUL) in human plasma. Retention times for SUL and the internal standard 
were 3.42 min and 4.42 min, respectively. The lower-limit of quantification (LLOQ) for SUL 
was 0.78 ng/mL (7.8 pg on-column). All QCs had intra-day accuracy (RE) and precision (RSD) 
ranging between 86.4-106.7% and 2.61-10.3% respectively. Inter-day accuracy and precision 
ranged between 91.3-97.0% and 3.99-7.11% respectively. Recovery was low and matrix 
effects high, but their consistency meant that quantification of SUL was not impeded. The 
assay was successfully used to analyse SUL in 21 participants (> 150 plasma samples) in the 
above-mentioned clinical trial. 
Chapter 5 reports and discusses the results from a controlled, dietary intervention crossover 
trial in Europeans and South Asians. A 500 g broccoli meal was consumed immediately 
before CYP phenotyping, and 500 g twice daily was consumed for a further six days before 
final CYP phenotyping. Diets high in CYP1A2 inducer foods were more prevalent in 
Europeans, whereas a predominantly curry diet was more common in the South Asian 
cohort. CYP1A2 activity was approximately 20% higher in Europeans after following a 
broccoli-enriched diet for six days, but this was not seen in South Asians. CYP2C19 activity 
was significantly related to genotype, and there was evidence of inhibition on Study Day 2 
(D2) followed by a rebound in activity by the end of the study at Study Day 9 (D9). The 
xiii 
 
CYP2C19*2 null allele showed a dose-response relationship with CYP2C19 activity. Within 
CYP2C19*1C and CYP2C19*17 genotype groups, enzyme activity was higher in Europeans 
than South Asians. CYP2C9 activity increased on D2 immediately after a broccoli meal and 
decreased back to baseline by the end of the study on D9. Interestingly, South Asians had 
nearly 2-fold higher CYP2C9 activity throughout the study, even within variant genotype 
groups. CYP2D6 activity was variable, and SNP genotype alone was not a significant 
predictor of activity in the three mixed-effects models used in its analysis. Of note, enzyme 
activity was 2- to 3-fold higher in Europeans than South Asians within CYP2D6*4 and 
CYP2D6*10 genotypes, as well as for those that had n = 1 copy of the CYP2D6 gene. No 
significant interactions or changes were seen in CYP3A4; however, variability was large, and 
post hoc sample size and power calculations suggest that more participants are needed 
when investigating this enzyme. 
Chapter 5 also discusses ancestry group differences in the exposure of the cruciferous 
vegetable constituent SUL, which is an inducer of drug-metabolising enzymes. A 
predominantly curry diet, GSTM1 and GSTP1 genotypes were significant predictors of SUL 
exposure. There was no evidence of a difference in SUL exposure between the two ancestry 
groups when statistically controlled for genotype and diet. The 4-h SUL plasma 
concentration-time point had a near 1:1 correlation with the AUC0-8 h, with the former being 
recommended as an ITC exposure metric in future studies. 
Overall, this thesis presents novel findings regarding how cruciferous vegetables, dietary 
practices, genetics and geographic ancestry interact to explain variability in drug 
metabolism. Future studies in this area are encouraged to simultaneously measure a variety 
of both intrinsic and extrinsic factors in ancestry group difference studies. 
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Recommendations are made for future research in this area, with specific guidance on study 
design and selection of high-quality characteristics.
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1 Introduction and background 
The aim of Chapter 1 is to review and summarise the relevant literature required to 
construct a rationale supporting the objectives of this thesis (section 1.9). Many topics are 
covered in this chapter, some more relevant to the thesis objectives than others. However, 
all aspects of clinical pharmacology reviewed and summarised herein have been chosen 
because of their importance to the overall goal of this thesis: to better understand how 
geographic ancestry, genetics and diet contribute to variability in drug metabolism. 
1.1 Variability in response to medicines 
Medicines display significant variability in a given group of people. In fact, one of the 
reasons that society needs healthcare professionals and biomedical researchers is because 
of this variability: if everyone had the same response to a particular dose of a particular 
drug, then pharmacotherapy would be a simpler affair. However, variability is rampant in 
pharmacology—as it is in the other biomedical sciences—and understanding the nature and 
causes of this variability is important, as this knowledge can be translated into improved 
patient outcomes through the safe and efficacious use of medicines (Sorich & McKinnon, 
2012). 
Patient variability in response to medicines can be thought of as being made up of two over-
arching subtypes of variability, namely: variability in pharmacokinetic processes, i.e. intra-
/inter-subject differences in the absorption, distribution, metabolism and elimination of 
drugs; and variability in pharmacodynamic processes, i.e. intra-/inter-subject differences in 
drug targets and (patho)physiological processes. These subtypes of variability can be further 
subdivided again, for example, variability in drug absorption can be explained in terms of 
intra-/inter-person differences in gastric acidity, gastric emptying rate, intestinal transit 
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time, and so on (Figure 1.1). With unlimited time and resources, all of these avenues could 
be comprehensively explored and commented on, which is the ultimate prerequisite for 
functioning personalised medicine. For the purposes of this thesis, however, the scope will 
be limited to better understanding how various intrinsic and extrinsic factors affect 
variability in drug metabolism, as a subset of variability in pharmacokinetics. 
Figure 1.1: Variability in response to medicines. This schematic lists some of the 
contributors to variability and their hierarchical sub-categories. 
 
1.1.1 Intrinsic and extrinsic factors 
The types of factors that affect drug metabolism in humans can be categorised as either 
intrinsic or extrinsic (Huang & Temple, 2008) (Figure 1.2). Intrinsic factors encompass those 
that are either hard to or cannot be changed, for example, age, geographic ancestry (see 
section 1.2), genetics and sex, whereas extrinsic factors are those that are environmental 
and usually modifiable, such as smoking, alcohol consumption, drug-drug/herb-drug/food-
drug interactions and diet. 
Variability in 
response to 
medicines
Pharmacokinetics
Drug metabolism Transporters
Pharmacodynamics
Drug targets Physiology
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Thus far, in the context of understanding variability in drug metabolism, the intrinsic factor 
genetics has received the most attention (Bjornsson et al., 2003). Specifically, variability 
arising from single nucleotide polymorphisms (SNPs) in genes that encode drug-
metabolising enzymes has been the focus (Yang, 2015). This approach follows on from the 
central dogma, i.e. genes encode proteins; enzymes are proteins, therefore understanding 
the genes that code for drug-metabolising enzymes should explain the observed variability 
in their activity. However, inter-individual differences in SNPs do not explain all of the 
variability in drug metabolism, and far less is known about the contributions of diet and the 
environment. 
The effect of genetics on drug-metabolising enzyme activity is discussed below in the 
various sub-sections of section 1.3.1. Diet, one of the most important and poorly-
understood extrinsic factors, is discussed below in section 1.2. 
Figure 1.2: Intrinsic and extrinsic factors that influence variability in response to 
medicines. Adapted from Huang and Temple (2008). 
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1.2 Geographic ancestry 
Intrinsic and extrinsic factors that affect drug metabolism tend to ‘clump’ together in 
packages that are often inherited and shared by sociocultural groups with a common 
geography. This idea often appears in the pharmacological literature under the guise of 
‘race’ or ‘ethnicity’. The use of these words in human biological studies and their underlying 
meaning and implications have been recently discussed by Yudell et al. (2016) in the 
prestigious journal, Science. Yudell and colleagues describe the use of race and ethnicity as 
biological concepts as being “…problematic at best and harmful at worst”. Their reasoning is 
sound: these concepts are actually social constructs as opposed to scientifically meaningful 
categories used to study population genetics, and cause great confusion when used in 
biological research. This “non-scientific misuse” of race and ethnicity makes it difficult, and 
sometimes impossible, to compare methodologies and data across population genetics 
studies. The list of issues that the use of these terms creates is growing: Yudell et al. 
mention difficulties with the interpretation of racial and ethnic effects (Kaufman & Cooper, 
2001), problems with making distinctions between self-identified/assigned and assumed 
racial categories (Rebbeck & Sankar, 2005), and “the haphazard use and reporting of 
racial/ethnic variables in genetic research” (Hunt & Megyesi, 2008). The suggested solution 
by Yudell et al. is the term “ancestry”, specifically “geographic ancestry”. Ancestry is a term 
with scientific intent and purpose: it defines how we relate to others through genealogical 
history as a “process-based” concept, whereas race is a “pattern-based” concept that leads 
people awry by encouraging misinterpretation of themes and data in contemporary studies. 
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Therefore, throughout this thesis, when discussing collections of intrinsic and extrinsic 
factors between groups of people, who are linked through genealogical history, the term 
‘geographic ancestry’ (‘ancestry’ for short) will be used instead of race or ethnicity.  
Importantly, genetics and diet vary extensively both within and between those of different 
ancestries, and few studies simultaneously investigate their interaction and effects on drug 
metabolism. The following sections introduce drug-metabolising enzymes (section 1.3.1), 
the various intrinsic and extrinsic factors that affect them (sections 1.3 and 1.7), and how 
these factors differ between ancestry groups (section 1.8). In the literature, some ancestry 
groups are better represented than others. Section 1.8 describes this in detail, highlighting 
that knowledge gaps exists for South Asian individuals relative to other groups, such as 
Europeans and East Asians. 
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1.3 Variability in pharmacokinetics  
1.3.1 Drug-metabolising enzymes 
Drug-metabolising enzymes are important because of their effect on the clearance of 
medicines, which in turn is a significant contributor to variability in response to medicines 
(Zanger et al., 2014; Zanger & Schwab, 2013). In fact, the first 3 sub-families of the 
cytochrome P450 (CYP) superfamily of drug-metabolising enzymes have been estimated to 
be involved in approximately 80% of oxidative drug metabolism, and almost 50% of the 
overall elimination of commonly used drugs (Wilkinson, 2005). For this reason, this thesis 
will focus on the CYPs and how diet, genetics and ancestry affect their activity. Other phase 
II conjugating enzymes are discussed too, as relevant to the thesis objectives set out in 
section 1.9. 
1.3.1.1 Cytochromes P450 
It has been estimated that over 90% of drugs are metabolised to some extent by five of the 
main CYP drug metabolising enzymes: CYP1A2, CYP2C19, CYP2C9, CYP2D6 and CYP3A4 
(Rodrigues, 1999). Ulrich M. Zanger and colleagues have dedicated decades of work to 
better understanding how the CYPs function, and what causes variability in their activity 
both within and between individuals. Variability in CYP activity is well known to be 
exorbitant; enzyme activity can vary 100-fold and more across the various isoenzymes.  
The following five sections of this thesis are dedicated to discussing these five CYP enzymes, 
their genetic variability and function, with reference to the two recent, comprehensive 
reviews published by Zanger et al. (Zanger et al., 2014; Zanger & Schwab, 2013). 
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1.3.1.1.1 CYP1A2 
The CYP1A2 gene is located on chromosome 15q24.1 and is mostly abundant in the liver 
(Kawakami et al., 2011; Nelson et al., 2004; Ohtsuki et al., 2012). The gene contains multiple 
aryl hydrocarbon receptor (AhR) response elements, therefore environmental sources of 
AhR ligands are strong inducers of CYP1A2 activity (Jorge-Nebert et al., 2010; Nebert et al., 
2004; Ueda et al., 2006). Clinically used substrates, inducers and inhibitors of CYP1A2 are 
listed in Table 1.1. 
Table 1.1: Substrates, inducers and inhibitors of CYP1A2. Adapted from the Australian 
Medicines Handbook (AMH, 2018), Zanger et al. (2014); Zanger and Schwab (2013). 
CYP1A2 substrates CYP1A2 inducers CYP1A2 inhibitors 
Agomelatine 
Amitriptyline 
Asenapine 
Axitinib 
Bendamustine 
Clozapine 
Duloxetine 
Erlotinib 
Fluvoxamine 
Imipramine 
Lidocaine 
Olanzapine 
Ondansetron 
Paracetamol 
Pirfenidone 
Pomalidomide 
Propranolol 
Rasagiline 
Ropinirole 
Ropivacaine 
Theophylline 
Warfarin (R‑isomer) 
Zolmitriptan 
Omeprazole 
Phenobarbital 
Phenytoin (moderate) 
Rifampicin (moderate) 
Ritonavir (moderate) 
Tobacco smoking 
Cimetidine 
Ciprofloxacin (strong) 
Combined oral 
contraceptives (moderate) 
Fluvoxamine (strong) 
Vemurafenib 
Verapamil 
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Two genetic variants have been flagged as being of clinical significance: rs2069514 
(CYP1A2*1C) and rs762551 (CYP1A2*1F). CYP1A2*1C is a −3860G>A SNP in the promotor 
region of the gene leading to decreased inducibility, and CYP1A2*1F is a −163C>A SNP in the 
intron 1 region of the gene leading to increased inducibility (Pharmacogene Variation 
Consortium at www.pharmvar.org). However, variations in these genotypes explain a low 
amount of the variability seen in CYP1A2 activity within and between individuals (Klein et 
al., 2010; Perera et al., 2012a), suggesting that environmental factors such as diet play a 
larger role in determining its activity than genetics. In fact, this is supported and confirmed 
by the large effect that diet has on CYP1A2 activity (Chapter 2). 
1.3.1.1.2 CYP2C19 and CYP2C9 
The CYP2C19 and CYP2C9 genes are located on chromosome 10q23.3. CYP2C9 is expressed 
in the liver approximately 10-fold higher than CYP2C19, which has been attributed to 
difficulties with the CYP2C19 promotor region interacting with hepatocyte nuclear factor 4α 
(HNF4α) (Coller et al., 2002; Koukouritaki et al., 2004; Ohtsuki et al., 2012; Rettie & Jones, 
2005). Clinically used substrates, inducers and inhibitors of CYP2C19 and CYP2C9 are listed 
in Table 1.2 and Table 1.3, respectively. 
Three CYP2C19 genetic variants are of particular clinical importance: rs4244285 
(CYP2C19*2), rs4986893 (CYP2C19*3) and rs12248560 (CYP2C19*17). CYP2C19*2 is a 
19154G>A splicing defect leading to a null allele and significantly reduced activity; 
CYP2C19*3 is a 17948G>A SNP also causing a null allele; and CYP2C19*17 is a −806C>T SNP 
in the promotor region of the gene causing increased expression and activity 
(Pharmacogene Variation Consortium at www.pharmvar.org). Because of these relatively 
prevalent null alleles, genotype-phenotype correlations are observed for CYP2C19. 
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Importantly, the interaction between diet, genetics and geographic ancestry and their 
combined effects on CYP2C19 activity have not been assessed. 
There are two CYP2C9 genetic variants that are of significance to variability in response to 
medicines: rs1799853 (CYP2C9*2) and rs1057910 (CYP2C9*3). CYP2C9*2 is a 3608C>T SNP 
leading to decreased activity and CYP2C9*3 is a 42614A>C SNP also causing decreased 
activity (Pharmacogene Variation Consortium at www.pharmvar.org). CYP2C9 is expressed, 
to a lesser extent, in extra-hepatic tissues such as the intestines and cardiovascular system, 
and therefore environmental agents that reach these tissues in high concentrations could 
affect activity (DeLozier et al., 2007). As with CYP2C19, the effects of diet, genetics and 
geographic ancestry have not been simultaneously investigated for CYP2C9.  
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Table 1.2: Substrates, inducers and inhibitors of CYP2C19. Adapted from the Australian 
Medicines Handbook (AMH, 2018) and Zanger et al. (2014); Zanger and Schwab (2013). 
CYP2C19 substrates CYP2C19 inducers CYP2C19 inhibitors 
Amitriptyline 
Axitinib 
Bortezomib 
Brivaracetam 
Citalopram 
Clopidogrel 
Cyclophosphamide 
Diazepam 
Escitalopram 
Esomeprazole 
Etravirine 
Imipramine 
Lansoprazole 
Omeprazole 
Pantoprazole 
Phenobarbital 
Phenytoin 
Propranolol 
Voriconazole 
Warfarin (R‑isomer) 
Zolmitriptan 
Efavirenz (moderate) 
Enzalutamide (moderate) 
Rifampicin (strong) 
Ritonavir (strong) 
St John’s wort 
Cimetidine 
Clarithromycin 
Efavirenz 
Esomeprazole 
Etravirine 
Fluconazole (strong) 
Fluoxetine (strong) 
Fluvoxamine (strong) 
Ketoconazole 
Omeprazole 
Oxcarbazepine 
Topiramate 
Voriconazole (moderate) 
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Table 1.3: Substrates, inducers and inhibitors of CYP2C9. Adapted from the Australian 
Medicines Handbook (AMH, 2018) and Zanger et al. (2014); Zanger and Schwab (2013). 
CYP2C9 substrates CYP2C9 inducers CYP2C9 inhibitors 
Amitriptyline 
Bosentan 
Celecoxib 
Cyclophosphamide 
Etravirine 
Fluoxetine 
Fluvastatin 
Glibenclamide 
Gliclazide 
Glimepiride 
Glipizide 
Ibuprofen 
Phenytoin 
Rosiglitazone 
Rosuvastatin 
Ruxolitinib 
Tamoxifen 
Voriconazole 
Warfarin (S‑isomer) 
Aprepitant (moderate) 
Bosentan 
Carbamazepine (moderate) 
Dabrafenib 
Enzalutamide (moderate) 
Rifampicin (moderate) 
Ritonavir (moderate) 
St John’s wort 
Amiodarone (moderate) 
Benzbromarone (moderate) 
Efavirenz 
Etravirine 
Fluconazole (moderate) 
Fluoxetine 
Fluvoxamine 
Miconazole 
Ritonavir 
Voriconazole 
 
1.3.1.1.3 CYP2D6 
The CYP2D6 gene is located on chromosome 22q13.1. As with some of the other CYP 
enzymes, CYP2D6 expression is, to some extent, regulated by HNF4α (Corchero et al., 2001; 
Hara & Adachi, 2002). Clinically used substrates and inhibitors of CYP2D6 are listed in Table 
1.5. 
The determinants of CYP2D6 activity are mostly due to SNPs in various splice variants 
(Zanger et al., 2001). In fact, CYP2D6 is almost exclusively under genetic control, with little 
evidence of environmental induction (Bock et al., 1994; Glaeser et al., 2005), apart from one 
isolated study reporting phenotypic increases in activity following rifampicin administration 
(Caraco et al., 1997) (this is why Table 1.5 lists substrates and inhibitors of CYP2D6 but no 
inducers). However, this long-held view has been challenged in recent years, with new in 
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vivo evidence demonstrating induction of CYP2D6 after administration of inducers of other 
CYPs such as corticosteroids (Farooq et al., 2016). CYP2D6 has the largest list of allelic 
variants known to affect its activity; the most significant of these are listed in Table 1.4. 
Frequencies of null alleles between geographic ancestry groups are discussed in section 1.8, 
however it is worth mentioning here that for CYP2D6, a quad-modal frequency distribution 
of population activity phenotypes is achieved by genotype. This distribution is made up of: 
ultra-rapid metabolisers (UMs), who have multiple copy variants of the CYP2D6 gene; 
extensive metabolisers (EMs), who are homozygous for the normal allele; intermediate 
metabolisers (IMs), who are either homozygous or heterozygous for reduced-activity alleles; 
and poor metabolisers (PMs), who are homozygous for at least one null allele of the CYP2D6 
gene (Raimundo et al., 2004; Zanger & Hofmann, 2008).  
Table 1.4: Clinically significant CYP2D6 SNPs. Adapted from Zanger and Schwab (2013). 
CYP allele 
(PharmVar) 
Accession no. (rs no.) SNP Effect 
CYP2D6*3 rs35742686 2549delA Null allele 
CYP2D6*4 rs3892097 1846G>A Null allele 
CYP2D6*5 Recombination n/a Null allele 
CYP2D6*6 rs5030655 1707delT Null allele 
CYP2D6*10 rs1065852 100C>T 
Reduced expression 
and activity 
CYP2D6*17 
rs28371706 
rs16947 
1023C>T 
2850C>T 
Reduced expression 
and activity 
CYP2D6*41 rs28371725 2988G>A 
Reduced expression 
and activity 
CYP2D6 copy no. Recombination 
Copy no. 
variations 
Increased 
expression and 
activity 
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Table 1.5: Substrates and inhibitors of CYP2D6. Adapted from the Australian Medicines 
Handbook (AMH, 2018) and Zanger et al. (2014); Zanger and Schwab (2013). 
CYP2D6 substrates CYP2D6 inhibitors 
Amitriptyline 
Aripiprazole 
Atomoxetine 
Bortezomib 
Brexpiprazole 
Carvedilol 
Chlorpromazine 
Cinacalcet 
Clozapine 
Codeine 
Dapoxetine 
Darifenacin 
Dextromethorphan 
Donepezil 
Duloxetine 
Flecainide 
Fluoxetine 
Fluvoxamine 
Galantamine 
Gefitinib 
Haloperidol 
Imipramine 
Lidocaine 
Metoclopramide 
Metoprolol 
Nebivolol 
Nortriptyline 
Olanzapine 
Ondansetron 
Oxycodone 
Paroxetine 
Perhexiline 
Propranolol 
Risperidone 
Tamoxifen 
Tolterodine 
Tramadol 
Venlafaxine 
Vortioxetine 
Abiraterone 
Amiodarone 
Bupropion (strong) 
Celecoxib 
Cimetidine 
Cinacalcet (moderate)  
Cobicistat 
Duloxetine (moderate) 
Fluoxetine (strong) 
Methadone 
Mirabegron (moderate) 
Paroxetine (strong) 
Terbinafine (strong) 
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1.3.1.1.4 CYP3A4 
The CYP3A4 gene is located on chromosome 7q22.1. By liver microsomal weight, it alone 
constitutes 14-24% of the CYPs (Lin et al., 2002; Ohtsuki et al., 2012; Shimada et al., 1994; 
Wolbold et al., 2003), emphasising its important contribution to oxidative drug metabolism 
in humans. It also has an important role in intestinally-mediated first-pass metabolism due 
to its relative abundance in enterocytes (Daly, 2006; Ding & Kaminsky, 2003; Von Richter et 
al., 2004). Upstream pregnane X receptor (PXR) and constitutive androstane receptor (CAR) 
binding sites make this gene readily inducible, as seen across a wide variety of endogenous, 
exogenous and xenobiotic substrates (Jover et al., 2009; Matsumura et al., 2004; Qiu et al., 
2010). Clinically used inducers and inhibitors of CYP3A4 are listed in Table 1.6; substrate lists 
are vast, and are therefore not displayed. 
Two CYP3A4 genetic variants of significance have been highlighted: rs2740574 (CYP3A4*1B) 
and rs35599367 (CYP3A4*22). CYP3A4*1B is a −392A>G polymorphism in the upstream 
promotor region of the gene that potentially leads to decreased activity, and CYP3A4*22 is a 
15389 C>T SNP in intron 6 causing decreased expression and activity (Pharmacogene 
Variation Consortium at www.pharmvar.org). While the interaction between CYP3A4 
substrates such as statins have been investigated for effects on activity by genotype, the 
effect of diet by geographic ancestry is less-represented in the literature. 
Overall, these five main CYP enzymes play a major role in the metabolism of commonly used 
medicines in humans. Importantly, their activity is differentially affected by SNPs in select 
variants and various environmental exposures. As a collective, they represent an ideal panel 
of important enzymes to study the effects of diet, genetics and geographic ancestry on drug 
metabolism in humans. 
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Table 1.6: Substrates, inducers and inhibitors of CYP3A4. Adapted from the Australian 
Medicines Handbook (AMH, 2018) and Zanger et al. (2014); Zanger and Schwab (2013). 
CYP3A4 inducers CYP3A4 inhibitors 
Aprepitant 
Bosentan (moderate) 
Carbamazepine (strong) 
Corticosteroids 
Dabrafenib 
Efavirenz (moderate) 
Enzalutamide (strong)  
Etravirine (moderate) 
Lumacaftor (strong) 
Modafinil (moderate) 
Nevirapine 
Phenobarbital 
Phenytoin (strong) 
Rifabutin 
Rifampicin (strong) 
Ritonavir 
St John’s wort (strong) 
Tipranavir 
Vemurafenib 
Aprepitant (moderate) 
Atazanavir (moderate) 
Ciclosporin (moderate) 
Cimetidine (moderate) 
Clarithromycin (strong) 
Cobicistat (strong) 
Crizotinib (moderate) 
Darunavir 
Diltiazem (strong) 
Erythromycin (moderate) 
Fluconazole (moderate)  
Fluvoxamine (moderate)  
Fosamprenavir (moderate) 
Grapefruit juice (moderate) 
Idelalisib (strong) 
Imatinib (moderate)  
Indinavir (strong) 
Isavuconazole (moderate)  
Itraconazole (strong) 
Ketoconazole (strong) 
Lopinavir 
Miconazole 
Netupitant 
Palbociclib 
Posaconazole (strong) 
Ritonavir (strong) 
Saquinavir (strong) 
Ticagrelor 
Tipranavir 
Verapamil (moderate) 
Voriconazole (strong) 
  
21 
 
1.3.1.2 Uridine 5’-diphospho-glucuronosyltransferases 
As discussed above, much of the drug metabolism literature focusses on the CYP 
superfamily of drug metabolising enzymes due to familiarity with their molecular genetic 
mechanisms and well-characterised substrate profiles (Daly, 1995). However, the depth of 
knowledge encompassing other enzyme superfamilies, such as the uridine-diphosphate 
glucuronosyltransferases (UGTs), has grown as a result of increased overall knowledge of 
drug metabolism and an evolving appreciation of how these superfamilies’ substrate 
specificities overlap and interact (Ginsberg et al., 2010; Yang et al., 2017). 
UGTs are responsible for the glucuronidation and elimination of a wide range of 
endogenous substances, xenobiotics, environmental pollutants, carcinogens and their phase 
I metabolites (Miners et al., 2002). UGTs are type I transmembrane proteins found in the 
smooth endoplasmic reticulum within cells and are expressed in high concentrations in the 
liver, but also expressed in extrahepatic tissues such as the lungs, kidney and 
gastrointestinal tract (GIT) (Cappiello et al., 1991). The primary function of UGTs is to 
catalyse the transfer of a sugar moiety from the cofactor uridine-diphosphoglucuronic acid 
(UDPGA) to hydroxyl, carboxylic, amino or sulphur constituents on the substrate (Ginsberg 
et al., 2010).  
The outcome of this chemical biotransformation is an increase in the substrate’s molecular 
weight and hydrophilicity, facilitating excretion in bile and/or urine via the liver and/or 
kidney. 
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The UGT superfamily is divided into three broad groups based on homology sequencing: 
UGT1A, found on chromosome 2; and UGT2A and 2B, found on chromosome 4 (Nagar & 
Remmel, 2006). UGT1 members have exons 2-5 in common and variations in exon 1 
determine the enzyme’s subtype, whereas UGT2 members have six exons—all of which are 
variable—that have no overlap with UGT1 exons (Maruo et al., 2005). At least 13 isoforms 
are encoded by the UGT1 locus, with nine of these being functional enzymes: UGT1A1, 1A3, 
1A4, 1A5, 1A6, 1A7, 1A8, 1A9 and 1A10 (Miners et al., 2002). Functional UGT2 subtypes 
include UGT2A1, 2B4, 2B7, 2B10, 2B11, 2B15, 2B17 and 2B28 (Levesque et al., 2001). 
Despite these subfamilies having differing amino acid sequences there is substantial overlap 
in their substrate specificity. While this redundancy is beneficial for the organism as it 
provides alternate glucuronidation pathways in the presence of inefficient variants or 
absent enzymes, the lack of substrate specificity between UGT subtypes creates difficulty in 
designing studies that assess single glucuronidation pathways. Although this overlap in 
specificity is prominent, the subfamilies do differ in their general affinity for endogenous sex 
Figure 1.3: An example of glucuronidation of 4-aminobiphenyl, adapted from Al-Zoughool and 
Talaska (2006). 
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Figure 1.4: Forest plot showing pooled estimate of standardised mean difference in CYP1A2 
activity during cruciferous vegetable versus basal/control diet. 
 
Figure 1.5: Forest plot sh wing pooled estimate of standardised mean difference in GST-α 
activity during cruciferous vegetable versus basal/control diet. 
 
Figure 1.6: Dose-response relationship between increase in CYP1A2 activity and daily cruciferous 
vegetable consu ption. 
 
Figure 1.7: Chromatogram overlays of the 10 analytes and internal standard phenacetin as a 
mixture in human plasma. 
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steroids. UGT1s appear to have greater activity against oestrogens and their catechol 
metabolites (Lepine et al., 2004), while UGT2s tend to better glucuronidate androgens 
(Belanger et al., 2003). A summary of known substrates by UGT subtype is displayed in Table 
1.7.  
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Table 1.7: Known substrates of UGT isoforms, adapted from Ginsberg et al. (2010) and 
Levesque et al. (2001). Note: References for substrates mentioned outside of these papers 
are listed in the far-right column. 
UGT 
Isoform 
Substrates References 
UGT1A1 Bilirubin, estrogens (β-estradiol, hydroxyestradiols, 
hydroxyestrones), 
buprenorphine, flavonoids, anthraquinone, 
4-nitrophenol, 2-amino-5-nitro-4-fluoromethylphenol, 
raloxifene1 
1Trontelj et al. (2009) 
UGT1A3 Estrone, hydroxyestrone, hydroxyestradiol, amines 
(cyproheptadine, losartan), anthraquinones, femoprofen, 
ibuprofen, umbelleferone, flavonoids 
 
UGT1A4 Amines (clozapine, aminobiphenyl, naphthylamine, benzidine, 
aminofluorene, imipramine), 4-hydroxytamoxifen, 
5α-pregnene-3α,20β-diol 
 
UGT1A5 
Unknown 
 
UGT1A6 Phenols (eugenol, β-naphthol, 4-nitrophenol), paracetamol, 
serotonin, amines, 2-amino-5-nitro-4-fluoromethylphenol, 
salicylic acids, deferiprone2 
2Benoit-Biancamano et al. (2009) 
UGT1A7 Phenols (α-naphthol), acetaminophen, 4-methlumbelliferone, 
octyl gallate, propyl gallate, benzo(a)pyrene metabolites 
 
UGT1A8 Estrogens (hydroxyestrone, hydroxyestradiol, 17α- 
ethinylestradiol), naltrexone, phenols, flavonoids, 
anthraquinones, phenolphthalein, mycophenolic acid, 
4-aminobiphenyl 
 
UGT1A9 Estrogens, retinoic acid, thyroid hormones, paracetamol, 
SN-38 (active metabolite of irinotecan), phenols, 4- 
methylumbelliferone, propofol, flavonoids, 
anthraquinones, mycophenolic acid 
 
UGT1A10 
β-estradiol, mycophenolic acid, phenols, flavonoids 
 
UGT2A1 Phenols (vanillin, 3-hydroxybiphenol, 4-hydroxybiphenol), 
scopoletin, aliphatic compounds (citronellol), steroids 
 
UGT2B4 Eugenol, catechol estrogens, hyodeoxycholic acid, 1-napthol, 
4-methylumbelliferone, 5β-pregnane-3α,20β-one 
 
UGT2B7 Estrogens (4-hydroxyestrone, 4-hydroxyestradiol), 
androsterone, 
morphine, dihydromorphine, codeine, oxycodone, naloxone, 
naltrexone, valproic acid, serotonin, hyodeoxycholic acid, 
losartan, flurbiprofen3, gemfibrozil4, haloperidol5, 6α-
hydroxyprogesterone6, 21-hydroxyprogesterone6, lorazepam7, 
trans-4-hydroxytamoxifen8, endoxifen8, 
3Wang et al. (2011), 4Mano et al. (2007), 5Kato 
et al. (2012), 6Bowalgaha et al. (2007), 7Chung 
et al. (2008), 8Blevins-Primeau et al. (2009) 
UGT2B10 
Unknown 
 
UGT2B11 
Unknown 
 
UGT2B15 Dienestrol, phenols, flavonoids (naringenin, apigenin), 
anthraquinones, estrogens, (2-hydroxyestrone, 4-
hydroxyestrone), 
bisphenol A, testosterone, dihydroxytestosterone, oxazepam9 
9He et al. (2009) 
UGT2B17 Androgens (androgen, testosterone, dihydrotestosterone, 
androstenediols) 
 
UGT2B28 Eugenol, etiocholanolone, androstane-3α,20β-diol, 4-
methylumbelliferone, 1-napthol, estradiol, androsterone, 
hyodeoxycholic acid, lithocholic acid, testosterone 
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1.3.1.3 Glutathione S-transferases 
The glutathione S-transferases (GSTs) are another type of important phase II drug-
metabolising enzyme, recently reviewed by Allocati et al. (2018). The GSTs catalyse the 
attachment of glutathione (GSH) to an electrophilic substrate, with the resulting conjugate 
being more water soluble than before, facilitating excretion in the urine (Pool-Zobel et al., 
2005). GSTs are localised within the cell into three main sub-categories: cytosolic, 
mitochondrial and microsomal GSTs (Hayes et al., 2005; Oakley, 2011; Sheehan et al., 2001). 
Important cytosolic GSTs in humans include the alpha, mu, pi and theta subtypes. The co-
substrate binding sites in these enzymes, termed the ‘H-site’, displays marked variability, 
leading to a vast array of substrate binding affinities. GSTs have numerous roles in 
endogenous cellular biology, including, but not limited to protecting the cell against 
oxidative stress, and biotransformation of leukotrienes and prostaglandins. However, this 
thesis is concerned with their role in the detoxification of drugs and their metabolites, and 
factors that contribute to variability in their activity. 
The GSTs are polymorphic like most of the other drug-metabolising enzymes presented in 
this chapter. Gene deletion can create a null allele for GSTM1 and GSTT1, and the GSTP1 
rs1695 A>G SNP is associated with reduced activity. GSTM1, GSTP1 and GSTT1 have an 
important role to play in the metabolism of numerous antineoplastic drugs, paracetamol 
and the isothiocyanates (section 1.7.1) (Whirl-Carrillo et al., 2012). In fact, isothiocyanate 
exposure (and subsequent changes in CYP1A2 activity) are modulated by the presence of 
the GSTM1 and GSTT1 null alleles (Peterson et al., 2009) (Chapter 2). Importantly, the 
effects of genetics, diet and geographic ancestry on GSTs have not been simultaneously 
assessed in the context of variability in response to medicines. 
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1.4 Transporters 
While outside the specific scope of this thesis, which focuses on drug metabolism, it is 
important to acknowledge the impact drug-transporting proteins have on variability in 
pharmacokinetics. As with drug-metabolising enzymes, polymorphisms in the genes that 
encode these transporters, and extrinsic factors such as drug interactions, can lead to a 
variable response, and hence differences in the systemic exposure of drugs between 
individuals. König et al. (2013) and Koo et al. (2015) provide excellent and comprehensive 
coverage of this topic. This section provides a brief overview of transporters, their genetic 
variability and effects on drug disposition. 
Transporters either efflux substrates back into the lumen on the apical side of the cell or 
uptake substrates into the cell through the basolateral membrane (König et al., 2013). Two 
well-studied examples of efflux transporters are P-glycoprotein (P-gp; encoded by the 
ABCB1 gene) and multi-drug resistance protein 2 (MRP2; encoded by the ABCC2 gene); well-
known uptake transporters include organic anion-transporting polypeptide (OATP)1B1 
(encoded by the SLCO1B1 gene) and organic cation transporter (OCT)1 (encoded by the 
SLC22A1 gene). 
Transporter genes are regulated by mechanisms similar to drug-metabolising enzymes, for 
example, induction can occur through interactions between the gene and the PXR, CAR and 
the vitamin D receptor (Tirona, 2011).  Several studies have shown transporter induction 
following exposure to rifampicin and St John’s wort (Dürr et al., 2000; Greiner et al., 1999). 
Polymorphisms in transporter genes have been shown to contribute to variability in drug 
exposure: in one study, the SLC22A2 808G>T SNP significantly affected metformin renal 
clearance in the presence of cimetidine (Wang et al., 2008). Another well-studied 
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polymorphism, the SLCO1B1 521T>C SNP (OATP1B1*5), has been shown to greatly reduce 
the activity of the OATP1B1 transporter. Assessing the relative frequencies of transporter 
SNPs in different geographic ancestries is of interest, as is the effect of diet on drug 
transporters, but both topics lie outside the scope of this thesis. 
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1.5 Epigenetics 
Epigenetics encompasses heritable gene expression patterns that cannot be explained in 
terms of the DNA sequence itself; it can be thought of as the processes that occur ‘on-top’ 
of the DNA (‘epi‘, meaning ‘upon’, in Greek), rather than what is coded in DNA itself. Such 
epigenetic mechanisms include DNA methylation, post-transcriptional modification of 
histones and gene expression changes by non-coding RNAs (ncRNAs) (Ivanov et al., 2012). 
The ways in which epigenetic mechanisms affect drug-metabolising enzymes and 
transporters are largely unknown, with this field still being in its infancy. This topic has been 
comprehensively reviewed by Zanger and Schwab (2013), Zanger et al. (2014), Kacevska et 
al. (2011) and Ivanov et al. (2012). Epigenetic mechanisms have an inhibitory effect on the 
expression of drug-metabolising enzyme genes: for a comprehensive list, the reader is 
directed to Table 1 in Kacevska et al. (2011)’s review in Clinical Pharmacology and 
Therapeutics. 
This territory remains largely uncharted, with epigenetic targets and mechanisms being 
referred to as “genetic dark matter” (Stefanska & MacEwan, 2015; Zanger et al., 2014). 
Further, extremely few studies have investigated how diet, genetics and geographic 
ancestry interact with epigenetics to cause variability in drug response. These themes lie 
outside the scope of this thesis, but as epigenetic methodologies evolve and improve, these 
avenues should be explored for the major drug-metabolising enzymes and transporters. 
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1.6 Measuring variability in drug-metabolising enzyme activity 
Appropriate in vivo bioanalytical methods are required before one can study the effects of 
intrinsic and extrinsic factors on drug metabolism in humans. In particular, estimation of CYP 
activity in humans requires in vivo measurement of selective substrates specific for the CYP 
enzyme(s) in question, along with a suitable, validated pharmacokinetic metric (Tucker et 
al., 1998). These probe drugs should ideally be easy to administer (preferably via the oral 
route), have no interactions amongst themselves and be well-tolerated by the patient at low 
doses (Ghassabian et al., 2009). Therefore, the design, validation and optimisation of these 
analytical methods are often complex, time consuming and resource-intensive. A significant 
investment is made to get these tools ‘right’, so that accurate and precise measurement of 
CYP activity can be made before and after interventions that test hypotheses in this area of 
clinical pharmacology. 
1.6.1 Simultaneous phenotyping of multiple CYP-isoenzymes: the ‘cocktail’ approach 
CYP-phenotyping cocktails aim to achieve the above simultaneously for multiple CYP450 
enzymes, namely CYP1A2, CYP2D6, CYP2C19, CYP2C9 and CYP3A4, by dosing individuals 
with enzyme-specific probe drugs, and using the resulting concentration-time data to 
calculate metrics that characterise CYP drug-metabolising activity. This approach has been 
colloquially called the CYP-phenotyping ‘cocktail’, and has recently been extensively 
reviewed by de Andrés and Llerena (2016).  
Multiple CYP-phenotyping methods using liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) have been developed with a range of probe drugs, internal 
standards, sampling strategies, biological matrices of interest and methods of analyte 
extraction (de Andrés & Llerena, 2016). To have utility as a diagnostic or investigative tool in 
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clinical and research settings, the phenotyping approach should be minimally invasive with 
simplified sample processing, and reduced costs wherever possible. Of note, complex, 
multiple-step analytical protocols have served as a barrier to the routine inclusion of CYP-
phenotyping in these contexts, with some methods requiring: different extraction 
techniques for their various analytes; specialised automated systems; lengthy incubations 
with reagents before extraction can occur; and different chromatographic conditions across 
analytes, which necessitate repeat sample processing and multiple injections (De Andrés et 
al., 2014; Ghassabian et al., 2009; Grangeon et al., 2017; Lammers et al., 2016). Lack of 
assay sensitivity also means that larger volumes (0.5 – 10 mL) of plasma are needed. 
Further, some methods employ probes such as flurbiprofen (Bosilkovska et al., 2014a) and 
tolbutamide (Yin et al., 2004), which are not widely available in appropriate dosage forms. 
Other issues arise with the use of foods containing the probe phenotyping compounds as 
opposed to standardised medicines (e.g. coffee or carbonated cola beverages as a caffeine 
source), which likely contain additional compounds that could affect drug-metabolising 
enzymes in humans (Bosilkovska et al., 2014a; Bosilkovska et al., 2016; Bosilkovska et al., 
2014b). Consequently, there exists a need for bioanalytical methods that address the above 
issues, which can be readily established for clinical studies requiring simultaneous CYP-
phenotyping.  
The design, validation and optimisation of one such CYP-phenotyping cocktail is covered in 
Chapter 3, aligning with the thesis objectives outlined in section 1.9. 
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1.7 Diet as an extrinsic source of variability in drug metabolism 
The old adage “you are what you eat” has been shown to be ostensibly true throughout 
decades of research across many disciplines. In the context of clinical pharmacology, a 
recent review by Yang (2015) pays tribute to the work of the late Allan Conney and 
colleagues, who pioneered work in this area. Conney et al. identified that polycyclic 
aromatic hydrocarbons, famously found in char-grilled meat, induce the metabolic activity 
of CYP1A1 and CYP1A2 (Conney, 1982), opening the door to diet and drug metabolism 
research in humans (Conney, 2003). This group of researchers is well-known for their work 
that identified ingested cruciferous vegetables as inducers of CYP1A2 (Pantuck et al., 1979), 
and a comprehensive review of such trials is discussed in Chapter 2 of this thesis. Because 
Cruciferae are found in diets throughout the world (Li et al., 2015), they were chosen as a 
candidate food to study in the context of variability in drug metabolism, and differences in 
this variability across geographic ancestries.  
1.7.1 Cruciferous vegetables and their constituents 
Due to their apparent anti-cancer properties, the isothiocyanates (ITCs) have been of 
interest to the scientific community over the past two decades (Gupta et al., 2014). These 
compounds are found in high concentrations in cruciferous vegetables such as broccoli, 
cabbage and watercress, which feature almost ubiquitously in many diets across the globe 
(Steinkellner et al., 2001). These compounds are present in plants as thioglycoside 
conjugates called glucosinolates, which are hydrolysed by myrosinase (released when plant 
cells are damaged by cutting, chewing, etc.) to isothiocyanates (Grubb & Abel, 2006) (Figure 
1.17). 
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Figure 1.17: The two most represented glucosinolates and their isothiocyanate hydrolysis 
products. Adapted from Cartea and Velasco (2008). 
 
One of the mechanisms by which these compounds elicit their cancer-protecting effects is 
through the induction of phase I and II drug-metabolising enzymes, which significantly 
contribute to the metabolism, and therefore clearance, of carcinogenic compounds and 
other xenobiotics (Cheung & Kong, 2010; Thornalley, 2002; Zhang, 2004). Most studies 
investigating these effects are designed to test hypotheses in a cancer-focussed context, 
with the two most represented ITCs being sulforaphane (SUL) and phenethyl isothiocyanate 
(PEITC) (Lamy et al., 2011) (Figure 1.17). However, few studies approach the interaction 
between Cruciferae and their constituents and drug-metabolising enzymes in a clinical 
pharmacology context. 
The majority of published studies investigating these effects focus on the CYP1A2 isoform 
(section 1.3.1.1.1). Generally, data show that the constituents in Crucifeae induce or 
increase the activity of this enzyme in vivo but have mixed effects in vitro (Chapter 2). 
Contrary to in vivo data, PEITC has been shown to inhibit CYP1A2, CYP2C19, CYP2C9, CYP2D6 
and CYP3A4 in vitro (Nakajima et al., 2001). Its glucosinolate precursor, gluconasturtiin, has 
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been detected in concentrations ranging from 0.1-0.9 µmol per gram of dry weight broccoli 
across 50 different accessions of broccoli subspecies (Kushad et al., 1999). Therefore, 
consumption of 500 g broccoli daily could lead to ingestion of up to 450 µmol of 
gluconasturtiin, and hence a corresponding amount of phenethyl isothiocyanate, in a 24-
hour period. A related isothiocyanate compound, sulforaphane, is present in high 
concentrations within broccoli as the thioglycoside conjugate glucoraphanin, and it has been 
estimated that consumption of 100 g of broccoli may release 40 µmol of this particular 
isothiocyanate (Hecht, 1995). As with PEITC, there is also evidence that sulforaphane can 
inhibit CYP1A2. Importantly, both PEITC and SUL have been detected in significant 
concentrations in plasma following cruciferous vegetable consumption (Fahey et al., 1997; Ji 
& Morris, 2003). These data suggest that it is reasonable to hypothesise that a clinically 
meaningful concentration of these bioactive phytochemicals may be achieved in hepatic 
tissues and other sites of drug metabolism, potentially leading to altered activity of 
important CYP-mediated xenobiotic elimination. 
The manner in which cruciferous vegetables are prepared in a culinary context for human 
consumption can affect the quantity of phytochemicals absorbed after their ingestion. A 
comprehensive review in this area outlines evidence for altered glucosinolate 
concentrations in cruciferous vegetables following “domestic cooking” (boiling), steaming, 
microwaving and stir-fry cooking (Verkerk et al., 2009). Verkerk et al. identified that some 
glucosinolates and their metabolites are water-soluble, and cooking methods involving 
submerging vegetables in water, or with high surface area contact with water, could 
facilitate leeching and a reduced concentration of these phytochemicals within plant tissues.  
This is supported by a study that showed a 77% decrease in glucosinolate content within 
broccoli that was boiled for 30 minutes (Song & Thornalley, 2007). 
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Studies that involve microwaving cruciferous vegetables display mixed effects on 
glucosinolate content. Vallejo et al. (2002) showed that microwaving broccoli for five 
minutes at 1000 W power reduced glucosinolate levels by 74%. In contrast, a similar study 
found no significant decrease in glucosinolate content when microwaving for three minutes 
at 900 W power (Song & Thornalley, 2007). It remains unclear if microwaving can truly 
affect phytochemical levels within cruciferous vegetables, however it is worth noting that in 
vivo broccoli diet studies with a drug-metabolising enzyme endpoint report significant 
changes in enzyme activity even if the broccoli was allowed to be microwaved (Hakooz & 
Hamdan, 2007; Kall et al., 1997). 
Importantly, ITCs are predominantly metabolised by GSTs (section 1.3.1.3), therefore factors 
affecting GST activity are also likely to contribute to variability in ITC exposure. The 
contributions of GST genotype and cruciferous vegetable preparation and cooking methods 
to variability in ITC exposure should not be ignored, and trials that measure their 
concentration should have appropriate measures in place to control for this variability. 
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1.8 Differences in CYP activity between Europeans and South Asians 
Chapter 1 has introduced the reader to the theme of variability in response to medicines 
(section 1.1), with a focus on intrinsic and extrinsic factors affecting this variability (section 
1.1.1), geographic ancestry (section 1.2), drug-metabolising enzymes (section 1.3.1), and the 
effects of Cruciferae-enriched diets on drug metabolism (section 1.7.1). Often, these factors 
interact and co-vary within geographic ancestry groups, which can be useful when 
attempting to explain variability in response to medicines in these populations.  
Ultimately, ancestry is a ‘cluster’ of various intrinsic and extrinsic factors that vary or co-vary 
within a particular geographic ancestry group, such as frequencies of SNPs in drug-
metabolising genes, or dietary practices. Therefore, any study that aims to address 
hypotheses in this area should measure the effect of individual intrinsic and extrinsic factors 
and how they themselves vary between ancestry groups. Further, doing so allows for 
appropriate statistical control of particular factors, which is useful in determining whether 
there remains residual, unexplained variability in a given endpoint. Several good examples 
of this are demonstrated in Chapter 5 of this thesis, such as CYP2C19 activity being higher in 
Europeans than South Asians within genotype groups, i.e. despite having the same alleles in 
the variants tested, one ancestry group still had higher activity than the other, some of 
which could be explained by relative differences in dietary practices between the groups. 
This approach allows for identification of new avenues of research to explore and a better 
understanding of the relative contribution of factors affecting variability in response to 
medicines. 
Of all geographic ancestries, the most is known about Europeans, as much of the modern 
clinical pharmacology movement originated in either Europe or America (in the early to mid-
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1900s, most Americans were European immigrants or their descendants) (Dollery, 2006). In 
fact, because most drugs have traditionally been developed in European patient cohorts, 
they are also the reference group for comparison when registering a drug for use in non-
European populations. In the modern pharmaceutical industry context, global clinical trials 
aim to address the pharmacological differences between ancestry groups, and the 
International Council for Harmonisation (ICH) sets out guidelines to streamline and improve 
this process (Ichimaru et al., 2010). Compared to Europeans, fewer trials are conducted in 
those people of South Asian ancestry: less than 1% of global clinical trials are conducted in 
populations hailing from the Indian sub-continent (Thiers et al., 2008). However, this region 
of the world has one of the highest population growth rates and high annual growth in 
pharmaceutical infrastructure and demand. Further, the effects of diet and genetics on 
drug-metabolising enzyme activity in South Asians are under-represented in 
pharmacogenomic databases such as PharmGKB (https://www.pharmgkb.org) (Whirl-
Carrillo et al., 2012) and The Allele Frequency Database (ALFRED) 
(https://alfred.med.yale.edu) (Rajeevan et al., 2003). Therefore, better understanding the 
variability in response to medicines between Europeans and South Asians is of growing 
importance, hence choosing to focus on these two geographic ancestries in this thesis. 
The remainder of this section will discuss the currently known differences in CYP genetics 
between Europeans and South Asians, and finally comment on known differential effects of 
diet practices on CYP activity between these groups. 
1.8.1 Differences in CYP SNP frequencies between Europeans and South Asians 
The 1000 Genome Project (http://www.internationalgenome.org) was a vast collaborative 
undertaking that aimed to identify and catalogue as many gene variants as possible in select 
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ancestry groups across the globe (Auton et al., 2015). Table 1.8 summarises some of the 
data from this project, namely frequencies of important CYP SNPs in both Europeans and 
South Asians. It can be seen that for many of these important variants, frequencies of 
activity change alleles are higher in one group over the other. For example, with regards to 
CYP2C19, Europeans have a higher proportion of the increased activity genotypes (TT, CT) 
for CYP2C19*17, and South Asians have a higher frequency of the CYP2C19*2 null allele 
genotypes (AA, AG), suggesting that with all else being equal, Europeans would have higher 
CYP2C19 activity than South Asians. Similar allelic patterns are seen for CYP1A2, with 
Europeans having higher frequencies of the increased inducibility genotypes for CYP1A2*1F 
(AA, AC), with South Asians having higher frequencies of the decreased inducibility 
genotypes for CYP1A2*1C (AA, AG). For CYP2C9 and CYP3A4, the ancestry group differences 
in high or low activity genotype frequencies are similar. CYP2D6 is highly polymorphic 
(section 1.3.1.1.3), and variants that cause either reduced or no activity are numerous. 
Frequencies of the null or reduced activity CYP2D6 variant genotypes are higher in 
Europeans for CYP2D6*3, CYP2D6*4, CYP2D6*6 and CYP2D6*10, but more prevalent in 
South Asians for CYP2D6*42 (Auton et al., 2015). 
Ultimately, though, it is the enzyme activity in vivo (i.e. the phenotype) rather than the 
genotype that dictates whether a particular CYP-substrate is effectively metabolised or not. 
Therefore, environmental factors known to affect CYP activity, such as diet, should also be 
investigated when aiming to explore variability in response to medicines between 
geographic ancestries.   
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Table 1.8: Important CYP SNPs, their details, effects and frequencies in European and 
South Asian populations. Data sourced from the 1000 Genome Project 
(http://www.internationalgenome.org) (Auton et al., 2015). 
CYP allele designation (rs no.) [SNP] | function Genotype frequency (count) 
CYP1A2*1C (rs2069514) [−3860G>A] | ↓ inducibility GG AA AG 
European 0.960 (483) Nil 0.040 (20) 
South Asian 0.847 (414) 0.006 (3) 0.147 (72) 
CYP1A2*1F (rs762551) [−163C>A] | ↑ inducibility CC AA AC 
European 0.115 (58) 0.475 (239) 0.410 (206) 
South Asian 0.227 (111) 0.297 (145) 0.476 (233) 
CYP2C19*1C (rs3758581) [80161A>G] | undetermined GG AA AG 
European 0.865 (435) 0.002 (1) 0.133 (67) 
South Asian 0.787 (385) 0.006 (3) 0.207 (101) 
CYP2C19*2 (rs4244285) [19154G>A] | null allele GG AA AG 
European 0.722 (363) 0.012 (6) 0.266 (134) 
South Asian 0.436 (213) 0.151 (74) 0.413 (202) 
CYP2C19*3 (rs4986893) [17948G>A] | null allele GG AA AG 
European 1.000 (503) Nil Nil 
South Asian 0.975 (477) Nil 0.025 (12) 
CYP2C19*17 (rs12248560) [−806C>T] | ↑ activity CC TT CT 
European 0.596 (300) 0.044 (22) 0.360 (181) 
South Asian 0.753 (368) 0.025 (12) 0.223 (109) 
CYP2C9*2 (rs1799853) [3608C>T] | ↓ activity CC TT CT 
European 0.773 (389) 0.022 (11) 0.205 (103) 
South Asian 0.933 (456) 0.002 (1) 0.065 (32) 
CYP2C9*3 (rs1057910) [42614A>C] | ↓↓ activity AA CC AC 
European 0.857 (431) 0.002 (1) 0.141 (71) 
South Asian 0.787 (385) 0.006 (3) 0.207 (101) 
CYP2D6*3 (rs35742686) [2549delA] | null allele TT -T -- 
European 0.968 (487) 0.026 (13) 0.006 (3) 
South Asian 0.996 (487) 0.004 (2) Nil 
CYP2D6*4 (rs3892097) [100C>T] | null allele CC TT CT 
European 0.674 (339) 0.046 (23) 0.280 (141) 
South Asian 0.806 (394) 0.025 (12) 0.170 (83) 
CYP2D6*6 (rs5030655) [1707delT] | null allele AA -A -- 
European 0.960 (483) 0.040 (20) Nil 
South Asian 0.998 (488) 0.002 (1) Nil 
CYP2D6*10 (rs1065852) [4180G>C] | ↓ activity GG AA AG 
European 0.646 (325) 0.050 (25) 0.304 (153) 
South Asian 0.710 (347) 0.039 (19 0.252 (123) 
CYP2D6*17 (rs28371706) [1023C>T]; (rs16947) [2850C>T] | 
↓ activity 
rs28371706 
 GG AA AG 
European 0.996 (501) Nil 0.004 (2) 
South Asian 1.000 Nil Nil 
 rs16947 
 GG AA AG 
European 0.461 (232) 0.147 (74) 0.392 (197) 
South Asian 0.427 (209) 0.151 (74) 0.421 (206) 
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CYP allele designation (rs no.) [SNP] | function Genotype frequency (count) 
CYP2D6*41 (rs28371725) [2988G>A] | ↓ activity CC TT CT 
European 0.827 (416) 0.014 (7) 0.159 (80) 
South Asian 0.779 (381) 0.022 (11) 0.198 (97) 
CYP3A4*1B (rs2740574) [−392A>G] | undetermined TT CC CT 
European 0.946 (476) 0.002 (1) 0.052 (26) 
South Asian 0.922 (451) 0.002 (1) 0.076 (37) 
CYP3A4*22 (rs35599367) [15389 C>T] | ↓ activity GG AA AG 
European 0.903 (454) 0.002 (1) 0.095 (48) 
South Asian 0.988 (483) Nil 0.012 (6) 
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1.8.2 Differences in diet and CYP activity between Europeans and South Asians 
One of the largest cross-sectional observational studies to investigate how diet, genetics 
and CYP1A2 activity vary between Europeans and South Asians was conducted by Perera et 
al. (2012a). In this study, median CYP1A2 activity was 29% higher in the European cohort 
compared to the South Asians. This was attributed to different frequencies of diets known 
to affect CYP1A2 activity, namely those high in foods that induce or inhibit the CYPs (see 
section 1.7). Heavy consumption of CYP1A2 inducer foods was relatively higher in the 
Europeans, whereas heavy inhibitor consumption was more prevalent in the South Asians. 
Further, a predominantly curry diet was more frequent in the South Asian ancestry group. 
Indian curries contain foods known to inhibit CYP1A2, such as turmeric, celery, cumin and 
dill (Lampe et al., 2000b; Peterson et al., 2006; Peterson et al., 2009), which could explain 
some of this variability in enzyme activity between the ancestry groups. 
Studies like this are rare, with this one being unique in the sense that it was the first 
observational study to simultaneously investigate genetics, diet and CYP activity in 
Europeans and South Asians. Importantly, these observational results have not yet been 
confirmed in a follow-up, controlled, crossover trial, nor have the other four main CYP 
enzymes been investigated in this context. Because the CYPs share so many overlapping 
molecular regulatory mechanisms, it is likely that factors affecting CYP1A2 also affect the 
activities of CYP2C19, CYP2C9, CYP2D6 and CYP3A4 (Zanger & Schwab, 2013). These 
potential avenues of enquiry were used to form the thesis objectives in the following 
section of this thesis.  
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1.9 Thesis objectives and outline 
Chapter 1 has summarised and discussed the published literature surrounding variability in 
response to medicines and the tools required to measure and explore this variability. 
Ultimately, a growing understanding of this observed variability is needed to produce better 
patient outcomes by providing new ways to account for intra- and inter-patient differences 
in the efficacy and safety of drugs. 
In this context, the importance of the CYP superfamily of drug-metabolising enzymes was 
discussed in detail, alongside the importance of several key phase II drug-metabolising 
enzymes. Further, the way in which diet affects these enzymes was discussed, with a focus 
on how cruciferous vegetables and their constituents induce and inhibit drug-metabolising 
enzymes. The concept of geographic ancestry as a collection of known (and unknown) 
intrinsic and extrinsic factors affecting response to medicines was introduced, and the 
relevant background for European and South Asian ancestries was covered. It was identified 
that relatively few studies have investigated how diet and genetics interact between and 
within ancestry groups such as Europeans and South Asians, and a need for more studies in 
this area was commented on. 
Before hypotheses can be constructed that examine ancestral differences in CYP enzyme 
activity, the literature must be searched systematically to identify what has already been 
studied, how well these studies were designed and where gaps in the literature exist. 
Therefore, apart from the objectives of Chapter 1 (above), the first main objective of this 
thesis was, for the first time, to conduct a systematic review of all published cruciferous 
vegetable intervention trials with drug metabolism endpoints. The sub-objectives of this 
review are stated in the introduction of Chapter 2, but ultimately, results from this review 
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were used to generate hypotheses that aimed to investigate the relationships between diet, 
genetics, geographic ancestry and drug metabolism. 
Further, before such hypotheses can be tested, appropriate bioanalytical methods must be 
designed, validated and optimised to ensure timely analysis of participant samples. The CYP 
phenotyping cocktail approach was introduced in section 1.6.1 as a technique with 
increasing popularity in pharmacokinetic phenotyping studies. However, these assays are 
complex and resource intensive, often with cumbersome, time-consuming methods. 
Therefore, the second main objective of this thesis was to design, validate and optimise a 
UHPLC-MS/MS CYP-phenotyping cocktail assay that was relatively simple, sensitive and 
high-throughput compared to similar assays. This process is described, reported and 
discussed in Chapter 3. 
Similarly, a bioanalytical method was required to measure sulforaphane, a candidate 
isothiocyanate affecting changes in CYP activity, in a biological matrix. Previously published 
methods have long chromatographic run times, require large sample volumes and have 
complicated sample extraction procedures (discussed in section 4.4). Therefore, the third 
main objective of this thesis was to design, validate and optimise a UHPLC-MS/MS assay to 
measure sulforaphane in human plasma that was relatively simple, sensitive and high-
throughput compared to similar assays. 
Lastly, the hypotheses generated in Chapter 2 were tested through designing and 
conducting a dietary intervention trial in Europeans and South Asians. The sub-objectives of 
this trial are outlined in section 5.1, however in short, for the first time, this trial aimed to 
explore the effects of cruciferous vegetable consumption, other dietary components, 
genetics and geographic ancestry on the activities of CYP1A2, CYP2C19, CYP2C9, CYP2D6 
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and CYP3A4. Because these five CYP enzymes contribute to the metabolism of the majority 
of medicines used in humans, factors that affect their activity significantly contribute to 
variability in response to medicines. Therefore, exploring the way in which diet, genetics, 
and European and South Asian ancestries interact with these drug-metabolising enzymes 
will aid in better understanding variability in response to medicines, and in turn, contribute 
to the safer and more efficacious use of drugs in these populations. 
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2 The effects of cruciferous vegetable-enriched diets on drug 
metabolism: a systematic review and meta-analysis of dietary 
intervention trials in humans 
2.1 Introduction 
As discussed in section 1.1, variability in response to medicines has a significant impact on 
the clinical outcomes of drug therapy. Ultimately, a complex interplay of intrinsic and 
extrinsic factors explains why individuals respond differently when given the same dose of 
the same medicine (section 1.1.1). Studies in this area aim to explore differences in the 
expression and activity of drug-metabolising or drug-transporter proteins, as these proteins 
significantly contribute to the clearance of a drug, and therefore influence its systemic 
exposure (Yasuda et al., 2008). Variability in the genes that encode these enzymes and 
transporters has been identified as a major source of inter-individual differences in systemic 
drug exposure (Bjornsson et al., 2003). 
Section 1.7.1 outlined the effects of cruciferous vegetables or their constituents, which are 
an important portion of many people’s diets, on drug-metabolising activity in humans. 
Cruciferous vegetables contain isothiocyanates (ITCs), which are phytochemicals considered 
to cause the enzyme induction and inhibition observed after eating Cruciferae-enriched 
diets (Steinkellner et al., 2001). Phenethyl isothiocyanate (PEITC) and sulforaphane (SFN) are 
the two most widely studied ITCs (Lamy et al., 2011). In general, the ingestion of cruciferous 
vegetables is associated with induction of cytochrome P450 (CYP) 1A2 activity in vivo 
(Perera et al., 2012a), however there is contention between findings, and the clinical 
significance of the potential diet-drug interactions remains uncertain. 
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Chapter 2 outlines the methods, results, discussion and conclusions of a systematic review 
which aimed to 1) systematically review dietary intervention trials in humans that 
investigated the effects of cruciferous vegetables on drug-metabolising enzymes; 2) critically 
analyse the design of these studies; 3) interpret the findings in the context of study quality; 
4) where possible, conduct meta-analyses on the collected data to determine the size and 
significance of any Cruciferae-induced changes in drug metabolism; and 5) use this 
information to generate hypotheses which examine the interactions between diet, 
geographic ancestry, genetics and drug metabolism. 
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2.2 Methods 
2.2.1 Databases and searches 
The Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (Higgins & 
Green, 2011) was used to guide the design of the methodology of this review. Medline, 
Embase and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched 
from their earliest entries through to July 2017 via the Ovid platform (Wolters Kluwer, 
2017). Search terms and the strategies used for each database are listed in Appendix 8.1. 
The reference lists from potentially relevant studies were hand-searched to identify 
additional dietary intervention trials. The search was limited to studies published in English. 
Study abstracts were screened for potential relevance by one author and two authors 
independently assessed the published papers for eligibility as per Section 2.2.2. Any 
differences were discussed until agreement was reached. 
2.2.2 Assessment of study eligibility 
Studies were deemed eligible if they included healthy volunteers or patients, implemented a 
dietary intervention which involved cruciferous vegetables and had a pharmacokinetic 
phenotyping metric as an endpoint. A phenotyping metric was defined as an index derived 
from the administration of an enzyme-specific probe drug or substrate followed by 
measurement of the concentration of the parent compound and/or metabolite(s) in a 
biological matrix (plasma, urine, saliva, etc.). Studies using endogenous markers (e.g. 
conjugated/unconjugated bilirubin as a probe for UDP-glucuronosyltransferase (UGT) 
activity) were also included. Interventions involving cruciferous vegetable extracts and/or 
their phytochemical isolates were excluded. Observational, cross-sectional studies were not 
included in this review. 
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2.2.3 Data extraction and study quality assessment 
Data that were gathered included: number of subjects/place of study participant 
demographics; the drug-metabolising enzymes studied; the size and nature of any changes 
in enzyme activity following cruciferous vegetable consumption; duration and details of the 
dietary intervention; number of dietary intervention periods tested; and the type of study 
design (randomised crossover, non-randomised crossover or parallel). For reported 
pharmacokinetic metrics, point estimates and descriptive statistics were extracted using a 
uniform data extraction sheet (Appendix 8.2) and checked by a second author. In the event 
that numeric point estimates were not available, data were extracted from figures and 
graphs using WebPlotDigitizer (http://arohatgi.info/WebPlotDigitizer/app). Where data 
were available and computation/imputation was possible, the size, variability and 
significance of enzyme activity changes following dietary interventions involving cruciferous 
vegetable between studies were calculated. 
Several methodological characteristics were taken into consideration when assessing the 
quality of each study. Selected guidelines from the Consolidated Standards of Reporting 
Trials (CONSORT) statement (Schulz et al., 2010), the CONSORT Explanation and Elaboration 
document (Altman et al., 2001) and criteria outlined by Mills et al. (2004) were used to 
guide the choice of study characteristics included in the critical analysis. Study 
characteristics indicating higher quality included: study design (with randomised crossover 
being the highest quality followed by non-randomised crossover, then parallel group study 
design); similarity between groups (for designs using more than one group of participants); 
sample size ≥ 10 participants (rationale by Kakuda et al. (2014)); inclusion of a basal control 
diet; kJ- and/or participant weight-standardised diets; appropriate choice of statistical 
analyses, previous/concurrent validation of assay methods; and measures to ensure 
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participant adherence to study protocols, including diet diaries and supervised consumption 
of the intervention diet. 
2.2.4 Statistical analyses 
The methods outlined in the Cochrane Handbook (Higgins & Green, 2011) and those of 
Elbourne et al. (Elbourne et al., 2002) were used to calculate mean differences and their 
standard errors of study endpoints. The upper limits of P-value inequalities were used when 
calculating standard errors of mean differences to ensure that any estimates were 
conservative (e.g. P < 0.05 taken as P = 0.05). Due to most studies recruiting < 60 
participants, appropriate values from the Student’s t-distribution were used in the 
calculation of 95% confidence intervals (CI) for the mean difference between experimental 
and control periods (Higgins & Green, 2011).  
As all but one study used a crossover or pre-test, post-test design, within-subject correlation 
coefficients for endpoints across study periods were necessary to estimate the standard 
deviation of the mean difference between experimental and control periods. Correlation 
coefficients were directly calculated for studies when the individual participant data were 
available (Higgins & Green, 2011), however the majority of studies did not allow for this. For 
CYP1A2, correlation coefficients from the data presented in Chapter 5 were used. Because 
repeated-measures pharmacokinetic data generally display high within-subject correlation 
across study periods in crossover trials (Shen et al., 2006), an average value of 0.8 
(estimated using within-subject correlation data presented in Chapter 5) was used in the 
estimation of the standard deviations of the mean difference for enzymes where calculation 
or imputation of correlation coefficients was not possible. 
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For studies reporting natural log-back-transformed geometric mean ratios of point 
estimates, the method of Higgins et al. (2008) was used to estimate the mean difference 
and its standard error on the non-logarithmic scale. 
Meta-analysis was deemed appropriate for the studies that investigated the effects of 
cruciferous vegetables on metrics of CYP1A2 activity and GST-α. As the studies used a 
variety of pharmacokinetic metrics to represent the activity of these two enzymes, the 
mean differences of endpoints were divided by their pooled standard deviations to allow for 
comparisons across measurement scales (Higgins & Green, 2011). For both enzymes, studies 
were meta-analysed using a random-effects model under the generic inverse-variance 
method in RevMan (Version 5.3). Heterogeneity across meta-analysed trials was formally 
assessed using the Chi2 method as outlined in the Cochrane Handbook (Higgins & Green, 
2011). 
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2.3 Results 
2.3.1 Database search results 
The database searches revealed 3,118 publications that were potentially relevant; this was 
reduced to 2,285 studies after removing duplicates between the databases (Figure 2.1). 
Ninety-one studies were confirmed to be clinical/in vivo after scanning titles and abstracts. 
The full-text of the 91 studies was read, and a further four studies for assessment were 
identified from the publication citations, which were also assessed for eligibility. In total, 23 
cruciferous vegetable dietary intervention trials investigating an impact on drug metabolism 
in humans were included in this systematic review (Table 2.1). 
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Figure 2.1: Flow diagram of study identification and selection processes with subtotals. 
 
 
Database search results 
CENTRAL: n = 21 
Embase: n = 1,852 
Medline: n = 1,245 
 
Total: n = 3,118 
Identified as potentially relevant based 
on title and abstract  
n = 91 
+ 
Scan of references  
n = 4 
 
Studies meeting inclusion criteria based 
on full text 
n = 23 
Duplicates 
n = 833 
Articles screened 
n = 2,285 
Excluded based on title and abstracts 
n = 2,194 
Excluded based on full text 
n = 72 
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Table 2.1: Drug-metabolising enzymes, probe drugs and phenotyping metrics represented in the literature by publication 
 
Study 
Sample size 
(n)1 
Enzymes Probe drugs (dose) Phenotyping metric2 
Mean difference in metric 
(95% CI)3 
de Waard et al. (2008) 6 
CYP1A2 
CYP2A6 
NAT2 
XO 
Caffeine (2 cups of tea or 1 cup of coffee) CYP1A2: (AFMU + 1X + 1U)/17U  
CYP2A6: 17U/(17U + 17X + 1U+ 1X+ AFMU) 
NAT2: AMFU/1X 
XO: 1U/(1U + 1X) 
0.99 (0.78, 1.19)a 
1.07 (0.93, 1.20)a 
1.01 (0.66, 1.36)a 
0.96 (0.90, 0.99)a 
Hakooz and Hamdan 
(2007) 
10 
CYP1A2 
CYP2A6 
Caffeine (100 mg) CYP1A2: (17U + 17X)/137X 
CYP2A6: 17U/(17U + 17X + 1U+ 1X+ AFMU) 
20.2 (10.4, 30.0) 
0.10 (0.06, 0.14) 
Kall et al. (1996) 16 
CYP1A2 
CYP2E1 
Caffeine (100 mg) 
Chlorzoxazone (500 mg) 
(AFMU + 1X + 1U)/17U 
2-h hydroxychlorzoxazone/chlorzoxazone plasma 
concentration 
1.19 (0.65, 1.73) 
0.07 (-0.03, 0.18) 
Lampe et al. (2000b) 36 
CYP1A2 
NAT 
XO 
Caffeine (200 mg) CYP1A2: (AFMU + 1X + 1U)/17U 
CYP1A2: (AFMU + 1X + 1U)/17X 
CYP1A2: (17U + 17X)/137X 
CYP1A2:17X/137X 
NAT: AFMU/(1X + 1U + AFMU) 
XO: 1U/(1U + 1X) 
0.97 (0.82, 1.12) 
0.006 (0.00, 0.01) 
1.00 (0.75, 1.25) 
0.99 (0.76, 1.22) 
0.00 (-0.02, 0.02) 
0.00 (-0.01, 0.01) 
McDanell et al. (1992) 6 
CYP1A2 Study 1: Caffeine (2 g Nescafe® in 200 mL 
water) 
Study 2: Caffeine (1 g Nescafe® in 100 mL 
water) 
Study 1: Caffeine AUC 
Caffeine MCR (dose/AUC) 
 
Study 2: Caffeine AUC 
Caffeine MCR (dose/AUC) 
55.0 (26.3, 83.7) 
-0.03 (-0.05, -0.01) 
 
53.0 (-42.7, 149) 
-0.02 (-0.05, 0.01) 
Murray et al. (2001) 20 
CYP1A2 Caffeine (2 mg/kg dissolved in decaffeinated 
coffee) 
Caffeine CL 
AUC0-∞ 
6.10 (2.81, 9.39) 
-0.15 (-0.07, 0.09) 
Pantuck et al. (1984) 10 
CYP1A2 
UGT1A9 
UGT1A6 
Antipyrine (1.8 mg/kg) 
Phenacetin (900 mg) 
Antipyrine CL 
Phenacetin AUC 
4-h conjugated/unconjugated APAP 
0.35 (0.17, 0.53) 
-2,565 (-3,514, -1,617) 
0.52 (0.16, 0.88) 
Peterson et al. (2009) 73 
CYP1A2 Caffeine (200 mg) (AFMU + 1X + 1U)/17U 0.39 (0.18, 0.61) 
Vistisen et al. (1992) 9 
CYP1A2 
NAT 
XO 
Caffeine (1-4 cups of coffee) CYP1A2: (AFMU + 1X + 1U)/17U  
NAT: AFMU/1X or AFMU/(1U + 1X + 17U) 
XO: 1U/(1U + 1X) 
0.35 (-0.45, 1.14) 
0.06 (-0.24, 0.36) 
0.01 (-0.07, 0.09) 
Murphy et al. (2001) 15 
CYP2A6 Coumarin (5 mg) Urine 7-hydroxycoumarin concentration 0.00 (-0.28, 0.28) 
Desager et al. (2002) 9 
CYP2E1 Ethanol (0.5 g/kg in cold water) Ethanol AUC0-3.33 
Acetaldehyde AUC0-3.33 
-2.45 (-6.27, 1.37) 
2.94 (0.30, 5.58) 
53 
 
Study 
Sample size 
(n)1 
Enzymes Probe drugs (dose) Phenotyping metric2 
Mean difference in metric 
(95% CI)3 
Leclercq et al. (1998) 10 
CYP2E1 Chlorzoxazone (500 mg) Chlorzoxazone AUC0-∞ 
Chlorzoxazone CL 
Hydroxychlorzoxazone AUC0-∞ 
24.2 (12.8, 35.7) 
-0.91 (-1.34, -0.48) 
1.10 (-1.92, 4.12) 
Chen et al. (1996) 10 
CYP2E1 
(indirect) 
UGT1A9 
UGT1A6 
SULT1A1 
SULT2A1 
Paracetamol (1 g) APAP CL 
APAP AUC 
APAPG AUC 
APAPS AUC 
APAPC AUC 
APAPM AUC 
-0.50 (-1.14, 0.14) 
0.10 (-1.62, 1.82) 
14.7 (3.76, 25.6) 
2.20 (-4.52, 8.92) 
-0.70 (-1.13, -0.27) 
-0.18 (-0.22, -0.14) 
Bogaards et al. (1994) 10 
GST-α n/a Plasma concentration of enzyme 212 (100, 324) 
Lampe et al. (2000a) 43 
GST-α NBD-Cl (200 μM) 
CDNB (1.22 µM) 
Serum concentration of enzyme 
NBD-Cl extinction coefficient 
CDNB extinction coefficient 
386 (-35.8, 807.35) 
2.21, (-0.78, 5.21) 
0.22 (-0.20, 0.64) 
 
Navarro et al. (2009a) 67 
GST-α n/a Serum concentration of enzyme 327 (0.59, 653) 
Nijhoff et al. (1995) 10 
GST-α 
GST-π 
n/a GST-α: Plasma concentration of enzyme 
 
GST-α: Urine concentration of enzyme 
 
GST-π: Plasma concentration of enzyme 
 
GST-π: Urine concentration of enzyme 
 
 
0.30 (0.04, 0.56) (males) 
-0.04 (-0.14, 0.06) (females) 
0.07 (0.01, 0.13) (males) 
-0.03 (-0.08, 0.02) (females) 
0.42 (-0.83, 1.67) (males) 
0.21 (-0.67, 1.09) (females) 
0.11 (0.05, 0.17) (males) 
0.03 (-0.09, 0.15) (females) 
Riso et al. (2009) 20 
GST-α CDNB (20 mM) Formation of NBD-Cl -4.00 (-10.4, 2.39) 
Riso et al. (2014) 10 
GST-α CDNB (20 mM) Formation of NBD-Cl 8.80 (-4.51, 22.1) 
Chang et al. (2007) 
UGT1A1*6/*6: 26 
UGT1A1*6/*7: 23 
UGT1A1*7/*7: 14 
UGT1A1 Bilirubin (endogenous) UGT1A1*6/*6: serum total bilirubin 
UGT1A1*6/*6: serum indirect bilirubin 
UGT1A1*6/*6: serum direct bilirubin 
UGT1A1*6/*7: serum total bilirubin 
UGT1A1*6/*7: serum indirect bilirubin 
UGT1A1*6/*7: serum direct bilirubin 
UGT1A1*7/*7: serum total bilirubin 
UGT1A1*7/*7: serum indirect bilirubin 
UGT1A1*7/*7: serum direct bilirubin 
0.72 (-0.27, 1.71 
0.65 (-0.25, 1.55) 
0.80 (-0.05, 0.21) 
-0.76 (-1.97, 0.45) 
-0.72 (-1.82, 0.38) 
-0.04 (-0.20, 0.12) 
-3.49 (-7.10, 0.12) 
-3.34 (-6.70, 0.02) 
0.19 (-0.15, 0.53) 
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Study 
Sample size 
(n)1 
Enzymes Probe drugs (dose) Phenotyping metric2 
Mean difference in metric 
(95% CI)3 
Navarro et al. (2009b) 
UGT1A1*1/*1: 29 
UGT1A1*1/*28: 36 
UGT1A1*28/*28: 5 
UGT1A1 Bilirubin (endogenous) UGT1A1*1/*1: serum total bilirubin 
UGT1A1*1/*28: serum total bilirubin 
UGT1A1*28/*28: serum total bilirubin 
-1.03 (-2.06, -0.01) 
-0.17 (-2.15, 1.81) 
-3.42 (-6.84, -0.01) 
Navarro et al. (2011) 
Overall: 65 
UGT1A6*1/*1: 27 
UGT1A6*1/*2: 25 
UGT1A6*2/*2: 13 
UGT2B15*1/*1: 16 
UGT2B15*1/*2: 33 
UGT2B15*2/*2: 17 
Overall: 65 
UGT1A6*1/*1: 27 
UGT1A6*1/*2: 25 
UGT1A6*2/*2: 13 
UGT2B15*1/*1: 16 
UGT2B15*1/*2: 33 
UGT2B15*2/*2: 17 
UGT1A6 
UGT2B15 
SULT1A1 
SULT2A1 
Paracetamol (1 g) Overall: APAPG ratio 
UGT1A6*1/*1: APAPG ratio 
UGT1A6*1/*2: APAPG ratio 
UGT1A6*2/*2: APAPG ratio 
UGT2B15*1/*1: APAPG ratio 
UGT2B15*1/*2: APAPG ratio 
UGT2B15*2/*2: APAPG ratio 
Overall: APAPS/APAP 
UGT1A6*1/*1: APAPS/APAP 
UGT1A6*1/*2: APAPS/APAP 
UGT1A6*2/*2: APAPS/APAP 
UGT2B15*1/*1: APAPS/APAP 
UGT2B15*1/*2: APAPS/APAP 
UGT2B15*2/*2: APAPS/APAP 
2.70 (1.18, 4.22) 
3.20 (0.01, 6.40) 
2.60 (0.01, 5.20) 
2.30 (0.01, 4.60) 
4.60 (0.01, 9.20) 
2.10 (0.01, 4.20) 
2.20 (0.01, 4.40) 
-1.10 (-1.48, -0.52) 
-0.90 (-1.80, -0.01) 
-0.80 (-1.60, -0.01) 
-1.10 (-2.20, -0.01) 
-0.80 (-1.70, 0.10) 
-1.20 (-1.81, -0.59) 
-0.70 (-1.64, 0.24) 
Pantuck et al. (1984) 10 
UGT1A9 
UGT1A6 
UGT2B7 
UGT2B15 
SULT1A1 
SULT2A1 
Paracetamol (1.5 g) 
Oxazepam (45 mg) 
APAP plasma AUC  
APAP CL  
APAPG plasma AUC  
APAPS plasma AUC  
Oxazepam plasma AUC  
Oxazepam CL  
Oxazepam glucuronide plasma AUC 
-14.8 (-29.6, -0.01) 
2.90 (0.01, 5.80) 
-13.2 (-20.1, -6.35) 
-20.5 (-41.0, -0.01) 
-1,438 (-2,876, -0.01) 
1.10 (0.01, 2.20) 
-260 (-613, 92.9) 
1 Total sample size as reported in publication or by subgroup where appropriate. 
2 Abbreviations (as listed in column from top): AFMU, 5-acetylamino-6-formylamino-3-methyluracil; 1X, 1-methylxanthine; 1U, 1-methyluric acid; 17U, 1,7-dimethyluric acid; 17X, 1,7-
dimethylxanthine (paraxanthine); 137X, 1,3,7-trimethylxanthine (caffeine); t1/2, elimination half-life; CL, clearance; AUC, area under concentration-time curve; 4-h, 4-hour post-dose; APAP, N-
acetyl-p-aminophenol (paracetamol); AUC0-∞, AUC from time 0 extrapolated to infinity; MCR, metabolic clearance (dose/AUC); APAPG, paracetamol glucuronide; APAPS, paracetamol sulfate; 
APAPC, paracetamol cysteine; APAPM, paracetamol mercapturate; NBD-Cl, 7-chloro-4-nitrobenz-2-oxa-1,3-diaxole; CDNB,  1-chloro-2,4-dinitrobenzene; APAPG ratio, [APAPG/(APAP + APAPG 
+ APAPS)] x 100. 
3 The 95% confidence interval (CI) of the mean difference between experimental and control measures of enzyme activity (metricexperimental – metriccontrol) was estimated using the standard 
error of the mean difference and relevant values from the Student’s t-distribution. Mean difference and standard error are as reported in the literature, extracted from data using a web-
based digitiser programme ((http://arohatgi.info/WebPlotDigitizer/app) or calculated/imputed as outlined in the Methods section, unless otherwise stated. 
a Data are ratio of metricexperimental/metriccontrol with 95% CI as reported in the manuscript. 
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2.3.2 Nature of cruciferous vegetable dietary interventions 
Cruciferous vegetables used in the eligible dietary intervention studies reported included 
broccoli, Brussels sprout, cabbage, cauliflower, radish and watercress. All studies reported 
standardised preparation and weighing of any cruciferous vegetables consumed. Methods 
of preparing these vegetables included steaming, boiling, stir-frying and raw consumption, 
however, not all studies instructed participants to cook the vegetables in the same manner, 
with some leaving this decision to the participants (Hakooz & Hamdan, 2007; Kall et al., 
1996), and other studies not reporting this information (Chang et al., 2007; Lampe et al., 
2000b; Nijhoff et al., 1995; Peterson et al., 2009). Studies with controlled crossover designs 
included a washout period of at least 7 days between diets or between phenotyping 
sessions, with most allowing at least a 2- or 4-week washout. Table 2.2 summarises the 
types of dietary interventions and the cruciferous vegetables studied, alongside details of 
their preparation, consumption and any steps to standardise preparation. 
2.3.3 Drug-metabolising enzymes and probe drugs assessed 
The drug-metabolising enzymes investigated were CYP1A2 (n = 9) (de Waard et al., 2008; 
Hakooz & Hamdan, 2007; Kall et al., 1996; Lampe et al., 2000b; McDanell et al., 1992; 
Murray et al., 2001; Pantuck et al., 1979; Peterson et al., 2009; Vistisen et al., 1992), CYP2A6 
(n = 3) (de Waard et al., 2008; Hakooz & Hamdan, 2007; Murphy et al., 2001), CYP2E1 (n = 3) 
(Chen et al., 1996; Desager et al., 2002; Leclercq et al., 1998), glutathione S-transferase 
(GST)-α (n = 6) (Bogaards et al., 1994; Lampe et al., 2000a; Navarro et al., 2009a; Nijhoff et 
al., 1995; Riso et al., 2009; Riso et al., 2014), GST-π (n = 1) (Nijhoff et al., 1995), UDP-
glucuronosyltransferase (UGT)1A1 (n = 2) (Chang et al., 2007; Navarro et al., 2009b), 
UGT1A6 (n = 4) (Chen et al., 1996; Navarro et al., 2011; Pantuck et al., 1984; Pantuck et al., 
1979), UGT1A9 (n = 3) (Chen et al., 1996; Pantuck et al., 1984; Pantuck et al., 1979), 
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UGT2B15 (n = 2) (Navarro et al., 2011; Pantuck et al., 1984), UGT2B7 (n = 1) (Pantuck et al., 
1984), N-acetyl transferase (NAT)2 (n = 3) (de Waard et al., 2008; Lampe et al., 2000b; 
Vistisen et al., 1992), sulfotransferase (SULT)1A1 (n = 3) (Chen et al., 1996; Navarro et al., 
2011; Pantuck et al., 1984), SULT2A1 (n = 3) (Chen et al., 1996; Navarro et al., 2011; Pantuck 
et al., 1984) and xanthine oxidase (XO) (n = 3) (de Waard et al., 2008; Lampe et al., 2000b; 
Vistisen et al., 1992) (Figure 2.2). The number of investigations (n = 46) was greater than the 
number of studies included in the review (n = 23) as some studies simultaneously 
investigated multiple drug-metabolising enzymes.  
The phenotyping probe drugs and metrics studied for each enzyme are listed in Table 2.1. 
Probe substrates used to investigate the enzymes were: caffeine for CYP1A2, CYP2A6, NAT2 
and XO activity; ethanol or chlorzoxazone for CYP2E1 activity; paracetamol for UGT1A6, 
UGT1A9, UGT2B15, SULT1A1 and SULT2A1 activity; oxazepam for UGT2B7 and UGT2B15 
activity; 1-chloro-2,4-dinitrobenzene or amount of enzyme for GST-α activity; and 
endogenous bilirubin for UGT1A1 activity. The phenotyping metrics used varied between 
studies, including metabolite-parent substrate ratios of relevant pharmacokinetic 
parameters (e.g. AUC or concentration at a particular time post-dose), changes in clearance, 
AUC or half-life of substrates.  
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Table 2.2: Details of the various Cruciferous vegetable dietary interventions by publication. 
Study 
Cruciferous 
vegetables consumed 
(amount/day)) 
Intervention details Preparation of diet Notes 
Bogaards et 
al. (1994) 
Brussels sprouts (300 
g) 
Two diets: basal (control) and Brussels sprouts. 
Diets consumed daily for 7 days each with no washout 
period before crossover. 
Not stated. Basal diet was “glucosinolate free” but further 
details not provided. 
Chang et al. 
(2007) 
Broccoli (100 g) 
Cabbage (35 g) 
Daikon radish sprouts 
(16 g) 
 
Dose adjusted per 55 
kg body weight 
Two diets: basal (control) and fruit and vegetable diet. 
Diets consumed daily for 2 weeks each with 2-week washout 
period before crossover. 
Not stated. Amount of cruciferous vegetables given 
standardised to a 55-kg body weight then 
adjusted for each participant to nearest 5 kg 
increment in body weight. 
Diets designed to contain 56% carbohydrate, 
16% protein and 28% fat overall. 
Study diets contained other fruit and 
vegetables alongside crucifers. 
Chen et al. 
(1996) 
Watercress (50 g) Two diets: habitual diet and watercress. 
Habitual diet followed throughout, with watercress 
consumed either at 10 pm night before phenotyping or not 
at all with a 2-week washout period before crossover 
(randomised crossover). 
Watercress consumed as a homogenate made by 
blending with 50 mL water for 2-3 minutes. 
 
de Waard et 
al. (2008) 
Broccoli (150 g) 
Brussels sprouts (300 
g) 
Two diets: grapefruit juice then cruciferous (sequential). 
Diets consumed daily for 3 days each with 3-week washout 
period. 
Broccoli prepared as a soup and Brussels sprouts 
served as part of a meal.  
Cruciferous vegetables and citrus fruits were 
avoided during the washout period. 
Desager et 
al. (2002) 
Watercress (50 g) Two diets: habitual diet and watercress. 
Habitual diet followed throughout with a standardised 
breakfast before each round of phenotyping. 
Watercress consumed either at 10 pm night before 
phenotyping, 7:30 am morning of phenotyping or not at all 
(randomised crossover). 
Watercress consumed as a homogenate made by 
blending with 250 mL water for 2 minutes. 
Standardised breakfast included 100 g bread, 
chocolate paste and 150 mL coffee. 
Hakooz and 
Hamdan 
(2007) 
Broccoli (500 g) One diet: broccoli (sequential) 
Broccoli consumed daily for 6 days. 
No details of washout period 
Broccoli eaten raw with salad and dressing, steamed, 
microwaved or boiled (participant’s preference). 
Broccoli added to participant’s normal diet. 
Kall et al. 
(1996) 
Broccoli (500 g) Three diets: basal (control), cruciferous-devoid then broccoli 
(sequential). 
Diets consumed daily for: 2 days (basal), 6 days (cruciferous-
devoid) and 12 days (broccoli)  
No washout period. 
Broccoli distributed evenly between lunch and 
dinner; lunch-broccoli eaten raw with bread and a 
pasta salad and dinner-broccoli either steamed, 
microwaved or boiled (participant’s choice). 
Basal diet based on bread, potatoes, rice and 
boiled meat. 
Lampe et al. 
(2000a) 
Radish sprouts (16 g) 
Cauliflower (150 g) 
Broccoli (200 g) 
Cabbage (70 g) 
Four diets: basal (control), cruciferous, allium and apiaceous. 
Diets consumed daily for 6 days 
2-week washout period. 
Not stated. Diets designed to deliver 2,000 kcal as 60% 
carbohydrate, 12% protein and 28% fat 
overall. 
‘Unit foods’ added to basal diet to maintain 
body weights of participants based on daily kJ 
requirements.  
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Study 
Cruciferous 
vegetables consumed 
(amount/day)) 
Intervention details Preparation of diet Notes 
Lampe et al. 
(2000b) 
Radish sprouts (16 g) 
Cauliflower (150 g) 
Broccoli (200 g) 
Cabbage (70 g) 
Four diets: basal (control), cruciferous, allium and apiaceous. 
Diets consumed daily for 6 days with 
2-week washout period  
Not stated. Diets designed to deliver 2,000 kcal as 60% 
carbohydrate, 12% protein and 28% fat 
overall. 
‘Unit foods’ added to basal diet to maintain 
body weights of participants based on daily kJ 
requirements.  
Leclercq et 
al. (1998) 
Watercress (50 g) Two diets: habitual diet and watercress. 
Habitual diet followed throughout with a standardised 
breakfast before each round of phenotyping. 
Watercress consumed either at 10 pm night before 
phenotyping, 7:30 am morning of phenotyping or not at all 
(randomised crossover). 
Watercress consumed as a homogenate made by 
blending with 250 mL water for 2 minutes. 
Standardised breakfast included 100 g bread, 
chocolate paste and 150 mL coffee. 
McDanell et 
al. (1992) 
Brussels sprouts (400 
g) 
Cabbage (800 g) 
Two studies: Study 1—basal (control) diet plus 200 g 
cabbage eaten for 3 meals in 24 hours; next day at 8:00 am 
basal diet plus 200 g cabbage for breakfast before 
phenotyping (sequential). 
Study 2—basal (control) diet plus 200 g Brussels sprouts 
eaten for 2 meals in 24 hours; phenotyping next morning 
while fasting (sequential). 
Vegetables lightly steamed.  
Murphy et 
al. (2001) 
Watercress (170.4 g) Two diets: habitual diet and watercress (sequential).  
Habitual diet followed for two weeks with three days of 
watercress consumption followed by phenotyping (56.8 g 
three times a day on two occasions and one 56.8 g serving 
immediately before phenotyping on one occasion). 
Watercress consumed fresh and uncooked.  
Murray et al. 
(2001) 
Broccoli (250 g) 
Brussels sprouts (250 
g) 
Three diets: habitual diet, cruciferous then habitual again 
(sequential). 
Diet consumed daily for 12 days  
No washout period. 
Brussels sprouts peeled and broccoli stalks removed. 
Broccoli or Brussels sprouts prepared as a soup for 
breakfast or dinner as part of a 6-day menu plan 
which was repeated during the 12-day cruciferous 
vegetable diet. 
Both soups were consumed each day; the 
vegetable not consumed at breakfast was 
eaten at dinner. 
Navarro et 
al. (2009a) 
Broccoli (203 g) 
Cauliflower (152 g) 
Red cabbage (36 g) 
Green cabbage (36 g) 
Radish sprouts (16 g)  
Dose adjusted per 70 
kg body weight  
Four diets: basal (control), cruciferous, double-cruciferous 
and cruciferous plus apiaceous. 
Diets consumed daily for 14 days  
Each with 3-week washout period. 
Not stated. Diets designed to deliver either 7 g/kg (single-
dose cruciferous and cruciferous plus 
apiaceous) or 14 g/kg (double-dose 
cruciferous) cruciferous vegetables. 
Amount of cruciferous vegetables given 
standardised to a 70-kg body weight then 
adjusted for each participant to nearest 5 kg 
increment in body weight.  
Navarro et 
al. (2009b) 
Broccoli (203 g) 
Cauliflower (152 g) 
Red cabbage (36 g) 
Green cabbage (36 g) 
Radish sprouts (16 g)  
Four diets: basal (control), cruciferous, double-cruciferous 
and cruciferous plus apiaceous. 
Diets consumed daily for 14 days  
Each with 3-week washout period. 
Not stated. Diets designed to deliver either 7 g/kg (single-
dose cruciferous and cruciferous plus 
apiaceous) or 14 g/kg (double-dose 
cruciferous) cruciferous vegetables. 
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Study 
Cruciferous 
vegetables consumed 
(amount/day)) 
Intervention details Preparation of diet Notes 
Dose adjusted per 70 
kg body weight  
Amount of cruciferous vegetables given 
standardised to a 70-kg body weight then 
adjusted for each participant to nearest 5 kg 
increment in body weight.  
Navarro et 
al. (2011) 
Broccoli (203 g) 
Cauliflower (152 g) 
Red cabbage (36 g) 
Green cabbage (36 g) 
Radish sprouts (16 g)  
Dose adjusted per 70 
kg body weight  
Four diets: basal (control), cruciferous, double-cruciferous 
and cruciferous plus apiaceous. 
Diets consumed daily for 14 days  
Each with 3-week washout period. 
Not stated. Diets designed to deliver either 7 g/kg (single-
dose cruciferous and cruciferous plus 
apiaceous) or 14 g/kg (double-dose 
cruciferous) cruciferous vegetables. 
Amount of cruciferous vegetables given 
standardised to a 70-kg body weight then 
adjusted for each participant to nearest 5 kg 
increment in body weight.  
Nijhoff et al. 
(1995) 
Brussels sprouts (300 
g) 
Two diets: basal (control) and Brussels sprouts. 
Diets consumed daily for 7 days each with no washout 
period before crossover. 
Not stated. Basal diet was “glucosinolate free” but further 
details not provided. 
Pantuck et 
al. (1979) 
Brussels sprouts (300 
g) 
Cabbage (200 g) 
Three diets: basal (control), cruciferous then basal again 
(sequential). 
Diets consumed daily for 10 days 
No washout period. 
Vegetables lightly steamed and distributed evenly 
between lunch and dinner. 
Diets designed to deliver 2,500-2,600 kcal 
with 60% carbohydrate, 12% protein and 28% 
fat overall. 
 
Pantuck et 
al. (1984) 
Brussels sprouts (300 
g) 
Cabbage (200 g) 
Three diets: basal (control), cruciferous then basal again 
(sequential). 
Diets consumed daily for 10 days 
No washout period. 
Vegetables lightly steamed and distributed evenly 
between lunch and dinner. 
Diets designed to deliver 2,500-2,600 kcal 
with 60% carbohydrate, 12% protein and 28% 
fat overall. 
Peterson et 
al. (2009) 
Broccoli (203 g) 
Cauliflower (152 g) 
Red cabbage (36 g) 
Green cabbage (36 g) 
Radish sprouts (16 g)  
Dose adjusted per 70 
kg body weight  
Four diets: basal (control), cruciferous, double-cruciferous 
and cruciferous plus apiaceous. 
Diets consumed daily for 14 days  
with 3-week washout period. 
Not stated. Diets designed to deliver either 7 g/kg (single-
dose cruciferous and cruciferous plus 
apiaceous) or 14 g/kg (double-dose 
cruciferous) cruciferous vegetables. 
Amount of cruciferous vegetables given 
standardised to a 70-kg body weight then 
adjusted for each participant to nearest 5 kg 
increment in body weight.  
Riso et al. 
(2009) 
Broccoli (200 g) Two diets: basal (control) and broccoli. 
Diets consumed daily for 10 days each with 20-day washout 
period before crossover. 
Broccoli steamed before consumption. Basal diet was habitual diet devoid of 
cruciferous vegetables. 
Riso et al. 
(2014) 
Broccoli (200 g) Two diets: basal (control) and broccoli (sequential). 
Basal diet consumed once the day before phenotyping and 
broccoli meal consumed immediately before phenotyping. 
Broccoli consumed steamed with cooked pasta, olive 
oil and salt. 
Basal diet consisted of three standardised 
meals 1 day before phenotyping: 
Breakfast—milk and shortbread biscuits; 
Lunch—two sandwiches (cooked ham and 
cheese and raw ham); 
Dinner—Steak with potatoes, pasta or rice 
with butter and Parmesan cheese and two 
slices of wheat bread. 
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Study 
Cruciferous 
vegetables consumed 
(amount/day)) 
Intervention details Preparation of diet Notes 
Vistisen et 
al. (1992) 
Broccoli (500 g) Three diets: habitual diet, broccoli and cruciferous-devoid. 
Diets consumed daily for 10 days  
4-week washout period.  
Broccoli lightly steamed and distributed evenly 
between lunch and dinner. 
No controlled basal diet; habitual diet 
involved following usual dietary consumption 
patterns. 
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Figure 2.2: Drug-metabolising enzymes represented in the dietary intervention literature 
by type of enzyme (name, n, % total) (total n = 46). 
CYP—Cytochrome P450s 
GST—Glutathione S-transferases 
NAT—N-acetyltransferase 
SULTs—Sulfotransferases 
UGTs— Uridine 5'-diphospho-glucuronosyltransferases 
XO—Xanthine oxidase 
 
 
 
  
CYPs, 14, 30%
UGTs, 12, 26%
SULTs, 6, 13%
GSTs, 8, 17%
NAT, 3, 
7%
XO, 3, 
7%
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2.3.4 Changes in drug-metabolising enzyme activity 
The extent of changes in drug-metabolising enzyme activity ranged from -20% to 450% 
following the various cruciferous vegetable dietary interventions (Table 2.1). The most 
consistent and significant increases were for CYP1A2, ranging from 11% to 249% (de Waard 
et al., 2008; Hakooz & Hamdan, 2007; Kall et al., 1996; Lampe et al., 2000b; Murray et al., 
2001; Pantuck et al., 1979; Peterson et al., 2009; Vistisen et al., 1992). Meta-analysis of the 
10 experiments investigating CYP1A2 showed a significant increase of 0.61 standardised 
units (95% CI = 0.26, 0.97; P = 0.0007) (Figure 2.3) following Cruciferae-enriched diets, which 
approximates to a 20-40% increase in CYP1A2 activity, depending on the metric of choice. 
These studies were highly heterogenous (Chi2 = 421.13 with 9 degrees of freedom; P < 
0.00001), likely caused by variability in intervention diets and study design across the 
CYP1A2 trials.
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Figure 2.3: Forest plot showing pooled estimate of standardised mean difference in CYP1A2 activity during cruciferous vegetable versus basal/control diet. 
64 
 
For CYP2A6 only one study reported a significant increase in CYP2A6 activity (MD 95% CI = 
0.10 [0.06, 0.14]; P = 0.002) (Hakooz & Hamdan, 2007) with the remaining two studies 
reporting no significant change in activity. One of the CYP2E1 studies reported a significant 
decrease in activity (inhibition) following a watercress-enriched diet intervention (MD 95% 
CI = -0.91 [-1.34, -0.48]; P < 0.05) (Leclercq et al., 1998). 
With regards to GST-α, four studies reported an increase in enzyme activity or plasma 
concentration of the enzyme ranging from 10-61% (Bogaards et al., 1994; Lampe et al., 
2000a; Navarro et al., 2009a; Nijhoff et al., 1995). Meta-analysis of the five GST-α trials 
showed a significant increase in activity of 0.41 standardised units (95% CI = 0.02, 0.81; P = 
0.04) (Figure 2.4) after the various cruciferous vegetable interventions, corresponding to an 
estimated 15-35% increase in GST-α activity. The GST-α trials were also highly heterogenous 
(Chi2 = 41.89 with 4 degrees of freedom; P < 0.00001). Only one study investigated GST-π 
and reported no significant effects of cruciferous vegetable consumption (MD 95% CI = 0.42 
[-0.83, 1.67]; P > 0.05) (Nijhoff et al., 1995).
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Figure 2.4: Forest plot showing pooled estimate of standardised mean difference in GST-α activity during cruciferous vegetable versus basal/control diet. 
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For NAT2, one study reported a small increase in activity (MR 95% CI 1.01 [0.66, 1.36]; P < 
0.05) (de Waard et al., 2008), however this study had a small sample size (n = 6) and only 
two quality characteristics. Heterogeneity and poor study design prevented detailed analysis 
of the results of XO activity studies, although one study (de Waard et al., 2008) 
demonstrated a decrease in activity after cruciferous vegetable consumption (MR 95% CI = 
0.96 [0.90, 0.99]; P < 0.05). 
UGT enzyme activity could not be compared across studies as the metrics chosen varied and 
all of the probe drugs administered to participants were non-selective substrates for the 
UGT enzymes (Chen et al., 1996; Pantuck et al., 1984). Nevertheless, one well-designed 
study examining UGT1A6 and UGT2B15 activity found evidence of a 4-5% increase in 
enzyme activity across different UGT genotype groups (MD 95% CI = 2.70 [1.18, 4.22]; P < 
0.0001) (Navarro et al., 2011). Of interest, in this same study, a corresponding 12% decrease 
in SULT1A1 and SULT2A1 activity was observed (MD 95% CI = -1.10 [-1.48, -0.52]; P < 
0.0001) following the cruciferous vegetable-enriched diet intervention. A similar result was 
reported in one of the other studies investigating sulfotransferases (Pantuck et al., 1984).  
Of note, three studies reported evidence of dose-response relationships between the 
amount of cruciferous vegetables consumed and the changes in CYP1A2 (Peterson et al., 
2009), UGT1A1 (Navarro et al., 2009b) and GST-α (Navarro et al., 2009a) activity. Consuming 
double the amount of cruciferous vegetables relative to a standard Cruciferae-enriched diet 
increased CYP1A2 activity in a dose-dependent manner (MDDouble-dose – Single-dose 95% CI = 0.35 
[0.17, 0.54]; P < 0.05) (Figure 2.5). Similar dose-response trends were seen for the UGT1A1 
(Navarro et al., 2009b) and GST-α (Navarro et al., 2009a) studies.
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Table 2.3: Critical analysis of quality characteristics across the 23 studies. 
  
1 Studies when participants were randomised to dietary 
intervention groups are (+) (pre-test, post-test designs 
marked as ‘-‘). 
2 Number of participants that completed the study. N ≥ 10 
was chosen as per the rationale discussed by Kakuda et al. 
(2014). 
3 Indicates whether participant groups were similar at 
baseline before randomisation (one-group designs, 
considering activity pre-diet modification post modification, 
post-test designs, marked as ‘-‘). 
4 Indicates whether design incorporated a control diet period 
(either standardised or Cruciferae-free?). 
5 Presence (+) or absence (-) of controlling kJ intake in 
participants throughout study or diet standardization based 
on initial participant weight in kg. 
6 Studies with at least two adherence measures (+), e.g. food 
diary, supervised meal consumption, other studies (-). 
7 Choice of statistical test was appropriate for design (+); 
failure to report marked as ‘-‘. 
8 Previous or concurrent validation of any analytical 
techniques used to analyse participant samples. 
9 Sum of number of ‘+’ attributes for the 10 quality 
characteristics recorded. 
Study Design Randomisation1 
n ≥ 
102 
Group 
similarity3 
Basal 
diet4 
kJ/weight 
standardization5 
Adherence6 
Statistical 
analyses7 
Analytical 
technique8 
Score9 
Chang, 2007 Crossover + + + + + + + + 8 
Lampe, 2000a Crossover + + + + + + + + 8 
Lampe, 2000b Crossover + + + + + + + + 8 
Navarro, 2009a Crossover + + + + + + + + 8 
Navarro, 2009b Crossover + + + + + + + + 8 
Navarro, 2011 Crossover + + + + + + + + 8 
Peterson, 2009 Crossover + + + + + + + + 8 
Nijhoff, 1995 Crossover + - + + - + + + 6 
Pantuck, 1979 Crossover - + - + + + + + 6 
Pantuck, 1984 Crossover - + - + + + + + 6 
Riso, 2009 Crossover + + - + - + + + 6 
Bogaards, 1994 Parallel - + + + - - + + 5 
Kall, 1996 Crossover - + - + - + + + 5 
Murray, 2001 Crossover - + - + - + + + 5 
Riso, 2014 Crossover - + - + - + + + 5 
Chen, 1996 Crossover + + - - - - + + 4 
Desager, 2002 Crossover + - + - - - + + 4 
Vistisen, 1992 Crossover + - - + - - + + 4 
Leclercq, 1998 Crossover - + - - - - + + 3 
Murphy, 2001 Crossover - + - - - - + + 3 
De Waard, 2008 Crossover - - - + - - - + 2 
Hakooz, 2007 Crossover - + - - - - - + 2 
McDanell, 1992 Crossover - - - - - - + - 1 
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2.3.5 Study design, quality and critical analysis 
Studies were first ranked based on their design (randomised crossover > non-randomised 
crossover > parallel group design) and then by other quality characteristics. Of the 23 
studies, 12 employed a randomised, controlled, crossover design (Chang et al., 2007; Chen 
et al., 1996; Desager et al., 2002; Lampe et al., 2000a; Lampe et al., 2000b; Navarro et al., 
2009a; Navarro et al., 2011; Navarro et al., 2009b; Nijhoff et al., 1995; Peterson et al., 2009; 
Riso et al., 2009; Vistisen et al., 1992) meeting four to eight of the quality characteristics; 10 
followed a non-randomised crossover (pre-test, post-test) design (de Waard et al., 2008; 
Hakooz & Hamdan, 2007; Kall et al., 1996; Leclercq et al., 1998; McDanell et al., 1992; 
Murphy et al., 2001; Murray et al., 2001; Pantuck et al., 1984; Pantuck et al., 1979; Riso et 
al., 2014) meeting one to six quality characteristics; and one study had a parallel design with 
two cohorts of participants (Bogaards et al., 1994), although it contained more quality 
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Figure 2.5: Dose-response relationship between increase in CYP1A2 activity and daily 
cruciferous vegetable consumption. 
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characteristics (five) than half of the lower-ranked non-randomised crossover studies. With 
regards to sample size, 78% of the studies had ≥ 10 participants (overall range: n = 6 to 73), 
which has been suggested to be a sufficient number in quasi-experimental crossover 
pharmacokinetic studies (Kakuda et al., 2014). The majority (74%) of study designs included 
a basal control diet. Participant adherence to study protocols was addressed in 61% of the 
studies, with the vast majority of these being randomised controlled trials. Adherence 
measures included diet diaries for the participants, supervised consumption of dietary 
intervention meals and housing participants in a research/clinical facility for the duration of 
the study. Two studies failed to report details of the statistical analyses used in significance 
testing (de Waard et al., 2008; Hakooz & Hamdan, 2007). All but one study (McDanell et al., 
1992) previously or concurrently validated the quantitative assays used to measure 
substrate and metabolite concentrations or enzyme levels 
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2.3.6 Discussion 
This systematic review investigated the effects of cruciferous vegetable dietary 
interventions on drug-metabolising enzymes in humans. While there was marked variability 
in the nature of cruciferous vegetable interventions implemented across the studies, the 
largest changes in enzyme activity were seen after dietary interventions containing broccoli, 
cabbage, cauliflower and Brussels sprouts. These cruciferous vegetables also demonstrated 
a dose-response relationship with CYP1A2 (Peterson et al., 2009), GST-α (Navarro et al., 
2009a) and UGT1A1 (Navarro et al., 2009b) activity, in that the increase in enzyme activity 
roughly doubled the when doubling the amount of these vegetables consumed. The dietary 
interventions studied affected enzyme activity after at least one week of exposure, with 
most dietary interventions being consumed for two weeks, giving time for enzyme induction 
to occur. Conversely, studies with enzyme inhibition hypotheses, such as those investigating 
CYP2E1, administered their dietary interventions within 12 hours of or immediately before 
phenotyping to ensure any effect on activity was observed (Chen et al., 1996; Leclercq et al., 
1998). Methods of preparing the cruciferous vegetables for the dietary intervention were 
different across the studies. It has been shown that there are significant differences in the 
ITC content of cruciferous vegetables depending on whether they are boiled, steamed, stir-
fried or microwaved (Verkerk et al., 2009). Therefore, it is difficult to meaningfully compare 
results between the different trials, especially those that did not use standardised dietary 
interventions. 
The investigated drug-metabolising enzymes included representative CYPs, UGTs and SULTs 
alongside GST-α, GST-π, NAT2 and xanthine oxidase. The most frequently studied enzymes 
across the 23 studies were CYP1A2, GST-α, UGT1A6 and UGT1A9 (Table 2.1), and most of 
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these studies had multiple high-quality characteristics. A wide variety of pharmacokinetic 
metrics were used especially for CYP1A2. Caffeine-derived composite metrics involving 
multiple metabolites, such as (AFMU + 1X + 1U)/17X, were used to quantify CYP1A2 activity. 
Simpler and less resource-intensive indices (by virtue of requiring the analysis of fewer 
metabolites, therefore allowing for simpler assays) have since been validated, such as the 4-
h paraxanthine/caffeine concentration ratios in plasma or saliva (Perera et al., 2012b; 
Perera et al., 2011). In general, the CYPs have more validated in vivo phenotyping probes 
than the UGTs (Argikar et al., 2008; Miners et al., 2006). While some relatively enzyme-
specific UGT probes have shown promise in human studies (Court, 2005; Court et al., 2002), 
substrate redundancy means that most drugs used for phenotyping UGTs are not specific for 
the one UGT (Miners et al., 2006). The UGT studies included in this assessment used 
substrates that were metabolised by more than one enzyme, i.e. paracetamol, racemic 
oxazepam and endogenous bilirubin. Therefore, it is not possible to determine the specific 
UGT enzymes induced following cruciferous vegetable consumption, as is also the case for 
the SULT studies reviewed. However, because it is the overall clearance of a drug that 
affects systemic concentrations, these studies provide information regarding the potential 
for diet-drug interactions, even if they cannot identify the specific enzymes involved. It is 
worth noting that the included studies investigating UGT enzyme activity all reported a link 
between UGT genotype and ITC exposure—something that has not been formally addressed 
in the context of how ITC exposure related to changes in CYP activity. 
With regards to changes in enzyme activity, of particular note are the studies that 
investigated CYP1A2 and GST-α. Nearly all of these studies scored highly with regards to 
their quality characteristics. Further, findings were consistent across these studies, with 
CYP1A2 and GST-α activity being increased by cruciferous vegetable diets. Individual studies 
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reported increases in enzyme activity ranging from 15-40% (Table 2.1). The meta-analyses 
performed demonstrated a significant effect on CYP1A2 and GST-α, with consumption of 
Cruciferae increasing the activities of these enzymes by 20-40% and 15-35%, respectively. 
Changes in the pharmacokinetics of a medicine as measured by changes in AUC, clearance 
or phenotyping metrics in the order of 20-30% (Macaluso et al., 2015) can be considered to 
be of potential clinical relevance, warranting further investigation. This suggests that diets 
high in cruciferous vegetables could affect the efficacy of drugs (or toxicity of prodrugs) 
which are substrates for these enzymes. Importantly, all studies included in this review 
enrolled healthy volunteers; the effect of cruciferous vegetable diets on drug-metabolising 
enzymes in specific patient groups remains unknown. Therefore, future controlled crossover 
studies with pharmacokinetic and pharmacodynamic endpoints would be of benefit to 
ascertain whether specific dietary recommendations are needed for patients undergoing 
drug therapy with CYP1A2 and GST-α substrates. 
Overall, the quality of the literature in this area was considered below average, with only 
48% of the 23 included studies found to have adequate sample sizes for their intended 
purpose, employ a controlled, crossover design, and have multiple high-quality 
characteristics. These ‘gold-standard’ studies all implemented resource-intensive adherence 
measures, such as housing participants for the duration of the study and supervising 
consumption of dietary intervention meals (Chang et al., 2007; Lampe et al., 2000a; Lampe 
et al., 2000b; Navarro et al., 2009a; Navarro et al., 2011; Navarro et al., 2009b; Nijhoff et al., 
1995; Peterson et al., 2009; Riso et al., 2009). Importantly, nearly all of these studies were 
framed in the context of a cancer research, in order to understand their contribution to 
carcinogen clearance as a proposed mechanism of anti-cancer properties (Peterson et al., 
2009). This review provides a new commentary and perspective on these data in a clinical 
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pharmacology context, highlighting how these effects might affect drug therapy patient 
outcomes.  
One limitation of this systematic review was that any database-searchable studies published 
in languages other than English would not be included. However, the studies included using 
these methods did not find any papers in other languages during the title and abstract 
scanning stages of the search process. Meta-analysis was not possible for all enzymes in this 
review due to the heterogeneous nature or limited number of studies, which was a direct 
result of deliberately including all drug-metabolising enzymes represented in this literature. 
While this review has achieved its aims as set out above, it is important to note that the 
search strategy identified at least 2,000 in vitro and other in vivo studies that didn’t meet 
the inclusion criteria, and these studies could also provide valuable insight into the 
mechanisms by which phytochemicals in cruciferous vegetables bring about the observed 
effects on drug-metabolising enzyme activity reported here. Lastly, the choice to exclude 
studies that used cruciferous vegetable or ITC isolates in their interventions greatly limited 
the number of studies included in the review. This decision was made while designing the 
review’s methodology such that any literature included represented dietary interventions 
which were as ‘real-world’ as possible, i.e. whole-food or food-homogenate dietary 
interventions similar to those consumed in the community. Conversely, the strengths of this 
review lie in its design, with methods adapted from guidelines such as The Cochrane 
Handbook for Systematic Reviews of Interventions (2011), increasing confidence that all 
published literature in this area has been included in these findings.  
Despite several in vitro reports regarding ITCs inhibiting detoxification enzymes (Hamilton & 
Teel, 1996; Nakajima et al., 2001; Skupinska et al., 2009a; Skupinska et al., 2009b), the 
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findings of this review are that cruciferous vegetable-enriched diets induce drug metabolism 
across multiple phase I and II enzymes rather than inhibit it. One explanation for these 
observations could be that ITCs affect drug-metabolising enzymes in a similar fashion to 
isoniazid, i.e. short-term inhibition followed by eventual induction of detoxification enzymes 
(O'Shea et al., 1997; Zand et al., 1993), which is in-line with the above in vitro/animal and 
human studies. Therefore, future in-human studies in this area should include a cruciferous 
vegetable intervention immediately before phenotyping as well as after 1-2 weeks of 
consumption to assess potential short-term inhibition and longer-term induction of drug-
metabolising enzymes. The proposed mechanisms for ITC-induction of drug metabolism are 
comprehensively discussed and reviewed elsewhere (Cheung & Kong, 2010; Thornalley, 
2002; Zhang, 2004). 
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2.3.7 Conclusions 
In summary, diets high in cruciferous vegetables increase the activity of CYP1A2 and GST-α 
in healthy volunteers by between 15-40%, with these findings being supported by meta-
analysis of multiple studies exhibiting high-quality characteristics. Therefore, people 
regularly eating large amounts of cruciferous vegetables and concomitantly taking 
medicines, which are substrates for these enzymes could have altered drug-exposure 
profiles, contributing to changes in the efficacy and toxicity of affected medicines. It follows 
that further prospective, controlled, dietary intervention trials involving different substrates 
of CYP1A2 and GST-α are needed to assess the clinical relevance of cruciferous vegetable 
food-drug interactions in their relevant disease-state contexts and patient populations. 
The quality of the evidence covering the other enzymes included in this review is below 
average, and it remains unclear if these and other important drug-metabolising enzymes are 
affected to a clinically significant extent. This statement is especially pertinent for the 
remaining members of the five main CYP enzymes, namely CYP2D6, 2C19, 2C9 and 3A4, for 
which there are no published studies that analyse their activity following a cruciferous 
vegetable intervention. 
These data suggest that any future trials investigating the interaction between CYP1A2 
activity and Cruciferae-enriched diets should show subsequent induction of CYP1A2 enzyme 
activity. It is important to note that none of the studies included in this review were 
designed to detect any differences in response to cruciferous vegetables between various 
geographic ancestries; South Asians were not represented in the data. Further, evidence has 
been presented that UGT and GST genotypes, especially the null-alleles of these genes, 
attenuate the response to ITC exposure.  
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Therefore, the findings of this review generate a rationale to explore how geographic 
ancestry, genetics and Cruciferae-enriched diets interact to affect CYP enzyme activity, 
which is of interest in Europeans and South Asians for the reasons laid out in Chapter 1. 
Hypotheses based on this rationale are presented and tested in a prospective, 3-period, 
controlled trial in Chapter 5 of this thesis.  
However, before conducting such a trial, appropriate bioanalytical methods that allow for 
the effective estimation of CYP activity in vivo and measurement of ITC systemic exposure 
are required. The design, validation and optimisation of two such assays are presented over 
the next two chapters, and their successful application in a clinical trial is reported in 
Chapter 5.  
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3 An improved and optimised version of the ‘Inje’ and 
‘Ghassabian’ cytochrome P450-phenotyping cocktails: a 
simplified and highly sensitive UHPLC-MS/MS cocktail assay in 
human plasma 
3.1 Introduction 
The importance of studying CYP enzyme activity has been reviewed and discussed in section 
1.3.1.1. Further, the utility of the CYP-phenotyping cocktail approach and its relevant 
background to this thesis was reviewed and discussed in sections 1.6. 
Chapter 3 therefore covers the design, validation and optimisation of a simplified UHPLC-
MS/MS CYP-phenotyping assay in human plasma, that can be used to simultaneously 
phenotype CYP1A2, CYP2C19, CYP2C9, CYP2D6 and CYP3A4 across a variety of clinical and 
research settings. The starting points for this study were the Inje (Ryu et al., 2007) and 
Ghassabian (Ghassabian et al., 2009) cocktails because of the wide global availability and 
previous internal and external validation of their CYP450 enzyme-specific probe drugs: 
caffeine (CYP1A2), omeprazole (CYP2C19), losartan (CYP2C9), dextromethorphan (CYP2D6) 
and midazolam (CYP3A4). 
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3.2 Methods 
3.2.1 Chemicals and reagents 
Caffeine, losartan potassium, omeprazole, paraxanthine and phenacetin were purchased 
from Sigma-Aldrich (Castle Hill, NSW, Australia); dextromethorphan, dextrorphan tartrate, 
midazolam and α-hydroxymidazolam were purchased from Kinesis (Redland Bay, QLD, 
Australia); 5-hydroxyomeprazole and losartan carboxylic acid (EXP-3174) were purchased 
from Ramidus AB (Lund, Sweden). Acetonitrile, methanol, water, ammonium formate and 
formic acid were purchased from Sigma-Aldrich (Castle Hill, NSW, Australia); all solvents and 
reagents were HPLC-grade or above. Oasis HLB solid-phase extraction (SPE) cartridges (3 mL, 
60 mg) were purchased from Waters (Dundas, NSW, Australia). 
3.2.2 Stock and working solutions 
Stock solutions (1 mg/mL) of analytes and the internal standard (IS) phenacetin were 
prepared by weighing and dissolving compounds in acetonitrile (phenacetin), water 
(caffeine and paraxanthine) or methanol (all other analytes); dextromethorphan, 
dextrorphan tartrate, midazolam and α-hydroxymidazolam were supplied as certified 
standard solutions in sealed amber vials (1 mg/mL in methanol). All stock solutions were 
stored at -20 °C in silanised vials (Shimadzu, Rydalmere, NSW, Australia). Working solutions 
for preparation of plasma calibrators and quality control (QC) samples were made by mixing 
microlitre aliquots of stock solutions and serially diluting with water:methanol:acetonitrile 
(2:1:1, v/v) to construct the standard curves (10 µL working solution added to 100 µL 
plasma). Working solutions were prepared with each batch of samples analysed and stored 
at -20 °C in 2 mL Eppendorf tubes (POCD, Artarmon, NSW, Australia). 
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3.2.3 Chromatographic conditions 
Separation of the analytes was achieved by using an Agilent Zorbax Eclipse XDB-C18 column 
(4.6 x 50 mm, 1.8 µm) fitted with a Zorbax Eclipse XDB-C18 (4.6 x 5 mm, 1.8 µm) guard 
column on an Agilent 1290 infinity LC system. Mobile phase A contained 0.1% formic acid 
(v/v) and 5 mM ammonium formate in water, with mobile phase B consisting of 0.1% formic 
acid (v/v) and 5 mM ammonium formate in methanol and acetonitrile (50:50, v/v). A 
gradient was started at 50% B and maintained isocratically for 13 min, then increased to 
95% B over 30 s and maintained for 1 min, returning to 50% B at 15 min for 1 min of 
equilibration. The injection volume was 10 µL with a total run time of 16 min at a flow rate 
of 0.5 mL/min. Column temperature was set at 30 °C and the autosampler was kept at 4 °C. 
3.2.4 Mass spectrometer settings 
The samples were analysed on an Agilent 1290 Infinity LC system in tandem with 6460A 
triple quadrupole mass spectrometers (Agilent Technologies, Santa Clara, CA, USA). Tandem 
MS was performed using electrospray ionisation equipped with jet stream technology in 
positive ion mode. The gas temperature was optimised at 350 °C with a flow rate of 
12 L/min, while the sheath gas was 375 °C with a flow rate of 11 L/min. Capillary voltage was 
3500 °C and the nebuliser pressure was 25 psi. All analytes were detected in multiple 
reaction monitoring (MRM) mode with fragment voltage set at 135 V using nitrogen as the 
collision gas. For each analyte and the IS, one quantitative and one to three qualitative ion 
transitions were monitored. To maximize the detection sensitivity, losartan and losartan 
carboxylic acid were monitored in a separate MRM time segment. The MS parameters for 
specific analyte ions are listed in Table 3.1. Data acquisition was performed using 
MassHunter B.07.01 and data analysis was conducted using the accompanied MassHunter 
qualitative and quantitative software (version B.07.00, Agilent Technologies). 
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Table 3.1: Mass spectrometer ion transitions for the 11 analytes. Transitions shown in 
bold were used for analyte quantification. 
Analyte 
Precursor (m/z) 
Product 
(m/z) 
Collision energy 
(eV) 
Caffeine 
 
195.2 
195.2 
123.0 
138.0 
20 
23 
Paraxanthine 
 
181.1 
181.1 
55.1 
123.9 
25 
27 
Omeprazole 
 
346.1 
346.1 
151.3 
197.8 
3 
15 
5-hydroxyomeprazole 
 
362.0 
362.0 
152.2 
213.9 
10 
25 
Losartan 
  
423.2 
423.2 
207.2 
405.1 
7 
15 
Losartan carboxylic acid 
 
437.2 
437.2 
179.8 
206.1 
37 
39 
Dextromethorphan 
 
272.3 
272.3 
272.3 
147.1 
171.0 
213.2 
30 
25 
25 
Dextrorphan 
 
258.3 
258.3 
258.3 
133.1 
157.1 
199.2 
25 
35 
30 
Midazolam 
 
326.2 
326.2 
222.8 
291.1 
30 
37 
α-hydroxymidazolam 342.1 
342.1 
203.1 
323.9 
25 
29 
Phenacetin (IS) 
 
180.2 
180.2 
93.1 
110.1 
20 
27 
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3.2.5 Method validation 
This assay was validated with reference to the US FDA guidelines for bioanalytical studies, 
which outline acceptable criteria for assay selectivity, sensitivity, accuracy and precision . All 
assay parameters were validated using drug-free human plasma which was donated by 
healthy volunteers who had abstained from all study medicines (including sources of dietary 
caffeine) for at least 72 hours. Calibrators and QCs were prepared by spiking drug-free 
plasma with known amounts of analytes; different stock and working solutions were used to 
make calibrators and QCs respectively. Peak area ratios of analytes to the IS across 8 
concentrations in plasma were used to generate calibration curves for each analyte.  
The linearity of the curves (Table 3.2) was assessed using least-squares regression, while 
accuracy of the calibrators was assessed by comparing their calculated concentrations with 
nominal concentrations (relative error; RE). QC samples were prepared at low, middle and 
high concentrations (Table 3.3) and were analysed in replicates of five across three different 
days. Inter- and intra-day accuracy were calculated using the RE of QC samples and inter- 
and intra-day precision was assessed using their relative standard deviation (RSD). Accuracy 
and precision were deemed acceptable if deviations at a given concentration were ≤ 15%, 
except at the lower limit of quantification (LLOQ), which could deviate up to 20%. The LLOQ 
was defined as the lowest point on the analyte calibration curves that met the above 
accuracy and precision criteria.  
Recovery and matrix effects were also investigated. Recovery was assessed by calculating 
the RE of analyte peak areas in plasma spiked pre-extraction relative to analyte peak areas 
in blank plasma spiked post-extraction. Matrix effects were evaluated using the RE of 
analyte peak areas in blank plasma spiked post-extraction relative to analyte peak areas in 
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water:methanol:acetonitrile (2:1:1, v/v) that contained the same amount of analyte. Formal 
stability studies were not conducted as these have previously shown no significant changes 
in analyte response for this cocktail during various sample storage and handling situations 
(Ghassabian et al., 2009; Grangeon et al., 2017; Oh et al., 2012; Ryu et al., 2007; Yin et al., 
2004), however, analyte response was monitored in the stock solutions, working solutions 
and reconstituted samples left in the autosampler at various times. All showed < 15% RE 
compared to concentrations derived from fresh calibration curves. Of interest, when left in 
acetonitrile at room temperature for up to a week, phenacetin showed concentration 
deviations of < 5% RE, indicating high stability in this solvent. 
Table 3.2: Retention times, LLOQs, calibration curve ranges and least-squares regression 
results. Linearity assessed over 3 different runs. 
Analyte Retention 
time (min) 
LLOQ (ng/mL) 
Calibration range 
(ng/mL) 
R2 (mean ± SD) 
(n = 3) 
Caffeine 1.19 23.4 23.4-3000 0.983 ± 0.011 
Paraxanthine 1.32 23.4 23.4-3000 0.991 ± 0.010 
Omeprazole 2.78 1.95 1.95-250 0.999 ± 0.001 
5-hydroxyomeprazole 1.70 7.81 7.81-1000 0.999 ± 0.001 
Losartan 6.32 3.58 3.58-458.7 0.993 ± 0.003 
EXP-3174 8.76 7.81 7.81-1000 0.993 ± 0.001 
Dextromethorphan 2.46 1.09 1.09-139.8 0.985 ± 0.012 
Dextrorphan 1.30 0.78 0.78-100 0.994 ± 0.004 
Midazolam 2.75 0.78 0.78-100 0.999 ± 0.000 
α-hydroxymidazolam 3.70 0.78 0.78-100 0.998 ± 0.001 
 
3.2.6 Sample preparation and analyte extraction 
All spiked and clinically-acquired plasma samples were stored at -80 °C until the time of 
analysis. Plasma aliquots (100 µL) were mixed with 400 µL of acetonitrile containing 2 ng IS 
and vortex-mixed for 1 min to precipitate plasma proteins, then centrifuged for 10 min at 
20 817 g. The resulting supernatant was transferred to a 2 mL Eppendorf tube and 
evaporated under vacuum at 45 °C using a centrifugal concentrator, followed by 
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reconstitution in 1 mL water and 1 min of vortex-mixing. The reconstituted samples (1 mL) 
were then loaded onto SPE cartridges which had been conditioned with 1 mL methanol 
followed by 1 mL. The cartridges were washed with 2 mL water followed by 2 mL 10% 
methanol in water (v/v) before elution of the analytes with 2 mL methanol. The eluent was 
evaporated under vacuum at 45 °C, reconstituted in 100 µL water:methanol:acetonitrile 
(2:1:1, v/v), vortex-mixed for 1 min and centrifuged for 10 min at 20 817 g before 
transferring to an autosampler vial containing a 200 µL insert. 
3.2.7 Clinical application 
Following validation, this assay was successfully used to analyse samples and phenotype six 
healthy volunteers. This study was approved by Sydney Local Health District Human 
Research Ethics Committee and required the participant to provide informed written 
consent during a face-to-face interview. In brief, after an overnight fast, a venous cannula 
was inserted into a forearm vein and a baseline t = 0 h blood sample was collected into a 
lithium-heparinised 10 mL tube (BD, North Ryde, NSW, Australia). Immediately afterwards, 
the participant was orally administered the CYP-phenotyping cocktail with 250 mL of plain 
water: caffeine 100 mg (No-Doz® tablets; Key Pharmaceuticals, NSW, Australia), omeprazole 
20 mg (Ozmep® enteric-coated tablets; Medis Pharma, NSW, Australia), losartan 25 mg 
(Cozavan® tablets; Alphapharm, NSW, Australia), dextromethorphan 30 mg (Bisolvon Dry® 
10 mg/5 mL liquid; Sanofi-Aventis Healthcare, QLD, Australia) and midazolam 2 mg 
(Midazolam Sandoz® 5 mg/5 mL vials for injection; Sandoz, NSW, Australia). Caffeine, 
omeprazole and losartan were administered as tablets, while dextromethorphan (15 mL) 
and midazolam (2 mL) liquids were swallowed immediately after being mixed together in a 
small disposable cup. Blood samples were then serially collected at t = 1, 2, 4 and 6 h post-
administration of the phenotyping medicines. Plasma was harvested from whole blood 
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samples by centrifuging the 10 mL collection tubes at 2000 g for 10 min followed by removal 
of the supernatant and storage at -80 °C until analysis. The remaining haematocrit was kept 
and stored at -80 °C for genotyping purposes. Participants were allowed to consume a small 
snack after the 2-h sample and lunch after the 4-h sample to minimise any potential food-
effects on the pharmacokinetics of the probe drugs. 
3.2.8 CYP-phenotyping and pharmacokinetic analyses 
The following plasma concentration-time-derived metrics were used to estimate in vivo CYP 
activity: CYP1A2 = paraxanthine/caffeine concentration ratio at 4-h; CYP2C19 = 5-
hydroxyomeprazole/ omeprazole concentration ratio at 4- or 6-h (due to variable lag in 
absorption); CYP2C9 = losartan carboxylic acid AUC0-6 h/losartan AUC0-6 h ratio; CYP2D6 = 
dextrorphan AUC0-6 h/dextromethorphan AUC0-6 h ratio; and CYP3A4 = α-
hydroxymidazolam/midazolam concentration ratio at 4-h. The previous validation of these 
metrics was discussed in Chapter 1. 
3.3 Results 
3.3.1 Selectivity and sensitivity 
Analyte-free plasma from six different healthy volunteers underwent sample extraction and 
was checked for interference at the mass transitions and retention times of the 10 analytes 
and IS. No overlapping peaks or signal abnormalities were detected. LLOQs were 
determined by choosing analyte concentrations that had peaks at least 5-times higher than 
the response of a blank sample, and that displayed accuracy of 80-120% and a precision of 
≤ 20%. Amounts of analyte injected on-column ranged from 7.80-234.4 pg, representing up 
to an 80-fold improvement in sensitivity compared to similar assays (Ghassabian et al., 
2009; Ryu et al., 2007; Yin et al., 2004). Analyte retention times and LLOQs are displayed in 
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Table 3.2, and blank plasma and analyte LLOQ chromatogram overlays are depicted in 
Figure 3.1. 
3.3.2 Calibration curves and linearity 
Linear equations with 1/x weighting provided the best-fit regression models for all analytes. 
All calibration curves had coefficients of determination (R2) of 0.983 or higher and spanned 
large concentration ranges (Table 3.2). 
3.3.3 Accuracy and precision 
Intra- and inter-day accuracy and precision for the 10 analytes and IS are shown in Table 3.3. 
All analytes had intra-day accuracy (RE) and precision (RSD) ranging between 90.7-110.2% 
and 0.46-11.4% respectively. Inter-day accuracy and precision ranged between 87.0-110.5% 
and 1.36-11.2% respectively. 
3.3.4 Recovery and matrix effects 
Recovery ranged from 34.1-104.9% across the analytes and IS at all tested concentrations 
with high reproducibility and consistency (RSD range 0.48-7.9%), indicating that 
quantification was not adversely affected for drugs with lower recoveries. Matrix effects 
varied widely across the analytes and IS at the tested concentrations (range 23.4-251.3%). 
The most marked ion enhancement was seen for α-hydroxymidazolam (233.0-251.3%), with 
caffeine (30.8-41.5%), paraxanthine (23.4-27.6%) and dextrorphan (37.4-40.3%) displaying 
significant ion suppression. In a similar fashion to recovery, matrix effects were consistent 
and reproducible across batches and plasma sources (RSD range 0.48-10.8%) and did not 
affect successful quantification of analytes across the tested concentration ranges. 
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3.3.5 Clinical application of assay 
A representative concentration-time profile for each probe drug and their metabolites in a 
single healthy volunteer receiving the CYP-phenotyping cocktail is shown in Figure 3.3. 
Calibrators and QCs from these batches all met accuracy (RE 85-115%) and precision (RSD 
< 15%) requirements. 
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Table 3.3: Accuracy and precision data for each analyte and the IS. Intra-day accuracy and 
precision n = 5 for each concentration. Inter-day accuracy and precision n = 15 for each 
concentration (5 x replicates across 3 different runs). 
 Analyte Nominal 
concentration 
(ng/mL) 
Intra-day 
accuracy (RE 
%) 
Inter-day 
accuracy (RE %) 
Intra-day 
precision 
(RSD %) 
Inter-day 
precision 
(RSD %) 
Caffeine 93.8 97.2 92.9 1.44 6.05 
  750 107.1 100.4 4.42 2.98 
  3000 93.2 89.9 2.62 3.54 
Paraxanthine 93.8 95.2 99.5 8.67 11.2 
  750 90.7 95.1 4.54 8.85 
  3000 94.4 97.3 3.40 9.00 
Omeprazole 7.81 103.8 103.8 2.54 3.95 
  62.5 107.6 107.1 1.24 1.36 
  250 97.6 97.4 2.00 1.61 
5-hydroxyomeprazole 31.3 100.8 95.8 8.90 4.28 
  250 98.3 99.1 1.82 2.20 
  1000 104.1 101.9 2.63 2.20 
Losartan 14.3 97.8 101.4 0.58 2.96 
  114.7 96.1 96.6 3.20 3.68 
  458.7 101.2 110.5 1.29 3.07 
EXP-3174 31.3 98.4 101.4 2.55 3.50 
  250 97.4 96.6 11.4 6.59 
  1000 110.2 110.5 1.30 3.69 
Dextromethorphan 4.37 93.1 104.3 7.88 7.80 
  35.0 99.4 102.0 0.46 5.11 
  139.8 101.6 102.1 8.31 6.32 
Dextrorphan 3.13 99.6 94.2 5.69 6.10 
  25 104.3 98.2 7.00 5.84 
  100 93.5 87.0 1.69 4.96 
Midazolam 3.13 102.4 104.3 3.57 3.45 
  25 104.3 101.5 1.13 2.14 
  100 98.2 97.9 1.18 1.63 
α-hydroxymidazolam 3.13 103.9 100.5 3.82 3.17 
  25 99.2 97.5 1.53 2.17 
  100 102.1 102.1 1.45 1.99 
Phenacetin (IS) 20 N/A N/A 2.87 5.71 
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195.2 → 138.0 
 
Paraxanthine 
938 pg 
181.1 → 123.9 
 
Omeprazole 
78.1 pg 
346.1 → 197.8 
 
5-hydroxyomeprazole 
313 pg 
362.0 → 213.9 
 
Losartan 
143 pg 
423.2 → 207.2 
 
Losartan 
carboxylic acid 
313 pg 
437.2 → 179.8 
 
Figure 3.1: Chromatogram overlays of the 10 analytes and internal standard phenacetin as a mixture in human plasma. 
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Chromatogram overlays of the 10 
analytes and internal standard 
phenacetin as a mixture in human 
plasma. Each figure is an overlay 
of a chromatogram of an analyte 
in plasma (black) and a blank 
plasma sample (red). Amount of 
analyte on-column (pg) and mass 
transitions (m/z) are displayed 
below the analyte name. 
Figure 3.2 (cont.): Chromatogram overlays of the 10 analytes and internal standard phenacetin as a mixture in human plasma. 
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Representative concentration-time profiles of the five probe drugs and their primary 
CYP450-mediated metabolites. Data shown from one healthy participant who was 
administered caffeine 100 mg, omeprazole 20 mg, losartan 25 mg, dextromethorphan 30 
mg and midazolam 2 mg. 
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Figure 3.3: Representative concentration-time profiles of the five probe drugs and their primary CYP-catalysed 
metabolites. 
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3.4 Discussion 
This improved and optimised analytical technique to measure a cocktail of CYP450 probe 
drugs (Ghassabian et al., 2009; Ryu et al., 2007) meets FDA-recommended specifications for 
specificity, sensitivity, accuracy and precision. Further, it has been used to analyse the 
samples from an investigator-initiated clinical trial of the probe drugs demonstrating its 
ability to be readily applied to clinical research. These methods allow for in vivo analysis of 
five CYP-phenotyping probe drugs, their metabolites and an internal standard in human 
plasma without evidence of low recovery or significant matrix effects impeding 
quantification. 
Several recently published assays simultaneously analyse more than five CYP-phenotyping 
probe drugs and their metabolites (Bosilkovska et al., 2014a; Donzelli et al., 2014; Grangeon 
et al., 2017), namely CYP2B6 and CYP2E1 substrates in addition to CYP1A2, CYP2C19, 
CYP2C9, CYP2D6 and CYP3A4, otherwise known as ‘the main five CYP enzymes’ (Zanger & 
Schwab, 2013). However, the CYP2B6 and CYP2E1 enzymes are estimated to contribute to 
only 10% of drug metabolism in humans (Zanger & Schwab, 2013), and including them in a 
cocktail of probe drugs can necessitate an analytical technique with multiple sample 
extraction steps and chromatographic conditions, along with duplicate sample injections 
(Grangeon et al., 2017). In fact, the added preparatory and chromatographic complexity 
when determining these two enzymes in addition to the main five CYP enzymes is 
significant. Grangeon et al. (2017) report two separate, multi-step analyte extraction 
protocols (one for caffeine and another for the remaining analytes) and three separate 
chromatographic runs per sample in order to analyse the activity of all seven CYP enzymes. 
Further, one of the extraction protocols has multiple evaporation and reconstitution sub-
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steps, each involving different reconstitution solutions depending on the analytes in 
question. This compares with the currently presented method, which uses a two-step 
extraction method (protein precipitation followed by SPE) and one set of chromatographic 
conditions for all analytes, considerably saving time and money by reducing labour and 
resource costs per sample. 
This optimised assay uses a non-isotopically-labelled IS (phenacetin) for quantification of the 
five probe drugs and their primary metabolites. Grangeon et al. (2017) suggest that using 
isotopically-labelled analytes as internal standards aids in minimizing matrix effects, which 
can be true in certain circumstances (Li et al., 2013). However, the extent to which this 
occurs would be negligible if the analytes do not affect the other analytes present, as is the 
case for the currently presented assay (Ryu et al., 2007). Further, Ghassabian et al. (2009) 
demonstrated that phenacetin serves as a suitable ‘all-rounder’ surrogate for the 
physicochemical profiles of the 10 cocktail analytes, and its use as an internal standard did 
not adversely affect the accuracy or precision of their quantification; a finding replicated in 
this improved version of the assay. 
Low recovery and significant matrix effects reduce the efficiency of the LC-MS/MS 
bioanalytical technique, which in turn can translate into a reduction in sensitivity, precision 
and accuracy (Taylor, 2005). Lower recoveries for paraxanthine, dextromethorphan and 
dextrorphan, and matrix effects for caffeine, paraxanthine, dextrorphan and α-
hydroxymidazolam were noted. While further improving the analytical efficiency of these 
analytes would be of value and interest, the recoveries and matrix effects were highly 
consistent within and across batches such that quantification was unaffected, even at the 
lowest concentrations. Of interest, nearly all similarly-designed cocktail assays report high 
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recoveries and little or no matrix effects for these analytes in human plasma (Grangeon et 
al., 2017; Lammers et al., 2016; Oh et al., 2012; Tanaka et al., 2014), which is in contrast 
with the current study. Only Wohlfarth et al. (2012) report ion suppression for dextrorphan 
(37-58%) at similar values. Further, neither Oh et al. (2012) or Ghassabian et al. (2009) 
published matrix effect values. Most studies fail to report RSDs of the matrix effects, and 
Grangeon et al. (2017) report using calibration curves to calculate matrix effects, which 
should instead be calculated using peak area ratios of samples spiked post-extraction (or 
from a post-column infusion) to pure analytes in solvent (Van Eeckhaut et al., 2009). 
Therefore, the true variability of the matrix effects for these analytes remains unknown, and 
future studies should report means, standard deviations and RSDs of any ion enhancement 
and suppression observations. 
This assay uses both protein precipitation and SPE to prepare the sample for UHPLC-MS/MS 
analysis. While this adds time and cost for sample preparation compared to simple dilution 
techniques, the addition of these steps was necessary when routinely injecting large 
numbers of samples onto the UHPLC system. Preliminary tests injecting untreated plasma 
on-column caused high-pressure issues and needle seat blockages as injecting untreated, 
diluted plasma on-column is widely accepted as being problematic for UHPLC-MS/MS 
systems in a general sense, including negative implications for sensitivity, selectivity and 
matrix effects (Bonfiglio et al., 1999; Müller et al., 2002). Even when using protein 
precipitation and SPE, large numbers of samples still caused some high-pressure issues, at a 
lower frequency and slower rate of pressure rise, highlighting the importance of sample 
clean-up steps when using sensitive, high-throughput setups Some recent cocktail assays 
injecting untreated human plasma directly on-column report no adverse effects on 
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sensitivity, selectivity or matrix effects (Bosilkovska et al., 2014a; Zadoyan et al., 2012), 
however these techniques do not discuss the effects on assay robustness. 
3.5 Conclusions 
In conclusion, the currently-presented analytical technique successfully uses UHPLC-MS/MS 
to simultaneously analyse five CYP phenotyping probe drugs, their primary CYP-mediated 
metabolites and an internal standard in human plasma. This technique can support the 
simultaneous in vivo phenotyping of the activity of CYP1A2, CYP2C19, CYP2C9, CYP2D6 and 
CYP3A4. This method meets US FDA recommendations for bioanalytical methods including 
selectivity, sensitivity, accuracy and precision. This assay’s relative simplicity and 
applicability compares favourably to other published assays for CYP probe drugs. This 
method represents an improved and optimised version of the internally- and externally-
validated cocktails used in the Inje (Ryu et al., 2007) and Ghassabian (Ghassabian et al., 
2009) assays, with increases in sensitivity of up to 80-fold, and a significant reduction in 
sample handling and preparatory complexity. 
Following validation of this assay, it was used as described at the end of Chapter 2 to 
estimate CYP activity in 21 people of either European or South Asian geographic ancestry 
before, during and after consuming a broccoli-enriched diet (Chapter 5). In a similar fashion, 
the next chapter outlines a second bioanalytical method that was needed to measure 
sulforaphane exposure when testing the other hypotheses set out in Chapter 5. 
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4 An improved UHPLC-MS/MS assay for measuring sulforaphane 
in human plasma following a broccoli-enriched diet 
4.1 Introduction 
The importance of the isothiocyanates (ITCs) and their effects on drug-metabolising 
enzymes were discussed in section 1.7.1 of this thesis. Briefly recapping, these compounds 
are found in relatively high concentrations in cruciferous vegetables such as broccoli, 
cabbage and watercress, which feature almost ubiquitously in many diets across the globe 
(Steinkellner et al., 2001). These compounds induce phase I and II drug-metabolising 
enzymes, which significantly contribute to the metabolism, and therefore the clearance, of 
carcinogenic compounds and other xenobiotics (Cheung & Kong, 2010; Thornalley, 2002; 
Zhang, 2004). Most studies investigating these effects are designed to test hypotheses in a 
cancer-focussed context, with the two most represented ITCs being sulforaphane (SUL) and 
phenethyl isothiocyanate (PEITC) (Lamy et al., 2011). 
Food-drug interaction studies require selective, sensitive, accurate and precise bioanalytical 
methods to quantify molecules of interest in biological matrices, which is usually achieved 
with high-performance liquid chromatography (HPLC) or liquid chromatography-tandem 
mass spectrometry (LC-MS/MS). Studies to validate and implement assays that quantify SUL 
that meet these criteria have been used with varying levels of success over the years 
(Agrawal et al., 2006; Alumkal et al., 2015; Ares et al., 2015; Clarke et al., 2011; Gasper et 
al., 2005; Hauder et al., 2011; Janobi et al., 2006; Kumar & Sabbioni, 2010; Platz et al., 
2015). However, these assays are not without their issues, including 13-35 minute 
chromatographic run times (Agrawal et al., 2006; Alumkal et al., 2015; Janobi et al., 2006) 
and relatively large plasma volumes (0.5 mL) (Hauder et al., 2011; Janobi et al., 2006). 
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Therefore, as outlined in the main objectives of this thesis (section 1.9), the aim of this study 
was to design, optimise and validate a simplified ultra-performance liquid chromatography 
(UHPLC)-MS/MS assay for sulforaphane in human plasma, which addresses the above issues 
and can readily be set up for use in food-drug and ITC-drug interaction studies. 
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4.2 Methods 
4.2.1 Chemicals and reagents 
Phenacetin (Internal standard) was purchased from Sigma-Aldrich (Castle Hill, NSW, 
Australia); (R,S)-sulforaphane was purchased from Abcam (Melbourne, VIC, Australia). 
Acetonitrile, methanol, water, formic acid and trifluoroacetic acid (TFA) were purchased 
from Sigma-Aldrich (Castle Hill, NSW, Australia). All solvents and reagents were HPLC-grade 
or above. Discovery C18 solid-phase extraction (SPE) cartridges (1 mL, 100 mg) were 
purchased from Sigma-Aldrich (Castle Hill, NSW, Australia). 
4.2.2 Stock and working solutions 
Stock solutions of SUL and the internal standard (IS) phenacetin were prepared at 1 mg/mL 
by weighing and dissolving the compounds in acetonitrile. All stock solutions were stored at 
-20 °C in silanised vials (Shimadzu, Rydalmere, NSW, Australia). Working solutions for 
preparation of plasma calibrators and quality control (QC) samples were made by mixing 
microlitre aliquots of stock solutions and serially diluting with 0.1% formic acid in water 
(v/v), such that 10 µL of working solution when added to 100 µL plasma produced analyte 
concentrations used to construct standard curves. Working solutions were prepared fresh at 
the start of a given batch of samples and stored at -20 °C in 2 mL Eppendorf tubes (POCD, 
Artarmon, NSW, Australia). 
4.2.3 Chromatographic conditions 
Analyte separation was achieved on an Agilent Zorbax Eclipse XDB-C18 column (4.6 x 
50 mm, 1.8 µm) fitted with a UHPLC Zorbax Eclipse XDB-C18 (4.6 x 5 mm, 1.8 µm) guard 
column. Mobile phase A contained 0.1% formic acid in water (v/v) and mobile phase B 
consisted of 0.1% formic acid in acetonitrile (v/v). A gradient was started at 50% B and 
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maintained isocratically for 5 min, then increased to 100% B over 1 min and maintained for 
1 min, returning to 50% B over 0.5 min followed by 1 min of equilibration. The injection 
volume was 10 µL with a total run time of 8.5 min at a flow rate of 0.2 mL/min. Column 
temperature was set at 30 °C and the autosampler was kept at 4 °C. 
4.2.4 Mass spectrometer settings 
Analyses were performed on an Agilent 1290 series UHPLC system in tandem with 6460A 
triple quadrupole mass spectrometers (Agilent Technologies, Santa Clara, CA, USA). Tandem 
MS was conducted using electrospray ionisation equipped with jet stream technology in 
positive ion mode. The gas temperature was optimised at 350 °C with a flow rate of 
12 L/min, while the sheath gas was 375 °C with a flow rate of 11 L/min. Capillary voltage was 
3500 °C and the nebuliser pressure was 25 psi. SUL and the IS were detected in multiple 
reaction monitoring (MRM) mode with fragment voltages set at 60 V and 80 V, respectively, 
using nitrogen as the collision gas. For both molecules, one quantitative and one qualitative 
ion transition were monitored. A detailed summary of the MS parameters for specific 
analyte ions is presented in Table 4.1. Data was acquired using MassHunter B.07.01 and 
data analysis was conducted using the accompanied MassHunter qualitative and 
quantitative software (version B.07.00, Agilent Technologies). 
Table 4.1: Mass spectrometer ion transitions for SUL and the phenacetin (IS). Transitions 
shown in bold were used for analyte quantification. 
Analyte Precursor (m/z) 
Product 
(m/z) 
Collision energy 
(eV) 
Sulforaphane 
 
178.0 
178.0 
72.0 
114.1 
40 
15 
Phenacetin (IS) 
 
180.1 
180.1 
65.1 
110.0 
35 
25 
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4.2.5 Method validation 
This assay was validated with reference to the US FDA guidelines for bioanalytical studies, 
which outline acceptable criteria for assay selectivity, sensitivity, accuracy and precision. All 
assay parameters were validated using ITC/drug-free human plasma, which was donated by 
healthy volunteers who had abstained from all medicines and cruciferous vegetables for at 
least one week. Calibrators and QCs were made by spiking ITC/drug-free plasma with known 
amounts of SUL; different stock and working solutions were used to make calibrators and 
QCs respectively. The peak area ratios of SUL to the IS across eight concentrations in plasma 
were used to generate calibration curves for the purpose of quantification. The linearity of 
the curve was assessed using least-squares regression, while accuracy of the calibrators was 
assessed by comparing their calculated concentrations with nominal concentrations 
(relative error; RE).  
QC samples were prepared at low, middle and high concentrations and were analysed in 
replicates of five across three different days. Inter- and intra-day accuracy were calculated 
using the RE of QC samples and inter- and intra-day precision was assessed using their 
relative standard deviation (RSD). Accuracy and precision were deemed acceptable if 
deviations at a given concentration were ≤ 15%, except at the lower limit of quantification 
(LLOQ), which could deviate up to 20%. Recovery and matrix effects were also investigated. 
Recovery was assessed by calculating the RE of SUL or IS peak areas in plasma spiked pre-
extraction with analyte peak areas in blank plasma spiked post-extraction. Matrix effects 
were evaluated using the RE of analyte peak areas in blank plasma spiked post-extraction, to 
analyte peak areas in 0.1% formic acid in water (v/v) that contained the same amount of 
analyte.  
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Formal stability studies in plasma were not conducted as these have been reported 
extensively by others (Janobi et al., 2006; Platz et al., 2015). However, SUL and IS responses 
were monitored in stock solutions, working solutions and reconstituted samples left in the 
autosampler at various times, all showing < 15% RE compared to concentrations determined 
from fresh calibration curves. 
4.2.6 Sample preparation and analyte extraction 
All spiked and clinically-acquired plasma samples were stored at -80 °C. Plasma aliquots 
(100 µL) were mixed with 10 µL of acetonitrile containing 5.5 ng IS and briefly vortex-mixed. 
Then, 20 µL of TFA was added to the samples followed by vortex-mixing for 1 min to 
precipitate plasma proteins, which were then centrifuged for 10 min at 20 817 g, 4 °C. The 
samples then underwent SPE: cartridges were conditioned with 1 mL methanol followed by 
1 mL 0.1% formic acid in water (v/v) prior to loading of the above supernatant (approx. 
140 µL). The cartridges were washed with 1 mL 5% methanol in water (v/v) before elution of 
the analytes with 2 x 0.5 mL 90% acetonitrile + 0.1% formic acid in water (v/v). The eluent 
was evaporated under vacuum at 45 °C, reconstituted in 100 µL 0.1% formic acid in water 
(v/v), vortex-mixed for 1 min then centrifuged for 10 min at 20 817 g, 4 °C, before 
transferring to an autosampler vial containing a 200 µL insert. 
4.2.7 Clinical application 
Following validation, this assay was successfully used to analyse samples provided by 
healthy volunteers on a broccoli-enriched diet (n = 21), which formed part of a larger study 
detailed in Chapter 5. The study had ethics approval from the Sydney Local Health District 
Ethics Committee and required participants to provide written informed consent during a 
face-to-face interview. Sample collection was as follows: after providing a baseline sample 
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and an overnight fast, participants ate a 200 g microwave-steamed broccoli meal followed 
by insertion of a venous cannula into a forearm vein. Serial blood samples were then 
collected into lithium-heparinised 10 mL tubes (BD, North Ryde, NSW, Australia) at t = 2, 3, 
4, 6 and 8 h post-broccoli consumption. Plasma was harvested from whole blood samples by 
centrifuging the 10 mL collection tubes at 2000 g for 10 min followed by removal of the 
supernatant and storage at -80 °C until analysis. Participants were allowed to have a small 
snack after the 4 h sample and lunch after the 6 h sample to minimise any potential food-
effects on the study endpoints. 
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4.3 Results 
4.3.1 Selectivity and sensitivity 
Analyte-free plasma from six different volunteers underwent sample extraction and was 
checked for interference at the mass transitions and retention times of SUL and the IS. No 
overlapping peaks or signal abnormalities were detected. LLOQs were determined by 
choosing analyte concentrations that had peaks at least 5-times higher than the response of 
a blank sample and that displayed accuracy of 80-120% and a precision of ≤ 20%. Amounts 
of analyte injected on-column ranged from 7.8-100 pg, representing up to a 227% increase 
in sensitivity compared to similar assays (Gasper et al., 2005). Retention times for SUL and 
the IS were 3.42 min and 4.42 min, respectively. The LLOQ for SUL was 0.78 ng/mL (7.8 pg 
on-column). Chromatogram overlays of blank plasma and SUL at low concentrations are 
shown in Figure 4.1. 
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Figure 4.1: Overlay of seven different sulforaphane chromatograms demonstrating assay 
selectivity and sensitivity. 
 
Six chromatograms are of blank plasma from six different volunteers and one internal control plasma 
with sulforaphane added at the low-QC concentration (3.13 ng/mL, 31.3 pg on-column; retention 
time = 3.83 min, peak area 2268).  
 
4.3.2 Calibration curves, linearity, accuracy and precision 
A linear equation with 1/x weighting provided the best-fit regression model for SUL. The 
coefficients of determination (R2) were of 0.989 or higher with concentrations ranging from 
0.78-100 ng/mL. 
Intra- and inter-day accuracy and precision for SUL and the IS are shown in Table 4.2. All SUL 
had intra-day accuracy (RE) and precision (RSD) ranging between 86.4-106.7% and 2.61-
10.3% respectively. Inter-day accuracy and precision ranged between 91.3-97.0% and 3.99-
7.11% respectively. 
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Table 4.2: Accuracy and precision data for SUL and the phenacetin (IS). 
Analyte 
Nominal 
concentration 
(ng/mL) 
Measured mean 
concentration 
(ng/mL) (mean ± 
SD) (n = 15) 
Intra-day 
accuracy (RE 
%) (n = 3) 
Inter-day 
accuracy (RE 
%) (n = 3) 
Intra-day 
precision 
(RSD %) (n = 
15) 
Inter-day 
precision 
(RSD %) (n 
= 15) 
SUL 100 92.4 ± 6.48 106.7 97.0 7.18 7.11 
  25 23.9 ± 1.32 101.2 95.6 2.61 3.99 
  3.125 3.03 ± 0.32 96.3 91.3 3.73 6.40 
IS 55 N/A N/A N/A 7.48 2.94 
 
4.3.3 Recovery and matrix effects 
Recovery was low for both SUL and the IS (Table 4.3). However, both molecules had 
reproducible and consistent recoveries across all tested concentrations (RSD range 6.82-
11.0%), therefore quantification was not adversely affected. With regards to matrix effects, 
ion suppression was seen for SUL and the IS (Table 4.3), although as with recovery, matrix 
effects were consistent and reproducible across batches and plasma sources (RSD range 
6.59-10.6%) and did not affect successful quantification of SUL across the tested 
concentration ranges. 
Table 4.3: Recovery (RSD% ± SD) and matrix effect data (mean ± SD) for sulforaphane and 
the phenacetin (IS). 
Analyte 
Nominal 
concentration 
(ng/mL) 
Recovery 
(mean ± SD) 
Recover
y RSD % 
Absolute matrix 
effect (mean ± 
SD) 
Absolute 
matrix effect 
RSD % 
SUL 100 34.7 ± 2.36 6.82 62.3 ± 4.11 6.59 
  25 25.2 ± 2.78 11.0 78.2 ± 8.29 10.6 
  3.125 26.4 ± 2.30 8.69 82.1 ± 7.29 8.88 
IS 55 46.3 ± 4.39 9.50 75.0 ± 7.52 10.0 
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4.3.4 Clinical application of assay 
This assay has been used to phenotype 21 participants (> 150 plasma samples) in the above-
mentioned clinical trial (these data are further explored and discussed in Chapter 5). 
Calibrators and QCs from these batches all met accuracy (RE = 85-115%) and precision (RSD 
< 15%) requirements. 
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4.4 Discussion 
This validated UHPLC-MS/MS assay meets appropriate specifications for selectivity, 
sensitivity, accuracy and precision, and has successfully been used to analyse SUL in over 
150 clinical trial samples, demonstrating its ability to be readily applied to dietary 
intervention studies. These methods allow for in vivo analysis of SUL in studies involving a 
cruciferous vegetable or SUL intervention, and provide evidence that low recovery and ion 
suppression do not impede analyte quantification. 
Other assays that analyse SUL and its metabolites have relatively long chromatographic run 
times of 13-35 min (Agrawal et al., 2006; Alumkal et al., 2015; Janobi et al., 2006), which is a 
barrier to high-throughput and efficiency when analysing large numbers of samples. The 
per-sample run time of the currently presented assay is 8.5 min, which represents up to a 4-
fold improvement compared to similar assays. 
In an effort to further reduce the resource demands and costs of this assay, a non-
isotopically-labelled IS (ILIS) was used for quantification of SUL in plasma. ILISs can help to 
reduce matrix effects (Grangeon et al., 2017; Li et al., 2013). However, phenacetin has been 
used as a suitable IS for a range of analytes with varying physicochemical properties 
(Ghassabian et al., 2009) (Chapter 3). Its use as an internal standard produced appropriate 
accuracy and precision for analyte quantification in these studies, which has also been 
observed for this SUL assay. 
As discussed in Chapter 3, sensitivity, precision and accuracy can be reduced by low 
recovery and significant matrix effects (Taylor, 2005). The presented methods demonstrate 
low recoveries and ion suppression for SUL and the IS. However, the recoveries and matrix 
effects were highly consistent within and across batches such that quantification was 
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unaffected, even at the lowest concentrations. Unfortunately, matrix effect comparisons 
with other studies are not possible, as published SUL assays with similar analyte extraction 
techniques do not report matrix effect data (Alumkal et al., 2015; Clarke et al., 2011; Gasper 
et al., 2005; Hauder et al., 2011; Janobi et al., 2006; Platz et al., 2015). Future studies should 
report the means, standard deviations and RSDs of any observed matrix effects in order to 
better assess whether they affect the quantification of the analytes being investigated. 
This assay uses both protein precipitation and SPE to prepare the sample for UHPLC-MS/MS 
analysis, which adds to sample preparation time in contrast to dilution and filtration 
methods. However, we found the addition of these steps necessary when injecting large 
numbers of samples onto the UHPLC system, as preliminary tests of injecting undiluted 
plasma on-column caused frequent high-pressure issues and needle seat blockages, 
consistent with previous reports that injection of untreated, diluted plasma on-column is 
problematic for UHPLC-MS/MS systems (Bonfiglio et al., 1999; Müller et al., 2002) (Chapter 
3). 
The sulforaphane concentration-time profiles generated using this assay are presented in 
Chapter 5, and highlight the utility of this assay in clinical studies that have cruciferous 
vegetable or isothiocyanate extract interventions. The sensitivity and resolution of this assay 
allow for quantification down to 7.8 pg on-column, representing plasma concentrations of 
0.78 ng/mL—high enough to detect sulforaphane up to 8 hours post-consumption. Due to 
its ready applicability, the use of this validated, simplified assay is encouraged when 
conducting future cruciferous vegetable/ITC studies. 
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4.5 Conclusions 
In conclusion, the currently-presented assay successfully uses UHPLC-MS/MS to analyse SUL 
and an internal standard in human plasma. The methods described meet recommendations 
for bioanalytical methods concerning selectivity, sensitivity, accuracy and precision (Booth & 
Kadavil, 2001). This assay’s relative simplicity and short chromatographic run times 
compared to other published SUL assays has been demonstrated by its use in analysing over 
150 samples. The presented method demonstrates an increase in sensitivity of up to 227% 
alongside reductions in sample handling and resource costs.  
Following validation of this assay, it was used as described at the end of Chapter 2 to 
measure the plasma concentrations and exposure profiles of SUL in 21 people of either 
European or South Asian geographic ancestry before, during and after consuming a broccoli-
enriched diet (Chapter 5). This assay and the CYP-phenotyping cocktail assay presented in 
Chapter 3 were both used successfully to test hypotheses generated from the thesis 
objectives (section 1.9), and these data are analysed and discussed in the next chapter.  
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5 The effects of broccoli consumption, sulforaphane exposure and 
genetics on the activity of drug-metabolising enzymes in people 
of European and South Asian ancestry 
5.1 Introduction 
Thus far, this thesis on variability in drug metabolism has explored the effects of cruciferous 
vegetables on phase I and II enzymes, identifying that in particular, CYP1A2 is significantly 
induced in persons consuming diets rich in these foods. The theme of geographic ancestry 
has also been introduced in Chapter 1, and understanding geographic ancestry as a 
composite of known and unknown intrinsic and extrinsic factors that affect the 
pharmacokinetics of drugs has been discussed. Suitable bioanalytical methods are required 
in order to conduct prospective human trials that explore the interactions between 
cruciferous vegetable-enriched diets, ancestry and drug metabolism; the design, 
optimisation and validation of two such assays have been described in Chapters 3 and 4.  
This chapter unites all of the themes and research presented thus far, by demonstrating the 
application of the presented assays to answering hypotheses involving geographic ancestry, 
genetics, cruciferous vegetable-enriched diets and drug metabolism. 
CYP1A2 activity has been shown to vary in populations of European or South Asian ancestry 
and the presence or absence of Cruciferae in the diet (Chapters 1 and 2). In one particular 
observational study, broccoli consumption was associated with increased CYP1A2 activity in 
the European cohort, but lower activity in the South Asian cohort (Perera et al., 2012a). It 
was hypothesised that differences in food preparation, including the currying of foods, could 
be producing this difference in enzyme activity, alongside other unknown ancestry-specific 
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differences. Of note, these findings have not been confirmed in a prospective, controlled 
trial. 
Further, CYP2C19, CYP2C9, CYP2D6 and CYP3A4 have not been investigated in this context 
(Chapter 2) and no studies were identified that have investigated the effects of both 
geographic ancestry and Cruciferae on these enzymes. There are common overlaps between 
the CYPs with respect to induction mechanisms and hence a molecule that induces CYP1A2 
could also, via the same pathways, induce other CYP enzymes (Tompkins & Wallace, 2007). 
Therefore, the known effects of broccoli on increased CYP1A2 activity may also be reflected 
in the effects on other CYP enzymes represented in the phenotyping cocktail. 
Therefore, the aims of this clinical trial were to: 
1) Investigate the acute and medium-term effects of a broccoli-enriched diet on 
CYP1A2, CYP2C19, CYP2C9, CYP2D6 and CYP3A4 activities; 
2) Establish if the above effects vary between healthy subjects of European and South 
Asian ancestry; 
3) Explore the effects of diet and genetics on SUL exposure, and see if these vary 
between Europeans and South Asians; 
4) Confirm that CYP1A2 is induced in Europeans on a broccoli-enriched diet, with no or 
a reduced change in South Asians; and 
5) Explore the contribution of diet, genetics and geographic ancestry on CYP1A2, 
CYP2C19, CYP2C9, CYP2D6 and CYP3A4 activities in the two ancestry groups. 
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5.2 Methods 
This trial received general ethics approval and site-specific approval (SSA) from the Sydney 
Local Health District (SLHD) ethics committee at Concord Repatriation General Hospital 
(CRGH) (Approval ID HREC/12/CRGH/206) (Appendices 8.3 and 8.4). The study was 
conducted in an outpatient clinic at CRGH. The trial was prospectively registered with the 
Australian New Zealand Clinical Trials Registry (ANZCTR) (Trial ID ACTRN12613001112752) 
(Appendix 8.5), which is a World Health Organisation International Clinical Trials Registry 
Platform (WHO ICTRP). The Therapeutic Goods Administration (TGA) was notified of the use 
of the study medicines as CYP enzyme probe drugs (Appendix 8.6). 
5.2.1 Participants 
The study population consisted of healthy, community-dwelling males aged between 18-55 
years (n = 21; see section 5.2.7.1 for sample size calculations). Participants were of 
European (n = 11) and South Asian (n = 10) geographic ancestry who were willing to 
participate in a dietary intervention trial. All participants were screened for study eligibility 
at a face-to-face interview during which a questionnaire was completed (Appendix 8.7), 
ensuring that the inclusion criteria were met and no exclusion criteria were met (Figure 5.1). 
Patients were labelled as ‘self-reported healthy’ if they reported no diseases or concurrent 
therapeutic substance use as per the questionnaire. After eligibility was confirmed, written, 
informed consent to participate was obtained (Appendix 8.8) and a copy of the Participant 
Information Sheet (PIS) was given (Appendix 8.9). 
Previous reports of differences in CYP activity by sex are varied, with findings being divided 
between no difference and activity being higher in men than women (Nehlig, 2018). Further, 
CYP1A2 activity can be influenced by sex hormones, including the contraceptive pill (Perera 
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et al., 2012a). Therefore, to reduce the potential for confounding by the influence of sex 
differences, it was decided to recruit only male participants in this study in order to achieve 
higher confidence in and better explain the observed interactions between diet, ancestry 
and genetics. 
Geographic ancestry was self-determined by each participant based on the geographic 
origins of the participant’s four grandparents. Participants were eligible to participate if all 
four of their grandparents (explicitly, their biological parents’ biological parents) were of the 
same geographic ancestry. 
Participants were recruited via university noticeboards and web distribution services by 
means of a poster (Appendix 8.10) and electronic advertisements approved by the HREC. On 
successful and full completion of the study, participants received A$500 to compensate 
them for their time and effort.  
Participants were assigned a random number and thus de-identified in paper and electronic 
records. Hard copy consent forms and survey questionnaires were stored in a locked cabinet 
in a secured room. All information obtained from participants was coded in spreadsheets 
and password protected. Data will be kept for at least six years and then disposed of 
through deletion (in the case of computer files), shredded (in the case of hardcopy 
documents) or disposed in clinical waste (for clinical samples). All procedures were in 
accordance with the University of Sydney Research Data Management Policy, 2014 
(http://sydney.edu.au/policies/showdoc.aspx?recnum=PDOC2013/337&RendNum=0, 
retrieved 17/01/18) and Research Data Management Procedures, 2015 
(http://sydney.edu.au/policies/showdoc.aspx?recnum=PDOC2014/366, retrieved 
17/01/18). 
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Inclusion criteria 
i. Male, aged 18-55 years 
ii. European or South Asian geographic ancestry 
iii. Non-smoker or ex-smoker that has abstained from smoking for at least 6 months 
iv. Ability to comply with the planned procedures and provide written informed 
consent which requires a level of English language competency to effectively 
understand the protocol and adequately meet the definition of informed consent  
v. Self-reported healthy with no reported or diagnosed acute or chronic health 
conditions 
vi. Access to a microwave with an appropriate cooking setting 
Exclusion criteria  
i. Known hypersensitivity or intolerance to any of the five drugs used in the study 
ii. History of clinical signs of hypotension, specifically fainting, light-headedness 
and/or a blood pressure lower than 80/60 mmHg 
iii. Female 
iv. Known food allergies or intolerances that limit participation in this study 
v. Oral antimicrobial use within the past 3 months 
vi. Body mass index (BMI) outside of 18.5-32.5 kg.m-2 
vii. Currently taking or using any prescription, over-the-counter, herbal, 
complementary or illicit medicines 
viii. Given blood or participating in another clinical study in the last 3 months 
Figure 5.1: Participant inclusion and exclusion criteria. 
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5.2.2 Study design 
This study adopted an open-label, 3-period, sequential, crossover dietary intervention trial 
design. Participants completed two 3-day food diaries (Appendices 8.11 and 8.12) over the 
three days leading up to Day 1 and during Days 6-8, inclusive. Figure 5.2 outlines the study 
design. On Day 1, the CYP probe cocktail (see section 5.2.3 below) was administered 
following an overnight fast. All food and beverages were provided on-site during the study 
days; a plain muffin, choice of a chicken and salad or plain salad sandwich and water were 
offered to the participants. Each study day, this food was ordered from the same on-site 
canteen at the same time of day to minimise the introduction of any potential variability. 
The muffin was offered after collecting the 2-hour blood sample and the sandwich was 
offered after the 4-hour blood sample was collected. Water was freely available throughout 
the study days. 
On Day 2, 200 g of microwave-steamed broccoli (see 5.2.3 below) was consumed 2 hours 
before the CYP probe cocktail was administered to assess the acute effects of broccoli 
consumption on CYP activity. After the last venous blood sample was collected at six hours 
post-dose, participants were provided with pre-packaged and labelled ‘snap-lock’ bags 
containing weighed broccoli servings to be microwaved and consumed for the next six days 
(Days 3-8).  
From Days 3-8, participants consumed 200 g of broccoli with lunch and dinner whilst 
following their usual dietary habits. Participants were instructed to maintain their usual diet 
throughout the study and make no major changes to the types and quantities of food that 
they usually consume. They were also asked to avoid consumption of grapefruit juice 
throughout the study, have no more than 4 standard drinks of alcohol on any one occasion 
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and avoid caffeine on the mornings that the CYP phenotyping cocktail was being 
administered. As mentioned above, a second food diary was completed during this period to 
monitor foodstuffs consumed and encourage adherence to the study protocol. On Day 9, 
participants returned following an overnight fast for the final administration of the CYP 
probe cocktail. 
To ensure participant safety, pressure and pulse (via automated blood pressure monitor), 
respiratory rate and level of sedation were monitored hourly throughout the study period. 
This monitoring process is described in Appendix 8.13. 
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Figure 5.2: Summary diagram of sequential timeline of the clinical study. 
 
5.2.3 Broccoli procurement and preparation 
Broccoli was purchased fresh from one local supplier (Stewart Dickson Produce Pty Ltd) to 
reduce inter-batch variability. For the duration of the study, an arrangement was made with 
the supplier that broccoli would come from the same two growers, who had neighbouring 
farms. The broccoli was washed for 5 seconds under running tap water and then cut at the 
short part of the stem with the florets still attached into easily eaten pieces. The pieces 
were then weighed and divided into 200 g quantities, placed in snap-lock sealable plastic 
bags and stored at 4 °C until use. Participants were instructed to ensure that the broccoli 
Days -2 to 0: 3-day diet diary 
Day 1: Baseline CYP phenotyping
Day 2: CYP phenotyping with 
consumption of 200 g broccoli to 
measure acute effects on CYP activity
Days 3 to 8: 200 g broccoli consumed at 
lunch and dinner in addition to normal 
diet. Food diary is kept on Days 6-8
Day 9: Final CYP phenotyping to 
measure medium-term effects of 
broccoli on CYP activity
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was kept refrigerated until consumed. Participants were provided with a BPA-free steaming 
container and instructed to microwave the broccoli at a wattage and time specified below in 
Table 5.1. These recommendations were based on Verkerk et al. (2009) and Song and 
Thornalley (2007) which suggested that microwave steaming for 3 min at 1000 W produced 
the lowest decrease in ITC content. During informal palatability testing it was determined 
that this could be further decreased to 2 min at 1000 W, which was then linearly scaled to 
produce the times in Table 5.1.  
Table 5.1: Recommended broccoli cooking times based on available microwave power and 
published evidence of broccoli constituent stability (Chapter 1). 
Microwave power (watts) Recommended cooking time (seconds) 
700 150 (2 min 30 s) 
800 135 (2 min 15 s) 
900 130 (2 min 10 s) 
1000 
1200 
120 (2 min) 
110 (1 min 50 s) 
 
Participants consumed the entire contents of the 200 g broccoli sample on each occasion. If 
this method of eating the broccoli was unappealing to the participant to the point of non-
compliance or drop-out, a small amount (< 10 mL) of salad dressing was permitted to be 
added before eating. Details on how to handle, prepare and consume the broccoli were 
given to participants in a handout (Appendix 8.14). 
5.2.4 CYP-phenotyping procedure 
The CYP probe drugs, metabolites, phenotyping metrics and sampling procedure used are 
described in section 3.2.7 of this thesis and summarised in Figure 5.3 below. 
118 
 
Figure 5.3: CYP probe drugs, metabolites and phenotyping metrics. 
 
5.2.5 Analytical methods 
UHPLC-MS/MS analytical methods for the 5 probe drugs, their 5 enzyme-specific 
metabolites (Chapter 3) (Figure 5.3) and sulforaphane (SUL) (Chapter 4) have been 
described in this thesis. Samples for CYP phenotyping were collected on all 3 study days, 
with SUL being analysed in the baseline D1 and D9 samples, as well as in all six samples on 
D2 to explore exposure after consuming a broccoli meal (200 g). 
5.2.6 Genotyping 
Each participant was genotyped for variants known to affect CYP activity or SUL metabolism 
(Chapter 1). The full list of SNPs and copy number assays for the relevant drug-metabolising 
enzymes in this study are listed in Appendix 8.16. However, only variants where genotype 
varied between participants were included in the analyses. DNA extraction/purification and 
subsequent genotyping was conducted by the Australian Genome Research Facility 
(Brisbane, QLD). DNA was purified and extracted from participant blood samples using the 
•Probe drug: caffeine (CAF) (100 mg)
•Metabolite: paraxanthine (PAR)
•Metric: 4-h PAR/CAF plasma concentration ratioCYP1A2
•Probe drug: omeprazole (OME) (20 mg)
•Metabolite: 5-hydroxyomeprazole (OH-OME)
•Metric: post-absorption OH-OME/OME plasma concentration ratioCYP2C19
•Probe drug: losartan (LOS) (25 mg)
•Metabolite: losartan carboxylic acid (EXP)
•Metric: EXP/LOS AUC0-6 h ratio
CYP2C9
•Probe drug: dextromethorphan (DXM) (30 mg)
•Metabolite: dextrorphan (DXR)
•Metric: DXR/DXM AUC0-6 h ratio
CYP2D6
•Probe drug: midazolam (MID) (2 mg)
•Metabolite: α-hydroxymidazolam (OH-MID)
•Metric: 4-h OH-MID/MID plasma concentration ratioCYP3A4
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methods outlined in Appendix 8.15. Genotyping was performed using the Agena Bioscience 
MassARRAY platform and the iPLEX ADME PGx panel according to the manufacturer’s 
protocols (Agena Bioscience, San Diego, CA) (Lee et al., 2016). 
5.2.7 Data and statistical analyses 
5.2.7.1 Sample size calculations 
When designing this study, the sample size was based on the assumption that a paired-
samples t test or non-parametric equivalent would be used. CYP1A2 activity metrics across 
the study days and between ancestry groups were used in the variability calculation due to 
familiarity with its variability and access to previous raw data. Using this information and a 
standard deviation of 0.30 for CYP1A2 activity (Ghassabian et al., 2009), a sample size of n = 
14 participants in each ancestry group (total n = 28) was calculated to detect up to a 25% 
difference in CYP1A2 activity with 80% power and a type I error (α) of 0.05. Because CYP1A2 
activity displays the largest intra- and inter-subject variability (Perera et al., 2012a), it was 
deemed a suitable surrogate for sample size approximation for the other CYP enzymes being 
simultaneously studied, n = 28 subjects allowed for detection of up to a 25% difference in 
CYP2C19, CYP2C9, CYP2D6 and CYP3A4 activity with 80% power and a type I α of 0.05. 
Mixed-effects models have been widely recommended due to their utility when analysing 
repeated-measured data arising from crossover trials (Goh et al., 2010; Kakuda et al., 2014; 
Nordmark et al., 2014; Turpault et al., 2009). Some of the reasons for this are their superior 
power compared to other types of analyses, their ability to include statistically-controlling 
covariates, which can greatly reduce the sample sizes needed to detect significant 
differences in endpoints, and control of familywise error across multiple comparisons 
(Gueorguieva & Krystal, 2004; Putt & Chinchilli, 1999). Because the method of sample size 
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calculation depends on the choice of planned statistical tests in a study’s analyses, sample 
size was also calculated based on the use of multiple mixed-effects models. 
As preliminary results had been collected by the time of this realisation, post hoc sample 
size re-calculations were possible. These were performed using the GLIMMPSE sample size 
calculator for crossover studies with repeat-measures found at 
http://glimmpse.samplesizeshop.org (Kreidler et al., 2013). The parameters constant across 
the 5 enzyme activities were power = 0.8 and α = 0.1 (for 90% confidence intervals, in a 
similar fashion to a bioequivalence design) (Kakuda et al., 2014; Nordmark et al., 2014) to 
detect a difference in enzyme activity of up to 25%. For each CYP enzyme activity, estimates 
of the standard deviations and within-subject correlation coefficients were derived from the 
preliminary data of this study, as well as from Turpault et al. (2009) (CYP2C19), Vogl et al. 
(2015) (CYP2C9), Dorado et al. (2012) (CYP2D6) and Dorne et al. (2003) (CYP3A4). The 
results are presented in Table 5.2, and indicate that n = 10-12 participants in each ancestry 
group is appropriate to test the proposed hypotheses (section 5.1) for most of the CYP 
enzymes. 
Table 5.2: GLIMMPSE sample size calculations from a linear mixed-effects model. 
Calculated n is for Study Day, Ancestry and Study Day*Ancestry in the linear model for 
each geographic ancestry group, unless specified otherwise. 
CYP enzyme Power Type I error 
Difference in 
metric (%) 
Calculated n 
CYP1A2 0.8 0.1 25 6 
CYP2C19 0.8 0.1 25 8 
CYP2C9 0.8 0.1 25 12 
CYP2D6 0.8 0.1 25 6 
CYP3A4 0.8 0.1 25 16 
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5.2.7.2 Pharmacokinetic analyses 
Non-compartmental methods were used to calculate pharmacokinetic parameters. Area 
under the concentration-time curves (AUCs) for each probe drug, metabolite and SUL were 
calculated from plasma concentrations using the linear trapezoidal rule. 
5.2.7.3 Food diary analyses 
The food diaries were analysed using the methods presented by Perera et al. (2012a). 
Participants were categorised based on their consumption of foods known to inhibit or 
induce CYP1A2 activity (Table 5.3) as well as their curry consumption (Table 5.4). The two-
tailed Pearson’s correlation coefficient was used to assess correlations between diet sub-
categories and CYP enzyme activity. 
5.2.7.4 Statistical analyses 
All data were analysed in SPSS Statistics for Windows, version 23 (IBM Corp., Armonk, N.Y., 
USA). Normality of endpoint and residual distributions was assessed using the Shapiro-Wilk 
test and by visually observing the distributions. Differences in food consumption category 
proportions were analysed using a 2-way chi-square test with a Bonferroni-corrected type I 
error to account for familywise error across multiple comparisons.  
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Table 5.3: Foodstuffs known to inhibit or induce CYP1A2. Methods by Perera et al. 
(2012a). 
CYP1A2 Inducers CYP1A2 Inhibitors Other Dietary Factors 
Bok Choy Carrots Chocolate consumption 
Broccoli Celeriac Tea consumption 
Brussels sprouts Celery Soft drink/energy drink consumption 
Cabbage Coriander Coffee consumption 
Cauliflower Cumin Alcohol consumption 
Char-grilled meats Grapefruit juice Any dietary restrictions 
Radish Parsnip Predominantly curry diet 
Rocket Parsley Vegetarian 
Wasabi   
 
Table 5.4: Categories used to define subject diets based on CYP1A2 inducer, CYP1A2 
inhibitor and curry consumption. 
 
The various CYP phenotyping metrics were natural log-transformed prior to statistical 
analysis to reduce variability and approximate normal distributions (Shen et al., 2006). A 
linear mixed-effects model was created for each CYP enzyme (with the exception of CYP2D6, 
whose analyses required three separate models—see section 5.3.4.4.3) to produce 
estimated marginal means (EMMs) (least-squares means) of log-transformed metrics. In the 
models, Study Day, Ancestry, Genotype and their various interactions were fixed effects and 
Category Definition 
High CYP inducer consumption 
Greater than 8 servings per week (across 
both food diaries) 
High CYP inhibitor consumption 
Greater than 6 servings per week (across 
both food diaries) 
Predominantly curry diet 
At least 1 serving of curry per day for a 
whole food diary 
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the intercept of each participant was a random effect. Post-hoc tests for significant factor 
interactions were performed using the Least Significant Difference (LSD) method. The type I 
error was set at 0.1 to produce 90% confidence intervals (CIs) for differences in log-
transformed EMMs between study days and between ancestry groups. These CIs were log-
back-transformed to produce geometric EMM (GEMM) ratios with corresponding 90% 
confidence intervals (see section 5.2.7.1 for a rationale supporting the use of these 
methods). The model structures, repeat-measures covariance structures, random-effects 
covariance structures and SPSS syntaxes are presented in Appendix 8.17. 
For SUL analyses, the two-tailed Pearson’s correlation coefficient was used to assess 
correlations between the various SUL time points and D2 AUC0-8 h after natural log-
transformation. A linear mixed-effects model was used to assess the differences in D2 SUL 
AUC0-8 h between geographic ancestry groups and explore the effects of genetics on SUL 
exposure. As with CYP activity metrics, the liberal type I error of 0.1 was used to assess 
statistical significance of differences in SUL concentrations and AUCs between ancestry 
groups. 
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5.3 Results 
All enrolled participants completed the study in full with no serious adverse events. 
Transient drowsiness and light-headedness were reported by some participants, which were 
attributed to fasting and taking the midazolam, dextromethorphan and losartan 
combination. 
5.3.1 Participant demographics 
Participant age, weight, height, BMI and ancestry are presented in Table 5.5. Differences in 
demographics between ancestry groups were not statistically analysed, as this study was 
not powered or designed to detect differences in these parameters. However, there were 
no major differences in the means and standard deviations of these demographics between 
the groups. 
5.3.2 Dietary data 
The proportions of those who reportedly consumed diets high in CYP1A2 inducers, CYP1A2 
inhibitors and curry are shown in Table 5.6, Table 5.7 and Table 5.8, respectively. Of those 
consuming low amounts of CYP1A2 inducer foods, 14% were European and 86% were South 
Asian (P < 0.05). With regards to high consumption of inducer foods, 71% were European 
and 29% were South Asian (P < 0.05). For CYP1A2 inhibitor foods, there were no significant 
differences between ancestry groups. However, with regards to curry consumption, 69% of 
low curry consumers were European and 31% were South Asian. Of those consuming a 
predominantly curry diet, 100% were South Asian (P < 0.05). 
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Table 5.5: Participant demographics. 
ID Geographic ancestry Age (years) Weight (kg) Height (m) BMI (kg.m-2) 
1 European 33 77.6 1.78 24.5 
2 South Asian 51 70.0 1.62 26.7 
3 European 18 62.0 1.60 24.2 
4 South Asian 18 79.8 1.78 25.3 
5 South Asian 43 71.2 1.77 22.9 
6 South Asian 19 92.9 1.76 30.0 
7 South Asian 24 63.4 1.78 20.0 
8 European 20 72.2 1.81 22.0 
9 European 22 56.0 1.77 17.9 
10 European 23 64.0 1.80 19.8 
11 European 19 72.1 1.86 20.9 
12 European 20 85.3 1.83 25.5 
13 European 23 89.8 1.84 26.4 
14 European 19 87.3 1.81 26.6 
15 European 23 62.7 1.81 19.1 
16 European 28 84.7 1.83 25.4 
17 South Asian 23 82.7 1.77 26.3 
18 South Asian 20 66.0 1.70 22.9 
19 South Asian 22 82.5 1.80 25.4 
20 South Asian 33 73.0 1.72 24.7 
21 South Asian 20 90.0 1.70 31.1 
 Mean ± SD (total) n = 21 24.8 ± 8.59 75.5 ± 10.8 1.77 ± 0.07 24.2 ± 3.40 
 Mean ± SD (European) n = 11 22.5 ± 4.46 74.0 ± 11.77 1.80 ± 0.07 22.9 ± 3.13 
 Mean ± SD (South Asian) n = 10 27.3 ± 11.35 77.2 ± 9.98 1.70 ± 0.05 25.5 ± 3.31 
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Table 5.6: Consumption of CYP1A2 inducers by ancestry. 
 
Geographic ancestry 
Total European South Asian 
CYP inducer diet Low consumption of CYP 
inducers 
Count (n) 1 6 7 
% within CYP inducer diet 14.3% 85.7% 100.0% 
% within Geographic 
ancestry 
9.1% 60.0% 33.3% 
% of Total 4.8% 28.6% 33.3% 
High consumption of CYP 
inducers 
Count (n) 10 4 14 
% within CYP inducer diet 71.4% 28.6% 100.0% 
% within Geographic 
ancestry 
90.9% 40.0% 66.7% 
% of Total 47.6% 19.0% 66.7% 
Total Count (n) 11 10 21 
% within CYP inducer diet 52.4% 47.6% 100.0% 
% within Geographic 
ancestry 
100.0% 100.0% 100.0% 
% of Total 52.4% 47.6% 100.0% 
Table 5.7: Consumption of CYP1A2 inhibitors by ancestry. 
 
  
 
Geographic ancestry 
Total European South Asian 
CYP inhibitor diet Low consumption of CYP 
inhibitors 
Count 9 8 17 
% within CYP inhibitor diet 52.9% 47.1% 100.0% 
% within Geographic 
ancestry 
81.8% 80.0% 81.0% 
% of Total 42.9% 38.1% 81.0% 
High consumption of CYP 
inhibitors 
Count 2 2 4 
% within CYP inhibitor diet 50.0% 50.0% 100.0% 
% within Geographic 
ancestry 
18.2% 20.0% 19.0% 
% of Total 9.5% 9.5% 19.0% 
Total Count 11 10 21 
% within CYP inhibitor diet 52.4% 47.6% 100.0% 
% within Geographic 
ancestry 
100.0% 100.0% 100.0% 
% of Total 52.4% 47.6% 100.0% 
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Table 5.8: Counts and frequencies of a predominantly curry diet by ancestry. 
 
Geographic ancestry 
Total European South Asian 
Predominantly curry diet Low curry consumption Count 11 5 16 
% within Predominantly 
curry diet 
68.8% 31.3% 100.0% 
% within Geographic 
ancestry 
100.0% 50.0% 76.2% 
% of Total 52.4% 23.8% 76.2% 
Predominantly curry diet Count 0 5 5 
% within Predominantly 
curry diet 
0.0% 100.0% 100.0% 
% within Geographic 
ancestry 
0.0% 50.0% 23.8% 
% of Total 0.0% 23.8% 23.8% 
Total Count 11 10 21 
% within Predominantly 
curry diet 
52.4% 47.6% 100.0% 
% within Geographic 
ancestry 
100.0% 100.0% 100.0% 
% of Total 52.4% 47.6% 100.0% 
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5.3.3 Sulforaphane exposure 
Sulforaphane (SUL) concentrations and AUCs after broccoli ingestion showed remarkable 
variability both overall and in the two ancestry groups, and required natural log-
transformation to achieve a normal distribution (Table 5.10). Across the seven time points 
where SUL was measured and D2 AUC0-8 h, CV% of log-transformed data ranged from 12-
76% in the European ancestry group, 18-55% in the South Asians and 15-71% overall. Mean 
concentration-time plots of SUL on D2 are shown in Figure 5.4. 
In the mixed-effects model, GSTM1 and GSTP1 genotypes had a significant effect on SUL 
AUC0-8 h (P < 0.05 for both), whereas GSTT1, GSTT2, UGT1A1 and geographic ancestry had no 
effect. The differences in SUL exposure by GSTM1 and GSTP1 genotypes are reported in 
Table 5.9. There was a genotype-exposure relationship, with SUL exposure being the highest 
in GSTM1 and GSTP1 null homozygotes, intermediate in GSTM1 and GSTP1 null 
heterozygotes, and lowest in those with two functional alleles. 
All natural log-transformed SUL concentration-time points and the D2 AUC0-8 h were 
correlated. In particular, the 3- and 4-h post-broccoli time points were strongly correlated 
with the AUC0-8 h (correlation coefficients 0.981 and 0.982, respectively [both P < 0.01]). Of 
note, SUL AUC0-8 was significantly correlated with a predominantly curry diet (correlation 
coefficient 0.441 [P = 0.045]). SUL AUC0-8 did not significantly correlate with the various 
activity metrics for all 5 CYP enzymes across the three study days. 
  
129 
 
Table 5.9: Back-transformed geometric EMM ratios of SUL AUC0-8 h activity with 90% CIs 
between GSTM1 and GSTP1 genotypes. 
GSTM1 rs1065411 CC~/CG# CC/GG$ GC/GG 
Overall 4.93 (1.97, 12.4)1 2.00 (1.07, 3.74)2 2.46 (1.09, 5.57)3 
GSTP1 rs1695a AA^/AG& AA/GG* AG/GG 
Overall 4.79 (2.39, 9.57)4 1.30 (0.40, 4.21) 3.70 (1.05, 13.0)5 
GSTM1 CC = homozygous null allele, CG = heterozygous null allele, GG = homozygous 
functional allele 
GSTP1 AA = homozygous null allele, AG = heterozygous null allele, GG = homozygous 
functional allele 
~: n = 8 
#: n = 2 
$: n = 11 
^: n = 14 
&: n = 6 
*: n = 1 
1. P = 0.007 
2. P = 0.069 
3. P = 0.072 
4. P = 0.001 
5. P = 0.088 
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Table 5.10: Natural log-transformed sulforaphane plasma concentrations and D2 AUC0-8 h by participant and ancestry. 
Participant 
ID 
Geographic 
ancestry 
D1 baseline 
(nM) 
D2 2-h 
(nM) 
D2 3-h 
(nM) 
D2 4-h 
(nM) 
D2 6-h 
(nM) 
D2 8-h 
(nM) 
AUC0-8 h 
(nM.h) 
D9 
(nM) 
1 European 1.94 5.13 4.81 4.40 4.18 3.58 6.52 2.58 
3 European 1.08 4.60 4.74 4.20 3.67 2.61 6.20 1.19 
8 European 1.91 5.57 5.32 5.03 4.67 3.74 7.03 3.52 
9 European 0.35 3.45 3.00 2.85 2.85 2.71 5.03 3.30 
10 European 1.59 5.90 5.49 5.38 5.08 4.59 7.41 3.29 
11 European 0.35 5.69 5.20 4.67 4.18 3.49 6.92 2.85 
12 European 0.39 4.95 4.49 4.19 3.54 2.71 6.19 2.64 
13 European 0.35 5.79 5.36 5.04 4.14 3.43 7.02 1.85 
14 European 0.72 5.31 4.38 3.76 3.36 2.54 6.26 1.50 
15 European 0.35 4.22 3.16 2.99 1.55 1.49 5.24 2.66 
16 European 0.42 4.63 4.79 4.23 3.80 3.29 6.26 2.84 
 Mean (Europeans) 0.86 5.02 4.61 4.25 3.73 3.11 6.37 2.57 
 SD (Europeans) 0.66 0.75 0.84 0.81 0.95 0.81 0.74 0.75 
 CV% 76.39 14.97 18.19 19.00 25.44 26.21 11.58 29.35 
2 South Asian 0.44 5.84 5.36 5.01 4.16 3.39 7.05 2.40 
4 South Asian 1.12 4.66 3.53 3.45 3.37 3.29 5.86 3.21 
5 South Asian 1.21 6.83 6.69 5.99 5.64 4.26 8.16 2.86 
6 South Asian 0.98 6.25 6.05 5.75 5.09 4.76 7.67 4.18 
7 South Asian 0.43 5.47 5.26 4.87 4.14 3.45 6.84 3.46 
17 South Asian 0.42 3.69 3.40 3.23 2.44 2.19 5.11 2.22 
18 South Asian 0.35 3.08 2.64 2.62 2.42 2.13 4.65 2.54 
19 South Asian 0.45 4.07 4.58 4.37 3.53 2.74 6.00 2.50 
20 South Asian 0.45 4.06 3.92 3.49 2.79 2.46 5.56 1.84 
21 South Asian 0.34 4.07 3.64 3.23 2.35 1.75 5.39 2.20 
 Mean (South 
Asians) 
0.62 4.80 4.51 4.20 3.59 3.04 6.23 2.74 
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Participant 
ID 
Geographic 
ancestry 
D1 baseline 
(nM) 
D2 2-h 
(nM) 
D2 3-h 
(nM) 
D2 4-h 
(nM) 
D2 6-h 
(nM) 
D2 8-h 
(nM) 
AUC0-8 h 
(nM.h) 
D9 
(nM) 
 SD (South Asians) 0.34 1.23 1.30 1.16 1.15 0.97 1.15 0.70 
 CV% 54.90 25.59 28.84 27.68 32.15 31.86 18.48 25.58 
 Mean (Total) 0.75 4.92 4.56 4.23 3.66 3.08 6.30 2.65 
 SD (Total) 0.53 0.99 1.06 0.97 1.03 0.87 0.93 0.72 
 CV% 71.40 20.08 23.15 22.88 28.03 28.25 14.83 27.03 
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Figure 5.4: Plasma concentration-time profile for SUL on D2 (natural log-transformed data). T = 0 data taken from baseline 
D1 SUL plasma sample, as participants consumed no Cruciferae between this sample and the D2 sampling window. 
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5.3.4 CYP activity 
5.3.4.1 CYP1A2 
5.3.4.1.1 Caffeine 
Changes in caffeine 4-h plasma concentrations and the CYP1A2 activity metric across study 
days showed marked variability, both overall and when stratified by ancestry (Table 5.11). 
The coefficient of variation (CV%) of 4-h caffeine plasma concentrations ranged from 27-
38% in Europeans and 55-63% in South Asians. Interestingly, these CV% varied little within 
ancestry groups across the study days, validating the choice of a repeated-measures 
prospective design for this trial. Individual participant caffeine plasma concentrations by 
ancestry and genotype across study days are shown in Figure 5.5. Caffeine plasma 
concentrations were higher throughout the study in the South Asian cohort compared to 
the Europeans (9,235 ± 5,535 nM vs 6,345 ± 2,131 nM, respectively). In the Europeans, 
mean caffeine concentrations increased immediately after a broccoli meal (D1 to D2), and 
decreased after 6 days of broccoli consumption (D1 to D9). In the South Asian ancestry 
group, mean caffeine concentrations decreased between D1 and D2, and decreased 
between D1 and D9.  
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Table 5.11: CYP1A2 data across study day by ancestry. 
 
Genotypes 
 
CYP1A2   
D1 D2 D9 
ID 
CYP1A2*1C 
rs2069514 
-3860G>A 
CYP1A2*1F 
rs762551 
-163C>A 
Geographic 
ancestry 
4-h 
CAF 
conc. 
(nM) 
4-h 
PAR 
conc. 
(nM) 
PAR/CAF 
4-h conc. 
ratio 
4-h 
CAF 
conc. 
(nM) 
4-h 
PAR 
conc. 
(nM) 
PAR/CAF 
4-h conc. 
ratio 
4-h 
CAF 
conc. 
(nM) 
4-h 
PAR 
conc. 
(nM) 
PAR/CAF 
4-h conc. 
ratio 
1 GG AC European 5350 3923 0.733 5696 3880 0.681 5003 4121 0.824 
3 GG CC European 6773 4190 0.619 6874 5632 0.819 5318 4660 0.876 
8 GG AC European 4532 541 0.119 4945 597 0.121 5160 598 0.116 
9 Fail AC European 10568 910 0.086 10845 1031 0.095 6859 1036 0.151 
10 GG AC European 8810 712 0.081 9392 549 0.058 6509 946 0.145 
11 GG AA European 5016 1344 0.268 3837 1275 0.332 3572 1091 0.305 
12 GG AA European 3255 3406 1.046 5120 4246 0.829 3042 3547 1.166 
13 GG AA European 6008 3257 0.542 6236 4550 0.730 6217 4487 0.722 
14 GG AA European 5352 5305 0.991 6599 4873 0.738 5023 5119 1.019 
15 GG CA European 11017 5541 0.503 10527 6351 0.603 8291 4289 0.517 
16 GG AA European 5840 5027 0.861 5024 3283 0.654 6778 7050 1.040  
  
Mean 
(Europeans) 
6593 3105 0.532 6827 3297 0.515 5616 3359 0.626 
 
  SD (Europeans) 2494 1914 0.357 2382 2101 0.303 1518 2125 0.395  
  CV% 37.8 61.7 67.1 34.9 63.7 58.8 27.0 63.3 63.1 
2 GG AA South Asian 18478 8207 0.444 21355 7751 0.363 18541 10152 0.548 
4 GG CC South Asian 5929 5489 0.926 7201 4320 0.600 4929 3615 0.733 
5 AG AA South Asian 9261 6916 0.747 12680 9302 0.734 14486 7738 0.534 
6 GG AC South Asian 5649 718 0.127 5045 380 0.075 4516 400 0.089 
7 GG AC South Asian 9584 763 0.080 9223 781 0.085 5985 596 0.100 
17 GG CA South Asian 16329 17165 1.051 14330 18093 1.263 11454 14636 1.278 
18 GA AA South Asian 15448 11003 0.712 11419 8848 0.775 11739 7180 0.612 
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Genotypes 
 
CYP1A2   
D1 D2 D9 
ID 
CYP1A2*1C 
rs2069514 
-3860G>A 
CYP1A2*1F 
rs762551 
-163C>A 
Geographic 
ancestry 
4-h 
CAF 
conc. 
(nM) 
4-h 
PAR 
conc. 
(nM) 
PAR/CAF 
4-h conc. 
ratio 
4-h 
CAF 
conc. 
(nM) 
4-h 
PAR 
conc. 
(nM) 
PAR/CAF 
4-h conc. 
ratio 
4-h 
CAF 
conc. 
(nM) 
4-h 
PAR 
conc. 
(nM) 
PAR/CAF 
4-h conc. 
ratio 
19 GG CC South Asian 7800 4179 0.536 9806 7896 0.805 8381 5556 0.663 
20 GG CA South Asian 3524 2100 0.596 1781 1328 0.745 3808 1551 0.407 
21 GA AA South Asian 4595 3652 0.795 2001 1355 0.677 1776 1651 0.930  
  
Mean (South 
Asians) 
9660 6019 0.601 9484 6005 0.612 8562 5308 0.589 
 
  
SD (South 
Asians) 
5298 5110 0.317 5952 5547 0.358 5354 4674 0.357 
 
  CV% 54.9 84.9 52.7 62.8 92.4 58.4 62.5 88.1 60.5  
  Mean (Total) 8053 4493 0.565 8092 4587 0.561 7018 4287 0.608  
  SD (Total) 4267 3976 0.332 4542 4240 0.325 4041 3617 0.368  
  CV% 53.0 88.5 58.8 56.1 92.4 58.0 57.6 84.4 60.5 
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Figure 5.5: Caffeine 4-h plasma concentrations across study days by ancestry and CYP1A2*1C (rs2069514) (A) and CYP1A2*1F (rs762551) (B) 
genotypes. 
 
 
 
 
 
A B 
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5.3.4.1.2 Paraxanthine 
Paraxanthine concentrations were more variable than caffeine concentrations: CV% of 
paraxanthine concentrations ranged from 62-64% in Europeans and 85-92% in South Asians, 
which were similar within the ancestry groups across study days. Individual participant 
paraxanthine plasma concentrations by ancestry, and genotype across study days are 
depicted below in Figure 5.6. Paraxanthine plasma concentrations were higher throughout 
the study in the South Asian cohort compared to the Europeans (5,777 ± 5,110 nM vs 3,254 
± 2,047 nM, respectively). In the Europeans, mean paraxanthine concentrations increased 
immediately after a broccoli meal (D1 to D2), and increased overall after 6 days of broccoli 
consumption (D1 to D9). In the South Asian ancestry group, mean paraxanthine 
concentrations decreased slightly between D1 and D2 and decreased overall between D1 
and D9. 
5.3.4.1.3 CYP1A2 activity 
The 4-h paraxanthine/caffeine ratio displayed large variability: CV% of CYP1A2 activity 
ranged from 59-68% in Europeans and 53-61% in South Asians, but this variability remained 
consistent within the ancestry groups across study days. There was a significant effect 
between Study Day and Ancestry in the mixed-effects model for the European cohort (F = 
3.499, P = 0.040). When examined further, there was a significant 20% increase in CYP1A2 
activity after 6 days of broccoli consumption (D1 to D9) in the Europeans (Table 5.12), but 
no changes in the South Asian cohort. With respect to genetics, overall, the CYP1A2*1C 
genotype did not significantly affect enzyme activity (F = 0.310, P = 0.584), however there 
was a significant 2.67-fold difference in activity between those who had the CC and CA 
CYP1A2*1F genotypes, respectively (GEMM ratio 2.69 [1.19, 6.10], P = 0.049) (Table 5.13). 
SUL exposure had no significant effect on CYP1A2 activity across the study days, in that 
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there was no significant correlation between SUL exposure and CYP1A2 activity. Individual 
changes in CYP1A2 activity by ancestry and genotype across study days are shown in Figure 
5.7. 
Table 5.12: Back-transformed geometric EMM ratios of CYP1A2 activity between study 
days with 90% CIs by ancestry group. 
 D2/D1 D9/D1 D9/D2 
Europeans (n = 11)  0.98 (0.85, 1.13) 1.20 (1.04, 1.38)* 1.22 (1.06, 1.41) 
South Asians (n = 10) 0.96 (0.84, 1.11) 0.96 (0.83, 1.10) 0.99 (0.86, 1.14) 
Overall (n = 21) 0.97 (0.87, 1.07) 1.03 (0.93, 1.14) 1.06 (0.96, 1.18) 
*P = 0.038 
Table 5.13: Back-transformed geometric EMM ratios of CYP1A2 activity with 90% CIs 
between CYP1A2*1F (rs762551) genotypes. 
 CC1/AC2 CC/AA3 AA/AC 
Overall 2.69 (1.19, 6.10)* 1.40 (0.48, 4.06) 1.93 (0.76, 4.85) 
1. N = 3 
2. N = 9 
3. N = 9 
*P = 0.049
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Figure 5.6: Paraxanthine 4-h plasma concentrations across study days by ancestry and CYP1A2*1C (rs2069514) (A) and CYP1A2*1F 
(rs762551) (B) genotypes. 
A B 
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Figure 5.7: CYP1A2 activity across study days by ancestry and CYP1A2*1C (rs2069514) (A) and CYP1A2*1F (rs762551) (B) genotypes. 
A B 
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5.3.4.2 CYP2C19 
5.3.4.2.1 Omeprazole 
As discussed in Chapter 3, omeprazole showed erratic absorption lag-times, such that 
concentrations are missing for some participants, who presumably did not absorb an 
appreciable amount of omeprazole in the 6-hour sampling window. Further, the post-
absorption plasma concentrations of omeprazole and 5-hydroxyomeprazole and their 
corresponding ratio were chosen to investigate CYP2C19, as these parameters displayed less 
variability than the calculated AUC0-6 h. The omeprazole post-absorption plasma 
concentrations showed marked variability, both overall and when stratified by ancestry 
(Table 5.14). Omeprazole CV% ranged from 53-66% in Europeans and 60-69% in South 
Asians; CV% varied little within ancestry groups across the study days. Individual participant 
omeprazole data by ancestry and genotype across study days are depicted in Figure 5.8. 
Omeprazole plasma concentrations were higher throughout the study in the European 
cohort compared to the South Asians (1,111 ± 674 nM vs 1,020 ± 662 nM, respectively). In 
the Europeans, mean omeprazole concentrations increased immediately after a broccoli 
meal (D1 to D2) and increased after 6 days of broccoli consumption (D1 to D9). In the South 
Asian ancestry group, they increased between D1 and D2 and decreased between D1 and 
D9. Omeprazole concentration data was available for n = 19, n = 21 and n = 15 participants 
on D1, D2 and D9, respectively.   
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Table 5.14: CYP2C19 data across study days by ancestry. Missing data marked with ‘-‘. Continues onto next page. 
 
Genotype 
 CYP2C19 
  D1 D2 D9 
ID 
CYP2C19*1C 
rs3758581 
80161A>G 
CYP2C19*2 
rs4244285 
19154G>A 
CYP2C19*17 
rs12248560 
-806C>T 
Geographic ancestry 
Post-
abs. 
OME 
conc. 
(nM) 
Post-
abs. OH-
OME 
conc. 
(nM) 
OH-
OME/OME 
post-abs. 
conc. ratio 
Post-
abs. 
OME 
conc. 
(nM) 
Post-
abs. OH-
OME 
conc. 
(nM) 
OH-
OME/OME 
post-abs. 
conc. ratio 
Post-
abs. 
OME 
conc. 
(nM) 
Post-
abs. OH-
OME 
conc. 
(nM) 
OH-
OME/OME 
post-abs. 
conc. ratio 
1 GG GG CC European 275 204 0.740 453 253 0.557 978 532 0.544 
3 AG GG CC European 632 465 0.736 1293 788 0.610 836 524 0.627 
8 GG GG CC European 408 114 0.278 954 557 0.584 - - - 
9 GG AG CC European 1673 341 0.204 1514 422 0.279 2221 754 0.340 
10 GG AG CC European 1724 662 0.384 1183 323 0.273 - - - 
11 GG GG CC European 1702 920 0.541 2973 899 0.302 2355 1221 0.519 
12 GG GG CT European 698 644 0.922 198 92 0.465 - - - 
13 GG AG CC European 1288 639 0.496 1428 637 0.446 1092 629 0.576 
14 GG GG CT European 133 152 1.144 1106 787 0.711 1174 946 0.806 
15 AG GG TT European 480 327 0.681 549 329 0.599 419 328 0.781 
16 GG GG CC European 1272 802 0.631 713 441 0.619 1109 690 0.622 
    Mean (Europeans) 935 479 0.614 1124 503 0.495 1273 703 0.602 
    SD (Europeans) 609 273 0.277 744 254 0.153 670 277 0.149 
    CV% 65.1 56.9 45.0 66.2 50.5 30.9 52.7 39.4 24.7 
2 GG AG CC South Asian 1066 341 0.320 2482 547 0.220 1238 568 0.459 
4 AG GG CC South Asian 391 395 1.010 465 486 1.046 383 370 0.968 
5 GG AA CC South Asian - - - 1918 105 0.055 - - - 
6 GG AG CC South Asian 945 218 0.231 1035 187 0.180 1477 192 0.130 
7 GG AG CT South Asian 636 330 0.520 1261 359 0.285 338 222 0.656 
17 GG GG CT South Asian 1134 676 0.596 355 135 0.381 678 310 0.458 
18 GG GG CT South Asian 566 400 0.707 430 629 1.462 739 647 0.876 
19 GG GG CC South Asian - - - 762 459 0.601 - - - 
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Genotype 
 CYP2C19 
  D1 D2 D9 
ID 
CYP2C19*1C 
rs3758581 
80161A>G 
CYP2C19*2 
rs4244285 
19154G>A 
CYP2C19*17 
rs12248560 
-806C>T 
Geographic ancestry 
Post-
abs. 
OME 
conc. 
(nM) 
Post-
abs. OH-
OME 
conc. 
(nM) 
OH-
OME/OME 
post-abs. 
conc. ratio 
Post-
abs. 
OME 
conc. 
(nM) 
Post-
abs. OH-
OME 
conc. 
(nM) 
OH-
OME/OME 
post-abs. 
conc. ratio 
Post-
abs. 
OME 
conc. 
(nM) 
Post-
abs. OH-
OME 
conc. 
(nM) 
OH-
OME/OME 
post-abs. 
conc. ratio 
20 GG AG CC South Asian 2461 188 0.076 2643 163 0.062 393 30 0.075 
21 GG AG CC South Asian 525 113 0.215 2111 214 0.101 - - - 
    Mean (South Asians) 965 333 0.459 1346 328 0.439 749 334 0.517 
    SD (South Asians) 662 173 0.308 877 191 0.470 448 216 0.343 
    CV% 68.6 51.9 67.1 65.2 58.2 106.9 59.8 64.7 66.2 
    Mean (Total) 948 417 0.549 1230 420 0.468 1029 531 0.562 
    SD (Total) 614 242 0.293 797 238 0.334 620 308 0.251 
    CV% 64.7 57.9 53.3 64.8 56.7 71.4 60.2 58.0 44.7 
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Figure 5.8: Omeprazole post-absorption plasma concentrations by study day, ancestry and CYP2C19*17 (rs12248560) (A), CYP2C19*1C 
(rs3758581) (B) and CYP2C19*2 (rs4244285) (C) genotypes. 
A B 
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Figure 5.8: Omeprazole post-absorption plasma concentrations by study day, ancestry and CYP2C19*17 (rs12248560) (A), CYP2C19*1C 
(rs3758581) (B) and CYP2C19*2 (rs4244285) (C) genotypes. Continued from previous page. 
C 
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5.3.4.2.2 5-hydroxyomeprazole 
5-hydroxyomeprazole (OH-OME) concentrations had comparable variability to omeprazole: 
CV% ranged from 40-57% in Europeans and 52-65% in South Asians (Table 5.14). Individual 
participant OH-OME plasma concentrations by ancestry, and genotype across study days are 
depicted below in Figure 5.9. Plasma concentrations were higher throughout the study in 
the European cohort compared to the South Asians (562 ± 268 nM vs 332 ± 193 nM, 
respectively). Mean OH-OME concentrations increased over the duration of the study (D1 to 
D2 to D9) in the European ancestry group and remained near-constant in the South Asians. 
As with OME, OH-OME concentration data was available for n = 19, n = 21 and n = 15 
participants on D1, D2 and D9, respectively. 
5.3.4.2.3 CYP2C19 activity 
In the European ancestry group, the 5-OH-OME/OME post-absorption ratio displayed 
relatively less variability than for other CYP enzymes, with CV% ranging from 25-45%. The 
opposite was observed for the South Asians, with CV% spanning 66-107%, attributed to two 
participants with higher values (4 and 18). However, the mixed effect model was able to 
account for missing data and adjust CYP2C19 activity according to ancestry and genotype, 
leading to detection of a significant effect across study days (F = 2.835, P = 0.072). When 
further explored, overall, CYP2C19 activity decreased 17% immediately after a broccoli meal 
(D1 to D2), then rebounded 18% by the end of the study after 6-days of broccoli 
consumption (D2 to D9) (Table 5.15). This pattern was reflected in the two ancestry groups, 
but did not achieve statistical significance (Study Day*Ancestry interaction F = 1.450, P = 
0.248). 
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CYP2C19 activity significantly varied by genotype in the mixed-effects model for 
CYP2C19*17 (F = 4.175, P = 0.029), CYP2C19*1C (F = 3.928, P = 0.060) and CYP2C19*2 (F = 
8.610, P = 0.001). The overall effects for each gene are listed in Table 5.16. Particular 
genotypes had large, significant effects on CYP2C19 activity as anticipated. For CYP2C19*17, 
CT individuals had 73% higher activity than those with the CC genotype; for CYP2C19*1C, GA 
individuals had 75% higher activity than GG individuals. For CYP2C19*2, there was roughly a 
dose-response relationship: CYP2C19 activity was 5.7-fold higher in GG individuals relative 
to AA individuals and 3.2-fold higher in GA individuals relative to those with the AA 
genotype. 
Genotype also interacted with ancestry in the model, with CYP2C19*17 CC Europeans 
having 90% higher CYP2C19 activity than CC South Asians (GEMM ratio 1.90 [1.16, 3.10], P = 
0.035). Further, there was a difference in enzyme activity between Europeans and South 
Asians with the CYP2C19*1C GG genotype (GEMM ratio 2.19 [1.41, 3.39], P = 0.005). This 
pattern was not repeated across those with CYP2C19*2 null alleles. 
High consumption of CYP1A2 inducers was positively correlated with CYP2C19 activity 
(correlation coefficient 0.661, P = 0.001) and high consumption of CYP1A2 inhibitors was 
negatively correlated with activity (correlation coefficient -0.742, P = 0.002). SUL exposure 
did not significantly correlate with CYP2C19 activity across the three study days. 
For better visualisation, individual changes in CYP2C19 activity by ancestry and genotype 
across study days are depicted below in Figure 5.10.
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Figure 5.9: 5-hydroxyomeprazole post-absorption plasma concentrations by study day, ancestry and CYP2C19*17 (rs12248560) (A), 
CYP2C19*1C (rs3758581) (B) and CYP2C19*2 (rs4244285) (C) genotypes. 
A B 
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 Figure 5.9: 5-hydroxyomeprazole post-absorption plasma concentrations by study day, ancestry and CYP2C19*17 (rs12248560) (A), 
CYP2C19*1C (rs3758581) (B) and CYP2C19*2 (rs4244285) (C) genotypes. Continued from previous page. 
C 
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Table 5.15: Back-transformed geometric EMM ratios of CYP2C19 activity with 90% CIs 
across study days by ancestry group. 
 D2/D1 D9/D1 D9/D2 
Europeans (n = 11)  0.85 (0.71, 1.03) 1.02 (0.83, 1.25) 1.19 (0.97, 1.47) 
South Asians (n = 10) 0.81 (0.66, 1.01) 0.96 (0.76, 1.20) 1.17 (0.94, 1.47) 
Overall (n = 21) 0.83 (0.72, 0.96)1 0.99 (0.85, 1.15) 1.18 (1.02, 1.38)2 
1. P = 0.036 
2. P = 0.072 
Table 5.16: Back-transformed geometric EMM ratios with 90% CIs of CYP2C19 activity 
between CYP2C19*17, CYP2C19*1C and CYP2C19*2 genotypes. 
CYP2C19*17 (rs12248560) 
CT~/CC# CT/TT$ TT/CC 
1.73 (1.22, 2.46)1 1.13 (0.51, 2.54) 1.53 (0.74, 3.15) 
CYP2C19*1C (rs3758581) 
AG^/GG*   
1.75 (1.08, 2.84)2   
CYP2C19*2 (rs4244285) 
GGx/AAy GG/AGz AG/AA 
5.66 (2.47, 12.9)3 1.78 (1.29, 2.47)4 3.17 (1.42, 7.05)5 
~: n = 5 
#: n = 15 
$: n = 1 
^: n = 3 
*: n = 18 
x: n = 12 
y: n = 1 
z: n = 8 
1. P = 0.013  
2. P = 0.060 
3. P = 0.001 
4. P = 0.006 
5. P = 0.020  
151 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: CYP2C19 activity across study days by ancestry and CYP2C19*17 (rs12248560) (A), CYP2C19*1C (rs3758581) (B) and CYP2C19*2 
(rs4244285) (C) genotypes. 
A B 
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Figure 5.10: CYP2C19 activity across study days by ancestry and CYP2C19*17 (rs12248560) (A), CYP2C19*1C (rs3758581) (B) and CYP2C19*2 
(rs4244285) (C) genotypes. 
 
C 
153 
 
5.3.4.3 CYP2C9 
5.3.4.3.1 Losartan 
Losartan AUC0-6 h CV% ranged from 41-49% in Europeans and 49-52% in South Asians; CV% 
varied little within ancestry groups across the study days (Table 5.17). Individual participant 
losartan data by ancestry and CYP2C9 genotype across study days are shown in Figure 5.11. 
Losartan plasma concentrations were similar in both ancestry groups (Europeans: 372 ± 162 
nM.h, South Asians: 375 ± 191 nM.h). In the Europeans, mean losartan concentrations 
increased throughout the study after 6 days of broccoli consumption (D1 to D2 to D9); in the 
South Asian ancestry group, the concentrations were stable immediately after a broccoli 
meal (D1 to D2) and decreased slightly after 6 days of broccoli consumption (D2 to D9). 
5.3.4.3.2 Losartan carboxylic acid 
Losartan carboxylic acid (EXP) concentrations had comparable variability to losartan: CV% 
ranged from 41-53% in Europeans and 56-58% in South Asians (Table 5.17). Individual 
participant EXP plasma concentrations by ancestry, and genotype across study days are 
shown in Figure 5.9. Plasma concentrations were higher throughout the study in the South 
Asian cohort compared to the Europeans (912 ± 520 nM.h vs 563 ± 251 nM.h, respectively). 
Mean EXP concentrations increased immediately after a broccoli meal (D1 to D2) then 
decreased after 6 days of broccoli consumption (D2 to D9), and this pattern was also 
observed in the South Asian ancestry group. 
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Table 5.17: CYP2C9 data across study days by ancestry. Continues onto next page. 
 
Genotype 
 CYP2C9 activity 
  D1 D2 D9 
ID 
CYP2C9*2 
rs1799853 
3608C>T 
CYP2C9*3 
rs1057910 
42614A>C 
Geographic 
ancestry 
LOS AUC0-6 h 
(nM.h) 
EXP AUC0-
6 h (nM.h) 
EXP/LOS 
AUC0-6 h 
ratio 
LOS 
AUC0-6 h 
(nM.h) 
EXP 
AUC0-6 
(nM.h) 
EXP/LOS 
AUC0-6 h 
ratio 
LOS 
AUC0-6 h 
(nM.h) 
EXP 
AUC0-6 h 
(nM.h) 
EXP/LOS 
AUC0-6 h 
ratio 
1 CT AA European 161 159 0.988 102 336 3.280 148 597 4.035 
3 CC AC European 221 230 1.039 289 471 1.632 229 300 1.310 
8 CT AA European 420 397 0.946 471 655 1.391 657 631 0.961 
9 CC AA European 514 595 1.157 499 789 1.580 420 402 0.958 
10 CC AA European 374 544 1.455 427 459 1.075 442 447 1.011 
11 CC AA European 822 987 1.201 598 958 1.602 423 648 1.530 
12 CC AA European 229 489 2.136 272 565 2.080 211 484 2.292 
13 CT AA European 203 208 1.021 208 321 1.543 248 247 0.997 
14 CC AA European 368 892 2.424 328 1179 3.588 295 1041 3.534 
15 CC AC European 446 492 1.103 559 598 1.070 382 423 1.108 
16 CC AA European 486 785 1.616 392 593 1.512 443 653 1.475 
   
Mean 
(Europeans) 
386 525 1.371 377 629 1.850 354 534 1.747 
   
SD 
(Europeans) 
189 276 0.497 153 260 0.833 145 218 1.086 
   CV% 49.0 52.5 36.2 40.6 41.3 45.0 41.0 40.8 62.2 
2 CC AA South Asian 535 1642 3.068 460 1930 4.195 438 1395 3.188 
4 CC AC South Asian 203 551 2.715 242 745 3.080 225 532 2.371 
5 CC AA South Asian 383 1533 3.999 312 939 3.006 429 1813 4.229 
6 CC AA South Asian 265 410 1.550 253 344 1.359 275 481 1.749 
7 CC AA South Asian 341 404 1.185 482 571 1.186 309 457 1.482 
17 CC AA South Asian 593 1242 2.096 682 1253 1.837 638 1145 1.795 
18 CC AA South Asian 626 1393 2.224 530 1836 3.462 517 1172 2.267 
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Genotype 
 CYP2C9 activity 
  D1 D2 D9 
ID 
CYP2C9*2 
rs1799853 
3608C>T 
CYP2C9*3 
rs1057910 
42614A>C 
Geographic 
ancestry 
LOS AUC0-6 h 
(nM.h) 
EXP AUC0-
6 h (nM.h) 
EXP/LOS 
AUC0-6 h 
ratio 
LOS 
AUC0-6 h 
(nM.h) 
EXP 
AUC0-6 
(nM.h) 
EXP/LOS 
AUC0-6 h 
ratio 
LOS 
AUC0-6 h 
(nM.h) 
EXP 
AUC0-6 h 
(nM.h) 
EXP/LOS 
AUC0-6 h 
ratio 
19 CC AA South Asian 600 978 1.630 608 884 1.454 546 842 1.542 
20 CC AA South Asian 125 480 3.834 105 756 7.221 127 520 4.077 
21 CC AA South Asian 138 372 2.700 135 471 3.491 123 251 2.036 
   
Mean (South 
Asians) 
381 901 2.500 381 973 3.029 363 861 2.474 
   
SD (South 
Asians) 
197 514 0.946 200 543 1.808 178 503 1.013 
   CV% 51.6 57.1 37.9 52.4 55.8 59.7 49.1 58.4 41.0 
   Mean (Total) 384 704 1.909 379 793 2.412 358 690 2.093 
   SD (Total) 188 440 0.927 172 445 1.477 158 407 1.091 
   CV% 49.0 62.6 48.6 45.4 56.1 61.2 44.0 59.0 52.1 
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Figure 5.11: Losartan AUC0-6 h across study days by ancestry and CYP2C9*3 (rs1057910) (A), CYP2C9*2 (rs1799853) (B) genotypes. 
A B 
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5.3.4.3.3 CYP2C9 activity 
In the European ancestry group, the EXP/losartan AUC0-6 h ratio CV% ranged from 36-62%. 
For the South Asian participants, CV% spanned 38-60%. There was a significant change in 
CYP2C9 activity across study days (F = 4.736, P = 0.014). When explored further, overall, 
CYP2C9 activity increased 25% from D1 to D2, but decreased 11% by the end of the study 
(D2 to D9) (Table 5.18). Ancestry had a significant overall effect in the model (F = 6.802, P = 
0.016), with South Asians having 1.94-fold higher CYP2C9 activity than Europeans ([1.25, 
3.00], P = 0.016). Further, there was a Study Day*Ancestry interaction in the European 
cohort (F = 4.180, P = 0.022): CYP2C9 activity increased 32% between D1 to D2 (Table 5.18). 
There were no significant overall effects in the model for differences in CYP2C9 activity 
between genotypes. However, the Ancestry*Genotype interaction in the model was 
significant, with CYP2C9 activity significantly varying by ancestry within genotypes for 
CYP2C9*3 (F = 6.016, P = 0.023) and CYP2C9*2 (F = 5.899, P = 0.024). The overall differences 
between the ancestry groups by genotype are listed in Table 5.19. For both variants, South 
Asians had higher activity than Europeans regardless of genotype. There was no significant 
correlation between SUL exposure and CYP2C9 activity across the study days. 
Individual changes in CYP2C9 activity by ancestry and genotype across study days are shown 
in Figure 5.13.
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Figure 5.12: Losartan carboxylic acid AUC0-6 h across study days by ancestry and CYP2C9*3 (rs1057910) (A), CYP2C9*2 (rs1799853) (B) 
genotypes. 
A 
B 
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Table 5.18: Back-transformed geometric EMM ratios of CYP2C9 activity with 90% CIs 
across study days by ancestry group. 
 D2/D1 D9/D1 D9/D2 
Europeans (n = 11)  1.32 (1.12, 1.54)1 1.17 (0.99, 1.37) 0.89 (0.76, 1.04) 
South Asians (n = 10) 1.12 (0.94, 1.32) 0.99 (0.84, 1.17) 0.89 (0.75, 1.05) 
Overall (n = 21) 1.25 (1.10, 1.41)2 1.10 (0.98, 1.24) 0.89 (0.79, 1.00)3 
1. P = 0.006 
2. P = 0.004 
3. P = 0.097 
Table 5.19: Back-transformed geometric EMM ratios of CYP2C9 activity with 90% CIs: 
differences between ancestry groups by CYP2C9*3 and CYP2C9*2 genotypes. 
 CYP2C9*3  CYP2C9*2 
Genotype South Asian/European Genotype South Asian/European 
AA~ 1.54 (1.14, 2.09)1 CC$ 1.80 (1.19, 2.74)3 
AC# 2.44 (1.10, 5.41)2 CT^ n/a 
~: South Asian n = 9, European n = 9 
#: South Asian n = 1, European n = 2 
$: South Asian n = 10, European n = 8 
^: South Asian n = 3, European n = 0 
1. P = 0.023 
2. P = 0.069 
3. P = 0.024  
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Figure 5.13: CYP2C9 activity across study days by ancestry and CYP2C9*3 (rs1057910) (A), CYP2C9*2 (rs1799853) (B) genotypes. 
A B 
161 
 
5.3.4.4 CYP2D6 
5.3.4.4.1 Dextromethorphan  
Dextromethorphan (DXM) AUC0-6 h CV% ranged from 53-60% in Europeans and 60-66% in 
South Asians; CV% varied little within ancestry groups across the study days (Table 5.20). 
Because of the large number of genotypes present in the CYP2D6 analyses, individual 
participant DXM spaghetti plots by ancestry and genotype across study days are displayed in 
Appendix 8.18, instead of within this chapter. DXM AUC was slightly higher in the South 
Asian ancestry group compared to the Europeans (45.6 ± 29.2 nM.h vs 36.8 ± 20.6 nM.h, 
respectively). In the Europeans, mean DXM concentrations increased immediately after a 
broccoli meal and then increased further after 6 days of broccoli consumption (D1 to D2 to 
D9); this pattern was also found in the South Asian ancestry group. Frequencies of DXM 
variant genotypes are displayed in Appendix 8.19. 
5.3.4.4.2 Dextrorphan 
Dextrorphan (DXR) concentrations had lower variability than DXM: CV% ranged from 35-
36% in Europeans and 43-46% in South Asians (Table 5.20). Individual participant DXR 
plasma concentrations by ancestry, and genotype across study days are depicted with the 
corresponding DXM data in Appendix 8.18. DXM AUC was higher throughout the study in 
the European cohort compared to the South Asians (96.8 ± 34.7 nM.h vs 84.0 ± 37.3 nM.h, 
respectively). In the Europeans, mean DXR concentrations decreased immediately after a 
broccoli meal and then decreased further after 6 days of broccoli consumption (D1 to D2 to 
D9); this pattern was also seen in the South Asian ancestry group. Frequencies of DXR 
variant genotypes are displayed in Appendix 8.19. 
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Table 5.20: CYP2D6 data across study days by ancestry. Continues onto next page. 
  CYP2D6 
  D1 D2 D9 
Participant Geographic ancestry 
DXM 
AUC0-6 h 
(nM.h) 
DXR 
AUC0-6 h 
(nM.h) 
DXR/DXM 
AUC0-6 h 
ratio 
DXM 
AUC0-6 h 
(nM.h) 
DXR 
AUC0-6 h 
(nM.h) 
DXR/DXM 
AUC0-6 h 
ratio 
DXM 
AUC0-6 h 
(nM.h) 
DXR 
AUC0-6 h 
(nM.h) 
DXR/DXM 
AUC0-6 h 
ratio 
1 European 43.9 101.1 2.303 26.1 62.5 2.392 32.0 56.5 1.766 
3 European 20.0 100.4 5.032 11.6 86.5 7.445 11.8 75.9 6.444 
8 European 40.4 76.7 1.900 55.9 72.7 1.301 67.6 95.5 1.412 
9 European 66.8 170.0 2.544 71.8 169.6 2.361 30.7 155.1 5.052 
10 European 47.4 161.5 3.405 38.7 123.3 3.182 51.2 158.0 3.086 
11 European 75.7 121.5 1.605 57.0 130.8 2.297 35.4 85.0 2.398 
12 European 44.4 59.8 1.347 52.7 62.2 1.180 54.9 53.7 0.979 
13 European 46.5 94.5 2.035 44.7 72.5 1.623 50.8 98.5 1.938 
14 European 12.5 92.3 7.398 14.1 83.9 5.952 7.12 75.1 10.551 
15 European 10.3 64.0 6.210 16.8 100.6 5.998 10.2 82.8 8.099 
16 European 17.4 72.9 4.182 27.3 91.1 3.342 22.1 88.9 4.024 
 Mean (Europeans) 38.7 101.3 3.451 37.9 96.0 3.370 34.0 93.2 4.159 
 SD (Europeans) 21.6 36.6 2.015 20.1 33.2 2.132 20.2 34.3 3.082 
 CV% 55.8 36.1 58.4 53.2 34.6 63.3 59.5 36.9 74.1 
2 South Asian 27.8 76.2 2.738 28.8 109.9 3.813 32.8 99.5 3.030 
4 South Asian 27.2 59.3 2.180 27.3 60.1 2.202 30.8 58.7 1.908 
5 South Asian 29.6 145.1 4.905 34.1 126.7 3.710 26.8 83.0 3.092 
6 South Asian 9.88 68.8 6.964 8.14 41.9 5.147 7.95 50.2 6.323 
7 South Asian 10.0 60.8 6.071 22.0 72.1 3.279 19.3 105.9 5.479 
17 South Asian 69.5 52.3 0.752 38.3 32.6 0.850 11.9 41.4 3.472 
18 South Asian 80.4 128.2 1.595 59.0 104.4 1.768 50.0 116.7 2.331 
19 South Asian 94.2 108.1 1.148 71.0 74.5 1.049 69.9 67.6 0.966 
163 
 
  CYP2D6 
  D1 D2 D9 
Participant Geographic ancestry 
DXM 
AUC0-6 h 
(nM.h) 
DXR 
AUC0-6 h 
(nM.h) 
DXR/DXM 
AUC0-6 h 
ratio 
DXM 
AUC0-6 h 
(nM.h) 
DXR 
AUC0-6 h 
(nM.h) 
DXR/DXM 
AUC0-6 h 
ratio 
DXM 
AUC0-6 h 
(nM.h) 
DXR 
AUC0-6 h 
(nM.h) 
DXR/DXM 
AUC0-6 h 
ratio 
20 South Asian 95.9 157.6 1.643 95.8 139.5 1.456 86.5 139.8 1.615 
21 South Asian 72.3 53.6 0.741 73.1 49.0 0.670 57.3 36.7 0.640 
 Mean (South Asians) 51.7 91.0 2.874 45.8 81.1 2.394 39.3 79.9 2.886 
 SD (South Asians) 34.1 40.2 2.279 27.6 37.0 1.512 25.8 34.7 1.842 
 CV% 66.0 44.2 79.3 60.4 45.7 63.2 65.7 43.4 63.8 
 Mean (Total) 44.9 96.4 3.176 41.6 88.9 2.906 36.5 86.9 3.553 
 SD (Total) 28.3 37.8 2.111 23.7 35.0 1.885 22.6 34.3 2.589 
 CV% 63.1 39.2 66.5 57.0 39.4 64.9 62.0 39.5 72.9 
 
  
164 
 
5.3.4.4.3 CYP2D6 activity 
Due to the large number of CYP2D6 variants and copy number variants tested, three linear 
mixed models were necessary to avoid over-parameterisation and allow for successful EMM 
generation. In the European ancestry group, the DXR/DXM AUC0-6 h ratio CV% ranged from 
58-74%. For the South Asian participants, CV% spanned 64-79%. There was a significant 
change in CYP2D6 activity across study days: activity increased 17% from D2 to D9 (F = 
1.806, P = 0.052), although this was not supported by statistically significant changes 
between the other study days (Table 5.21). Ancestry did not have a significant overall effect 
in the model, nor did Study Day*Ancestry. 
Genetic variants and gene copy number had no significant overall effects in the models due 
to the low numbers in each variant genotype sub-group. However, the Ancestry*Genotype 
interactions in the models were significant, with CYP2D6 activity significantly varying 
between ancestries by genotype for CYP2D6*10 (F = 4.202, P = 0.061), CYP2D6*4 (F = 6.725, 
P = 0.019) and copy number (F = 4.164, P = 0.059). The overall differences between the 
ancestry groups by genotype are listed in Table 5.22. For CYP2D6*10 GG and CYP2D6*4 CC 
individuals, Europeans had higher CYP2D6 activity than South Asians. For those individuals 
with one copy of the CYP2D6 gene, Europeans had 3-fold higher activity than South Asians.  
Table 5.21: Back-transformed geometric EMM ratios of CYP2D6 activity with 90% CIs 
across study days by ancestry group. 
 D2/D1 D9/D1 D9/D2 
Europeans (n = 11)  0.95 (0.78, 1.15) 1.08 (0.89, 1.32) 1.14 (0.94, 1.38) 
South Asians (n = 10) 0.91 (0.74, 1.11) 1.09 (0.89, 1.34) 1.20 (0.98, 1.47) 
Overall (n = 21) 0.93 (0.81, 1.06) 1.09 (0.95, 1.24) 1.17 (1.02, 1.35)1 
1. P = 0.052 
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Table 5.22: Back-transformed geometric EMM ratios of CYP2D6 activity with 90% CIs 
between ancestry by CYP2D6*4 and CYP2D6*10 genotypes and CYP2D6 gene copy 
number. 
 CYP2D6*4  CYP2D6*10  
CYP2D6 gene copy 
number 
Genotype 
European/South 
Asian 
Genotype 
European/South 
Asian 
Category 
European/South 
Asian 
GG~ 2.02 (1.10, 3.70)1 CC$ 2.13 (1.28, 3.52)2 1 copy& 3.02 (1.17, 7.81)3 
AG# 0.43 (0.10, 1.73) CT^ 0.42 (0.14, 1.30) 2 copies* 0.39 (0.12, 1.29) 
    
> 2 
copiesx 
1.70 (0.93, 3.10) 
~: European n = 7, South Asian n = 9 
#: European n = 4, South Asian n = 1 
$: European n = 7, South Asian n = 9 
^: European n = 4, South Asian n = 1 
&: European n = 2, South Asian n = 3 
*: European n = 3, South Asian n = 1 
x: European n = 6, South Asian n = 6 
1. P = 0.061 
2. P = 0.019 
3. P = 0.059  
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5.3.4.5 CYP3A4 
5.3.4.5.1 Midazolam 
The 4-h midazolam plasma concentration CV% ranged from 39-50% in Europeans and 36-
50% in South Asians; CV% varied little within ancestry groups across the study days (Table 
5.23). Individual participant midazolam data across study days by ancestry and genotype are 
shown in Figure 5.14. Mean 4-h midazolam plasma concentrations were similar in both 
ancestry groups (Europeans: 5.99 ± 2.68 nM, South Asians: 6.13 ± 2.73 nM). In the 
Europeans, mean 4-h midazolam concentrations increased immediately after a broccoli 
meal (D1 to D2), then decreased after 6 days of broccoli consumption (D2 to D9). 
Midazolam concentrations at 4-h increased from D1 to D2 to D9 in the South Asian ancestry 
group. 
5.3.4.5.2 α-hydroxymidazolam 
α-hydroxymidazolam (OH-MID) concentrations had larger variability than midazolam: CV% 
ranged from 37-64% in Europeans and 54-76% in South Asians (Table 5.23). Individual 
participant 4-h OH-MID plasma concentrations across study days by ancestry and genotype 
are shown in Figure 5.15. Mean 4-h plasma concentrations were very similar in both 
ancestry groups (Europeans: 2.93 ± 1.52 nM, South Asians: 2.42 ± 1.52 nM). Mean OH-MID 
concentrations increased between D1 to D2 then decreased between D2 to D9, and this 
pattern was also seen in the South Asian ancestry group.
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Table 5.23: CYP3A4 data across study days by ancestry. Continues onto next page. 
 
Genotype 
 CYP3A4 
  D1 D2 D9 
Participant 
CYP3A4*22 
rs35599367 
15389C>T 
Geographic ancestry 
4-h 
MID 
conc. 
(nM) 
4-h 
OH-
MID 
conc. 
(nM) 
OH-
MID/MID 
4-h conc. 
ratio 
4-h 
MID 
conc. 
(nM) 
4-h 
OH-
MID 
conc. 
(nM) 
OH-
MID/MID 
4-h conc. 
ratio 
4-h 
MID 
conc. 
(nM) 
4-h 
OH-
MID 
conc. 
(nM) 
OH-
MID/MID 
4-h conc. 
ratio 
1 CC European 4.08 2.43 0.595 5.87 4.98 0.848 5.48 3.06 0.558 
3 CT European 3.91 1.62 0.414 2.55 1.25 0.490 4.63 1.87 0.403 
8 CC European 2.84 1.70 0.598 3.71 2.44 0.657 5.13 3.79 0.739 
9 CC European 5.57 3.64 0.654 10.5 4.57 0.434 4.50 4.07 0.904 
10 CC European 9.09 2.99 0.329 10.7 3.68 0.345 8.89 2.77 0.312 
11 CC European 11.7 5.97 0.510 8.40 7.91 0.942 7.37 1.81 0.245 
12 CC European 2.71 1.12 0.413 4.20 0.99 0.235 3.92 1.25 0.318 
13 CC European 5.82 2.06 0.354 6.59 1.99 0.303 3.92 1.77 0.450 
14 CC European 3.89 3.13 0.804 3.01 2.28 0.759 2.53 2.17 0.858 
15 CC European 10.0 5.64 0.563 6.21 2.94 0.474 7.39 3.90 0.528 
16 CC European 6.72 2.32 0.345 6.31 1.92 0.304 9.45 2.51 0.266 
  Mean (Europeans) 6.03 2.97 0.507 6.19 3.18 0.526 5.75 2.63 0.508 
  SD (Europeans) 3.04 1.58 0.151 2.79 2.02 0.240 2.22 0.97 0.235 
  CV% 50.4 53.4 29.7 45.0 63.6 45.6 38.6 36.8 46.3 
2 CC South Asian 3.38 2.60 0.768 5.08 3.34 0.657 4.57 2.34 0.511 
4 CC South Asian 1.76 1.41 0.799 3.31 2.28 0.691 2.21 1.56 0.707 
5 CC South Asian 4.01 1.86 0.464 5.36 2.54 0.474 3.35 1.77 0.528 
6 CC South Asian 6.09 2.06 0.338 7.05 2.34 0.332 8.71 2.37 0.272 
7 CC South Asian 7.02 3.09 0.440 4.76 1.97 0.415 10.7 7.09 0.660 
17 CC South Asian 7.95 2.95 0.371 7.07 2.66 0.377 6.73 2.39 0.356 
18 CC South Asian 8.36 4.36 0.521 5.95 3.76 0.632 7.51 3.65 0.486 
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Genotype 
 CYP3A4 
  D1 D2 D9 
Participant 
CYP3A4*22 
rs35599367 
15389C>T 
Geographic ancestry 
4-h 
MID 
conc. 
(nM) 
4-h 
OH-
MID 
conc. 
(nM) 
OH-
MID/MID 
4-h conc. 
ratio 
4-h 
MID 
conc. 
(nM) 
4-h 
OH-
MID 
conc. 
(nM) 
OH-
MID/MID 
4-h conc. 
ratio 
4-h 
MID 
conc. 
(nM) 
4-h 
OH-
MID 
conc. 
(nM) 
OH-
MID/MID 
4-h conc. 
ratio 
19 CC South Asian 10.8 2.80 0.260 11.2 5.45 0.486 12.5 3.05 0.244 
20 CC South Asian 3.94 0.27 0.069 4.94 0.84 0.169 4.53 0.59 0.129 
21 CC South Asian 4.31 0.32 0.074 5.23 0.69 0.133 5.45 0.28 0.052 
  
Mean (South 
Asians) 
5.76 2.17 0.410 5.99 2.59 0.436 6.63 2.51 0.395 
  SD (South Asians) 2.76 1.27 0.248 2.14 1.39 0.193 3.28 1.91 0.220 
  CV% 48.0 58.5 60.5 35.6 53.6 44.2 49.5 76.0 55.7 
  Mean (Total) 5.90 2.59 0.461 6.10 2.90 0.484 6.17 2.57 0.454 
  SD (Total) 2.84 1.46 0.204 2.44 1.73 0.218 2.74 1.45 0.229 
  CV% 48.1 56.6 44.2 40.0 59.8 45.2 44.4 56.4 50.6 
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Figure 5.14: 4-h midazolam plasma concentrations across study days by ancestry and CYP3A4*22 (rs35599367) genotype. 
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Figure 5.15: 4-h α-hydroxymidazolam plasma concentrations across study days by ancestry and CYP3A4*22 (rs35599367) genotype. 
171 
 
5.3.4.5.3 CYP3A4 activity 
In the European ancestry group, the 4-h OH-MID/MID plasma concentration ratio CV% 
ranged from 30-46% (Table 5.23). For the South Asian participants, CV% spanned 44-61%. 
There was a no significant effect of Study Day on the mixed-effects model, and therefore no 
statistically significant changes in CYP3A4 activity across study days (F = 0.588, P = 0.560). 
Similarly, Ancestry had no significant overall effect on the model (F = 0.713, P = 0.410). 
Further, there was no significant effect of Study Day*Ancestry (F = 1.845, P = 0.172), but the 
post hoc test panel indicated that CYP3A4 activity decreased 19% between D2 to D9 (Table 
5.24). This should be interpreted cautiously due to a failed Study Day*Ancestry F test. 
Genotype had no significant overall effects on the model (F = 0.016, P = 0.902), nor was 
there an Ancestry*Genotype interaction (F = 1.825, P = 0.194) 
For better visualisation, individual changes in CYP3A4 activity by ancestry and genotype 
across study days are depicted below in Figure 5.16. 
Table 5.24: Back-transformed geometric EMM ratios of CYP3A4 activity with 90% CIs 
across study days by ancestry group. 
 D2/D1 D9/D1 D9/D2 
Europeans (n = 11)  0.98 (0.81, 1.19) 0.94 (0.78, 1.15) 0.96 (0.79, 1.17) 
South Asians (n = 10) 1.22 (0.99, 1.49) 0.99 (0.81, 1.21) 0.81 (0.66, 0.99)1 
Overall (n = 21) 1.05 (0.91, 1.22) 0.96 (0.83, 1.11) 0.91 (0.79, 1.05) 
1. P = 0.096  
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Figure 5.16: CYP3A4 activity across study days by ancestry and CYP3A4*22 (rs35599367) genotype. 
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5.3.5 Genetics 
Frequencies of drug-metabolising gene variants by ancestry group are shown in Appendix 
8.19. Statistical analyses on differences in allele frequencies between ancestry groups were 
not performed because this study was not designed nor powered around these 
comparisons. Further, with n = 21 participants overall, there were few subjects with 
variants, complicating any interpretation of statistical comparisons between ancestry 
groups. However, numerous variant genotypes were significant predictors of CYP enzyme 
activity and SUL exposure, and these have been reported above for the relevant mixed-
effects models studied described in this chapter.   
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5.4 Discussion 
This study is the first report of a simultaneous investigation into how diet, genetics and 
geographic ancestry affect the activities of five CYP enzymes, and how these effects can be 
related to SUL exposure. In this study, genetics and a predominantly curry diet were strong 
predictors of SUL exposure. In Chapter 2, studies were identified that showed a relationship 
between GSTM1, GSTP1 and UGT1A1 genotypes and ITC exposure, alongside corresponding 
increases in drug-metabolising enzyme activity. In particular, work by Peterson et al. (2009) 
report data showing that the GSTM1-null allele is associated with higher amounts of 
isothiocyanates excreted in urine, presumably due to inhibition of ITC metabolism. While 
none of the natural log-transformed CYP metrics significantly correlated with SUL D2 AUC0-8 
h, this does not preclude an effect, as local exposure following absorption on intestinal 
enzymes and transporters could contribute to these observations.  
There were no significant differences in SUL exposure between ancestry groups. However, 
as increased SUL exposure was strongly associated with a predominantly curry diet, curry 
constituents could inhibit the phase II enzymes that metabolise SUL (as they do with 
CYP1A2). It is worth noting that this study only measured one ITC, SUL (Chapter 4), and that 
phenethyl isothiocyanate (PEITC), indoles and glucosinolates themselves are also reported 
to affect drug-metabolising enzyme activity (Chapter 1). Future studies should measure the 
plasma concentrations of other ITCs and their active metabolites to further explore the 
mechanisms of ITC-induced increases in drug-metabolising enzyme activity. This study 
reports for the first-time data on optimal sampling times for SUL plasma concentrations as 
metrics for ITC exposure. SUL D2 AUC0-8 h significantly correlated with all other SUL 
concentration-time points, with the 3- and 4-hour samples having nearly 1:1 correlation. 
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These results are useful for future studies when measuring SUL exposure; one 4-h SUL 
sample provides information about systematic exposure equivalent to the 6 samples 
required to calculate the AUC0-8 h. 
Broccoli consumption significantly increased CYP1A2 in the European cohort, but not in the 
South Asians, in agreement with observations in a previous study (Perera et al., 2012a) and 
consistent with other controlled trials (Chapter 2). Further, the parent drug (caffeine) 
decreased and its CYP1A2-mediated metabolite (paraxanthine) increased in the European 
group, supporting a case for increased CYP1A2 enzyme activity in Europeans who consume 
broccoli-enriched diets. There was no evidence of short-term inhibition on D2 immediately 
following a broccoli meal. Genetics contributed to variability in CYP1A2 activity overall, with 
the CYP1A2*1F variant having the greatest effect. There were however no significant 
Ancestry*Genotype interactions in the model, therefore the difference in activity between 
ancestry groups were not explained in terms of a difference in SNP frequencies. Curry 
consumption was significantly higher in the South Asians and heavy CYP-inducer 
consumption was higher in the Europeans. Curry constituents are potential CYP1A2 
inhibitors (Chapter 1), and their higher consumption in South Asians could explain lower 
CYP1A2 activity in this group after broccoli consumption. 
There were issues encountered when studying CYP2C19 activity, namely erratic and 
unpredictable absorption of omeprazole from the commercial tablet used (and therefore 
erratic and unpredictable formation of 5-hydroxyomeprazole). Other studies have reported 
similar issues with using omeprazole as an in vivo probe for CYP2C19 activity in humans 
(Chapter 3). However, one of the strengths of the mixed-effects modelling approach for 
analysing pharmacokinetic crossover data is that the model can account for missing data 
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across the included factors. Therefore, even with some cases missing, an analysis was still 
made possible. There was evidence of short-term inhibition of CYP2C19 immediately after a 
broccoli meal, which then increased to approximately the same initial activity after 6 days of 
broccoli consumption. This was observed in both ancestry groups. Genotype played a large 
role in accounting for CYP2C19 variability, with activity differences for all three variants 
(CYP2C19*17, CYP2C19*1C and CYP2C19*2) studied in the model. Interestingly, there was 
also an ancestry group difference by genotype: Europeans tended to have higher activity 
than South Asians when their higher-activity variant genotypes were the same. One 
hypothesis to explain this is the increased curry consumption in the South Asian cohort: the 
CYPs share common molecular regulatory mechanisms, therefore if curry constituents can 
inhibit CYP1A2, they may also inhibit other CYP enzymes (Chapter 1). If an enzyme is being 
inhibited at the active site, induction will not produce an increased activity response, as any 
new enzyme formed will be inhibited by the presence of the dietary constituent. Moreover, 
CYP2C19 activity was positively associated with high CYP1A2 inducer consumption and 
negatively associated with a high CYP1A2 inhibitor diet. The CYP1A2 inducer diets were 
more prevalent in Europeans and the inhibitor diets more prevalent in South Asians, 
offering an explanation of these observations. In the mixed effects model, there was no 
overall effect of ancestry, nor an overall difference between ancestry groups across study 
days, indicating that individual gene variants and diet must be considered together when 
explaining the variability in CYP2C19 in dietary intervention trials. This study represents the 
first reported attempt to simultaneously explore the effects of diet, ancestry and genetics 
on CYP2C19 (Chapter 2).     
Similarly, the effects of cruciferous vegetable-enriched diets, genetics and geographic 
ancestry on CYP2C9 activity have not yet been reported (Chapter 2). Interestingly, activity 
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increased immediately after a broccoli meal, and then decreased following 6-days of 
broccoli consumption, as indicated by an increase in losartan and a decrease in EXP 
concentrations. South Asians had nearly 2-fold higher overall CYP2C9 activity than the 
Europeans, but this result could not be explained by differences in genotype, as the ancestry 
group difference was still noted in the variant genotype sub-groups. It remains uncertain 
why a marked difference in CYP2C9 activity between the ancestry groups was observed, 
especially given that it could not be explained by differences in the genotypes studies or diet 
data captured between Europeans and South Asians. Further, the various diet categories 
and SUL exposure did not correlate with CYP2C9 activity, complicating the interpretation of 
these findings. Lastly, losartan and EXP relative exposure patterns were the same in each 
ancestry group, suggesting that the changes were not a chance finding. 
The activity of CYP2D6 is largely influenced by genetics rather than environmental factors 
such as diet (Chapter 1), and therefore induction from cruciferous vegetables was not 
expected. However, there is some research suggesting potential inhibition by the SUL found 
in broccoli (section 1.7.1). In the current study, acute inhibition followed by an increase in 
activity between D2 to D9 (similar to CYP2C19) was observed, however only the D2 to D9 
difference was statistically significant. There were no overall differences in changes in 
relation to the broccoli-enriched diet between ancestry groups, either in general or by study 
day. Interestingly, despite the well-documented variability in CYP2D6 activity between 
variant genotypes (Chapter 1), genotype and gene copy number did not significantly 
account for variability in the various mixed-effects models used in this study. However, for a 
given variant genotype, and also for participants with one copy of the CYP2D6 gene, 
Europeans had 2- to 3-fold higher CYP2D6 activity than South Asians. Consequently, when 
genotype and ancestry are both considered factorially in the models, there is still a 
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difference between ancestry groups. Seeing as the only measured differentiating factor 
between the ancestry groups was a higher proportion of predominantly curry consumers in 
the South Asian cohort, perhaps the CYP-inhibiting constituents in the high-curry diet could 
explain the higher activity in Europeans when genotypes are equivalent. 
As expected, CYP3A4 displayed marked variability even within each ancestry group, and no 
significant differences in activity were observed between study days. Further, no resolution 
was possible in the mixed-effects model to determine if there were differences between 
ancestries across the study days, and there were no significant differences in CYP3A4 
activity by CYP3A4*22 genotype. However, post hoc sample size calculations (section 
5.2.7.1) suggested that this study was too small to meaningfully assess CYP3A4 across some 
of this study’s endpoints, and further investigation in larger subject cohorts is warranted. 
The main weakness of this study is its relatively small sample size (quality characteristics of 
dietary intervention trials were discussed in Chapter 2). While appropriate design measures 
and mixed-effects models were used, ultimately more participants are needed across the 
various genetic and diet sub-categories to perform sufficiently powerful comparisons in 
each sub-group. Further, some studies, for example, Peterson et al. (2009) and Navarro et 
al. (2009b), actively recruited by genotype to test specific hypotheses, which was not 
possible in this smaller study. It is clear though, that some of the CYPs—especially CYP2C19, 
CYP2C9 and CYP2D6—have interesting ancestry-diet-genotype interactions as reported in 
this study, and future investigations should consider recruiting sufficient participants of 
relevant genotypes for appropriately powered sub-group analyses. Also, with respect to 
design, this study recruited only male healthy volunteers, and therefore the effects of 
Cruciferae-enriched diets on CYP activity on females cannot be commented on from these 
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results. Larger, well-designed studies in this area recruited near-equal numbers of males and 
females, also incorporating sex as a factor or covariate into their mixed-effects models (see 
work by Navarro et al., Peterson et al. and Lampe et al. in Chapter 2). Future investigators 
are encouraged to take this approach of investigating the effect of sex on enzyme activity 
and response to dietary interventions into their study designs if resources allow. 
A further limitation of this study is a lack of methods to assess epigenetic effects on CYP 
activity and how these might differ between subjects of European and South Asian 
ancestries. As discussed in Chapter 1, epigenetics as a source of variability in drug-
metabolising enzymes is a largely uncharted landscape, and much research is required 
before a strong clinical foundation of these important concepts is established. Inheritable 
(or otherwise) epigenetic differences between ancestry groups could be the key to 
explaining some observations in this study. The activity of CYP2C9 in South Asians was 
consistently higher than Europeans, even when stratified by genotypes. Perhaps the answer 
lies in yet-undiscovered regulatory genes and proteins, or ancestry group differences in 
histone methylation. Future studies should incorporate these considerations into their study 
designs and testable hypotheses, perhaps through epigenetic ex vivo analysis of liver biopsy 
tissue. Similarly, constituents of foodstuffs have been shown to affect the activity of drug 
transporting proteins (Dolton et al., 2012) (section 1.4), and exploring differences in their 
expression and activity following cruciferous vegetable-enriched diets is warranted in future 
research. 
Lastly, with respect to design weaknesses, this study did not employ a standardised basal 
diet. Although participants were asked to make no major changes to their diet during the 
study period (which was confirmed qualitatively by comparing the two food diaries), having 
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a basal diet to which the cruciferous vegetable intervention is added allows for more robust 
control of dietary constituents, which if different at baseline, could confound results. While 
this study was able to consider the consumption of CYP1A2 inducers, inhibitors and high 
curry consumption for some of the enzymes, controlling them altogether in a control diet 
would be beneficial from a design standpoint, and future studies are encouraged to do so if 
resources and time allow. 
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5.5 Conclusions 
The significance of the research performed here can be framed in the context of the overall 
objectives of this thesis: to better understand how diet, genetics and geographic ancestry 
contribute to variability in drug metabolism. This trial is the first to report on how these 
factors affect five CYP enzymes simultaneously using the phenotyping cocktail approach. 
Further, data are presented from a prospective, controlled study suggesting that CYP1A2 
inducer foods, CYP1A2 inhibitor foods, a predominantly curry diet and a collection of genetic 
variants contribute to the interindividual variation in CYP activity, in particular for CYP1A2, 
CYP2C19 and CYP2C9. Some of the enzyme activity effect sizes observed are significant, 
ranging from approximately 20% to 4-fold differences between participant sub-groups. 
Effect sizes of this magnitude can be clinically significant for drugs with narrow therapeutic 
ranges that are substrates for these enzymes. Further research is needed to determine if 
differences in pharmacokinetics translate to differences in drug efficacy and safety. 
The results presented demonstrate successful and effective use of the analytical techniques 
developed and validated in Chapters 3 and 4. Further, a clear evidence framework has been 
provided explaining how cruciferous vegetable-enriched diets affect CYP1A2, and to a lesser 
extent, CYP2C19. The activity of these enzymes varies between individuals of European and 
South Asian ancestry in terms of genetics and other dietary constituents. There could be 
implications for patients eating appreciable amounts of cruciferous vegetables when taking 
medicines metabolised by these enzymes. These data should help investigators when 
designing future trials in this area of clinical pharmacology.  
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6 Overall conclusions and closing comments 
The research described in this thesis has explored the effects of various intrinsic and 
extrinsic factors on variability in response to medicines, specifically, on drug-metabolising 
enzyme activity (as a contributor to variability in pharmacokinetics). Chapter 1 described 
and explored the relevant background literature covering variability in response to 
medicines, and this was used to build a thematic, evidence-based framework from which 
testable hypotheses were formed and investigated. A systematic review with meta-analyses 
was conducted that assessed the results of studies investigating cruciferous vegetable 
interventions and drug metabolism (Chapter 2). The results of this review informed the 
design of a clinical study that investigated the effects of diet, genetics and geographic 
ancestry on the activities of CYP1A2, CYP2C19, CYP2C9, CYP2D6 and CYP3A4. Before this 
trial could be conducted, appropriate bioanalytical methods were developed and validated 
to analyse biological samples collected. The assays for the CYP-phenotyping cocktail and 
sulforaphane (SUL) are presented in Chapters 3 and 4, respectively. Finally, a 3-period 
crossover trial in Europeans and South Asians investigated CYP activity between ancestry 
groups by genotype and diet (Chapter 5). 
This body of work contributes to a better understanding of the variability in response to 
medicines between European and South Asian populations. The systematic review identified 
literature indicating that the activity of CYP1A2 and GST-α are significantly affected by 
Cruciferae-enriched diets. Further, the effects of cruciferous vegetable consumption on 
CYP2C19, CYP2C9, CYP2D6 and CYP3A4 activity have not been reported. The study 
characteristics that are considered appropriate for dietary intervention trials with 
pharmacokinetic endpoints were profiled. Of significance, none of the studies identified in 
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the systematic review were designed or powered to explore differences in the effects of 
Cruciferae-enriched diets on drug metabolising enzyme activity between geographic 
ancestry groups. 
For the pharmacokinetic study performed, the Inje and Ghassabian CYP-phenotyping 
cocktails were used as a platform for the development and validation of an optimised 
UHPLC-MS/MS CYP assay to measure analytes probing for CYP1A2, CYP2C19, CYP2C9, 
CYP2D6 and CYP3A4 activities. This assay was successfully used to phenotype the 21 healthy 
subjects of the study. Similarly, a simplified, optimised SUL assay was developed and 
validated to measure SUL concentrations following broccoli consumption. The use of these 
assays allowed for SUL systematic exposure to be measured at the same time as CYP-
phenotyping, enabling further exploration of the relationships between diet, genetics, 
ancestry and CYP activity in Europeans and South Asians.  
Since these assays were developed and used, a series of validation studies have been 
reported that use dry blood spots from capillary, finger-prick whole blood samples as their 
biological matrix of interest (Bosilkovska et al., 2014a; Bosilkovska et al., 2016; Bosilkovska 
et al., 2014b). While some of the probe drugs used in these studies are not available in 
Australia, and use cola beverages as a source of caffeine (see Chapter 3), the minimally-
invasive methods presented by Bosilkovska et al. are the way forward for in vivo 
phenotyping of CYP enzyme activity. Future pharmacokinetic studies should consider 
adopting a capillary blood-sampling approach, as using this method greatly reduces 
sampling volumes, sample handling and storage issues, as well as reducing risk to study 
participants. Further, with respect to the bioanalysis of ITCs, attempts were made to also 
incorporate phenethyl isothiocyanate (PEITC) into the SUL bioanalysis. However, due to 
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poor ionisation in both electrospray and atmospheric chemical ionisation modes (ESI and 
APCI, respectively), this was not possible. Previous reports indicate that ESI in particular 
struggles to produce a stable product ion or adduct for analyte quantification, which can be 
fixed by using APCI instead (Zheng & Zheng, 2015). Unfortunately, the methods and 
suggestions by Zheng et al. were not replicable on the Agilent UHPLC-MS/MS system used in 
the studies reported in this thesis, and PEITC was unable to be included in the analysis. 
There is a body of literature that suggests PEITC can affect drug-metabolising enzyme 
activity (section 1.7.1), therefore efforts to find ways of reliably quantifying this ITC in 
human biological matrices are encouraged. 
The clinical study performed represents the culmination of this research programme 
(Chapter 5). This study showed that CYP1A2 activity is increased in Europeans, but not South 
Asians, after a broccoli-enriched diet intervention, supporting previous reports (Perera et 
al., 2012a). This population difference in CYP1A2 activity could not be explained by ancestry 
group differences in the CYP1A2 variants explored. However, diet, and in particular, the 
consumption of CYP1A2 inducers relative to the consumption of CYP1A2 inhibitors, and 
differences in the preparation of curry between the ancestry groups could contribute to 
differences in enzyme activity. Further, GSTs can be inhibited by ITCs (section 1.7.1), and 
evidence supporting these previous reports is presented here. Sulforaphane exposure was 
positively correlated with a predominantly curry diet, suggesting that curry constituents can 
inhibit the GSTs responsible for their clearance. Further, the GSTM1 and GSTP1 null alleles 
were significant predictors of SUL exposure, and when ancestry and genotype were 
incorporated into the mixed model together, no significant difference was observed 
between Europeans and South Asians. GSTT1, GSTT2 and UGT1A1 variant genotypes did not 
significantly affect SUL exposure, nor did SUL correlate with any of the CYP enzymes studied. 
185 
 
The 4-h SUL plasma concentration was correlated with the AUC0-8 h, and future studies are 
encouraged to explore the use of this single time point as a metric for SUL exposure. 
This study is the first reported to simultaneously investigate the effects of diet and genetics 
on CYP2C19 activity between European and South Asian ancestry groups. Evidence of acute 
inhibition followed by return to baseline following broccoli consumption was presented in 
this study. Several drugs with narrow therapeutic concentration ranges are metabolised by 
CYP2C19, such as clopidogrel, cyclophosphamide, phenytoin, voriconazole and the R-isomer 
of warfarin (AMH, 2018). Therefore, variability in the activity of this enzyme caused by 
environmental and genetic influences can directly affect patient outcomes in those taking 
CYP2C19 substrates for various diseases (Amsden & Gubbins, 2017; Hicks et al., 2013; Li et 
al., 2012; Stingl & Viviani, 2015). It is interesting that CYP2C19 activity was higher in 
Europeans than South Asians with the same variant genotypes for CYP2C19*1C and 
CYP2C19*17. Allele frequencies of these variants were comparable to those found in the 
1000 genome project (Table 1.8 and Appendix 8.19). One hypothesis explaining this 
observation is that a heavy CYP1A2 inducer diet was more common in the Europeans than 
the South Asians, which could explain the overall higher activity when variant genotypes 
were equal. Relatively few studies have investigated the effects of genetics on CYP2C19 
activity in South Asian populations, but the ones that do report a similar gene-activity 
relationship with CYP2C19*17 and CYP2C19*2 compared to Europeans, suggesting diet (and 
other extrinsic factors) are responsible for explaining the difference in activity between 
these two ancestry groups (Arya et al., 2015; Jose et al., 2016; Mahadevan et al., 2014; 
Shalia et al., 2013; Sridharan et al., 2016; Tantray et al., 2017; Xavier et al., 2016). Future 
studies should also explore the effects of transporters and epigenetics on differences in 
CYP2C19 activity between these ancestry groups (sections 1.4, 1.5 and 5.4). 
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Similarly, there are no reports of how cruciferous vegetable-enriched diets and genetics 
affect CYP2C9 activity differently in Europeans relative to South Asians. Overall, enzyme 
activity increased immediately after a broccoli meal, and decreased slightly following 6 days 
of broccoli consumption. An ancestry group difference was present: South Asians had nearly 
2-fold higher CYP2C9 activity than Europeans throughout the study, even when stratified by 
the same variant genotypes. Further, none of the diet categories or SUL exposure correlated 
with CYP2C9 activity. Variant allele frequencies for CYP2C9*2 and CYP2C9*3 were 
comparable to those reported for Europeans and South Asians in the 1000 genomes project 
(Table 1.8 and Appendix 8.19). As CYP2C9 activity is regulated by genetics more than 
extrinsic factors, few studies have investigated the effects of diet on this enzyme. Therefore, 
it is difficult to attribute the higher activity in South Asians compared to Europeans of the 
same variant genotypes to differences in dietary practices. However, a recent clinical study 
has shown that overnight fasting before phenotyping significantly reduces CYP2C9 activity 
by up to 25% (Lammers et al., 2015). Perhaps the nature of this ‘fasting effect’ on CYP2C9 
activity could be different between those of different geographic ancestries, and should be 
explored further. Because CYP2C9 is involved in the metabolic clearance of medicines with 
narrow therapeutic indices, such as bosentan, cyclophosphamide, phenytoin, ruxolitinib, 
voriconazole and the S-isomer of warfarin, the 2-fold difference in enzyme activity between 
South Asians and Europeans presented in this study is of potential clinical significance, and 
ancestry group differences in the pharmacokinetics and dynamics of these substrate drugs 
should be investigated. 
The effects of cruciferous vegetables, dietary constituents, genetics and ancestry on CYP2D6 
and CYP3A4 have not previously been studied simultaneously before. In this research, 
CYP2D6 activity was 2- to 3-fold higher in Europeans than South Asians in CYP2D6*4 and 
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CYP2D6*10 homozygotes, and those with one copy of the CYP2D6 gene. Diet was unable to 
explain this difference between the ancestry groups, although there was evidence of 
enzyme inhibition following broccoli consumption in both groups. CYP2D6 is highly 
polymorphic, and haplotypes can be constructed from the numerous variant genotypes, 
which then correspond to activity phenotype sub-groups (Hicks et al., 2014; Hicks et al., 
2013). Because this study was relatively small, some variant genotype sub-groups had few-
to-no cases in them, and allele frequencies in Europeans and South Asians were different 
compared to those reported in the 1000 genome project (Table 1.8 and Appendix 8.19). 
Therefore, despite the gain in power from using mixed-effects models, the difference in 
CYP2D6 activity between ancestry groups within the same variant genotypes could be due 
to chance, rather than a true observed difference as a result of the small sample size. 
However, the ancestry group difference in activity is large, and therefore warrants further 
investigation in appropriately powered studies that recruit based on CYP2D6 variant 
haplotypes. Lastly, the difference in activity between Europeans and South Asians could be 
explained by differential involvement of other enzymes. While the conversion of 
dextromethorphan (DXM) to dextrorphan (DXR) has been shown to be mostly mediated by 
CYP2D6, other CYP enzymes also contribute, including CYP2C9 and CYP3A4 (Yu & Haining, 
2001). Perhaps ancestry-group differences in CYP2C9, as reported in this study, could be 
driving the observed difference in CYP2D6 activity between Europeans and South Asians of 
the same variant genotypes. 
CYP3A4 displayed marked interindividual variability in both ancestry groups, and post hoc 
sample size and power calculations suggest that a much larger sample size in each ancestry 
group would be needed to assess the studied effects further for this enzyme. CYP3A4 is far 
less polymorphic compared to CYP2C19, CYP2C9 and CYP2D6, and this was reflected in the 
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current study, with only one participant out of the 21 studies having a different genotype 
for CYP3A4*22, in alignment with data from the 1000 genome project (Table 1.8 and 
Appendix 8.19). From the results of this study, it remains unclear how intrinsic and extrinsic 
factors interact to explain differences in CYP3A4 activity between Europeans and South 
Asians. Future research should recruit large enough numbers in both ancestry groups to 
conduct appropriately powered sub-group comparisons of enzyme activity. 
Overall, this research project has explored factors contributing to variability in response to 
medicines, with a focus on how diet, genetics and geographic ancestry contribute to the 
activity of drug-metabolising enzymes. Specifically, the effects of cruciferous vegetables, 
CYP variant genotypes and dietary practices can contribute to variability in the activities of 
CYP1A2, CYP2C19, CYP2C9, CYP2D6 and CYP3A4. Future dietary intervention trials are 
encouraged to adopt a basal control diet, and appropriately power the study to account for 
intra- and inter-individual variability in CYP activity. Simultaneously investigating dietary and 
genetic information when aiming to understand ancestry group differences in CYP activity 
are recommended. Ideally, subjects of relevant enzyme variant genotypes should be 
considered. While numerous pharmacokinetic effects and interactions were explored in this 
research, it remains unclear if these differences in concentration and systemic exposure 
translate into clinically significant variability in patients. Ultimately, more trials are needed 
to assess whether Cruciferae-enriched diets can affect the safe and efficacious use of CYP 
substrates in pharmacotherapy. Some of the ancestry group differences in CYP activity 
reported in this research were large, and further investigations should explore how 
cruciferous vegetables and variant genotypes affect important therapeutic CYP substrates, 
such as theophylline, warfarin and voriconazole, in Europeans and South Asians.  
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8 Appendices 
8.1 Systematic review search terms and strategy 
The Cochrane Central Register of Controlled Trials (CENTRAL) 
CENTRAL was accessed online via the Ovid platform. Several keywords were used to search 
for relevant studies. These included ($ = truncation): cruciferous$, Brassica, Brassicaceae, 
Raphanus, Nasturtium, broccoli, cauliflower, watercress, radish, drug-metaboli$, drug 
metaboli$, GST$, UGT$, cytochrome$, and CYP$. Search results within each group 
(cruciferous vegetables and drug metabolism) were combined with the Boolean operator 
OR and the two groups then merged with AND. 
Embase 
Embase was accessed online via the Ovid portal. Medline Subject Headings (MeSH) were 
identified and chosen to encompass broad subject areas and were implemented in tandem 
with keywords to maximise the sensitivity of the search. MeSHs and keywords were divided 
into the two groups and combined using OR and AND as above.  
The MeSHs and keywords chosen within each group were: 
Drug metabolism MeSHs: 
- Cytochrome P-450 Enzyme System 
- Glucuronosyltransferase 
- Glutathione Transferase 
- Glutathione S-Transferase pi 
Drug metabolism keywords: 
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- Drug metaboli$ ($ = truncation)  
- Drug-metaboli$  
Cruciferous vegetables MeSHs: 
- Brassica 
- Brassicaceae 
- Glucosinolates 
- Isothiocyanates 
- Raphanus 
- Nasturtium 
Cruciferous vegetables keywords: 
- Cruciferous$ 
i. Medline 
Medline was accessed online via the Ovid platform. Medline Subject Headings (MeSH) were 
used in the same way as for Embase searches (above). MeSHs and keywords were divided 
into the same two groups: drug metabolism and cruciferous vegetables. All relevant MeSHs 
and keywords within these groups were combined with the Boolean operator OR and the 
two groups then merged with AND. The MeSHs and keywords chosen were the same as 
used for the Embase search (above). 
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8.2 Systematic review data extraction sheet 
Author (year): ____________________      Enzyme(s) studied: 
______________________________ 
Sample size: ____ Males: ____ Females: _____  Mean age: _____
 Mean weight: _____ Mean height: _____ Mean BMI: ___  
Participant group similarity: statistically significant difference(s) in participant demographic 
characteristics? Yes   □ No   □ Not stated explicitly   □ 
Study design:  Pre-test/post-test   □ Crossover   □ Parallel   □ 
Randomisation:      Yes   □      No   □     n/a (no bias plausible from design)   □ 
Aside from intervention, groups treated equally? Yes   □ No   □ 
Sample size/power/effect size calculation stated? Yes   □ No   □ 
 
  Dietary intervention details: 
 
Metric(s) chosen to measure PK endpoints: ______________________________________________ 
 Assay validated? Yes   □ No   □ 
 
 
 
 
 
 
Difference in enzyme activity (value, % change, SD, CI, P-value): 
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8.3 National Ethics Application Form (NEAF) approval 
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8.4 Site-specific Approval (SSA) approval 
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8.5 ANZCTR registration details 
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8.6 TGA CTN approval 
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8.7 Eligibility questionnaire 
   
Faculty of Pharmacy                                                                    Pharmacy Aged Care Research Lab 
The University of Sydney              Concord Repatriation General Hospital 
Broccoli and Drug Metabolism 
DATA COLLECTION SHEET   
1. Patient Demographics 
1.1 Patient initials: ____                         1.2 Date of Birth: ___/___/___         
1.3 Study Code: ____ (Investigator)              1.4 Age: ______                                                                    
1.5 Weight: ______ (kg)                                    1.6 Height: ______cm  
                                 
2. Ethnicity - General  
2.1 What is your ethnic ancestry?  ________________________ (European or South Asian) 
2.1.1 Where were you born? _________________________ 
2.2 Were all four of your biological grandparents born in the same country? □ Y  □ N 
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2.2.1 Please fill out the following table with country of birth: 
 Grandmother Grandfather 
Maternal (Mum’s side)   
Paternal (Dad’s side)   
 
2.3 How many years have you resided in Australia? ______ 
 2.3.1 Do your parents reside in Australia? If so, for how many years? ______ 
 
2.4 Is English your first language?    □ YES    □ NO 
2.4.1 What other languages do you speak at home? _________________________  
 
3. Ethnicity – South Asian 
3.1 If Indian Ancestry - What area of the Indian sub-continent is your family background?  
 □ North        □ South   
 3.1.1 How would you define your heritage? 
□ Himachal Pradesh  □ Uttar Pradesh  □ Punjab □ Andhra 
□ Pradesh    □ Tamil   □ Orissa □ Rajasthan 
□ Maharashtra   □ Sri Lankan/Sinhalese □ Sri Lankan/Tamil 
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4. Medication/Medical History 
4.1 Would you consider yourself healthy? _______________________ 
 4.1.1 Please list any previous or ongoing health problems you have (e.g. diabetes, 
high blood pressure) 
_________________________________________________________________________ 
________________________________________________________________________ 
4.2 How regularly would you take over the counter medicines (such as pain relieving 
medications e.g. paracetamol)? 
□ Two to three times a week   □ Once a week  □ Once a month  
□ Less than once a month   
4.3 How regularly would you take complementary medicines (such as health vitamins e.g. 
fish oil)? 
□ Two to three times a week   □ Once a week  □ Once a month  
□ Less than once a month  
4.4 Do you take any over-the-counter, complementary, herbal (such as gingko) or ayurvedic 
medicines? □ Y □ N 
 4.4.1 If so, please list 
___________________________________________________________________________
___________________________________________________________________________ 
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5. Alcohol & Illicit Drugs 
5.1 How would you describe your alcohol consumption? 
□ Over three drinks per day            □ 1-2 drinks per day  □ 1-2 drinks per week 
□ Over six drinks per week                □ 3-6 drinks per week              
□ Don’t drink alcohol 
5.2 Do you regularly use illicit drugs (e.g. marijuana, ecstasy, cocaine, etc.)? 
 □ Y  □ N  
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8.8 Participant consent form 
Consent form 
   
Faculty of Pharmacy   Pharmacy Aged Care Research Lab 
The University of Sydney  Concord Repatriation General Hospital
  
 
RESEARCH STUDY INTO  
Broccoli and Drug Metabolism 
PARTICIPANT CONSENT FORM 
 
I,   .………………………………………………………………..…….……… [name]  
 
of ……………………………………………………………………………… [address]  
 
have read and understood the Information for Participants for the above-named research 
study and have discussed the study with the study researchers. 
 
• I have been made aware of the procedures involved in the study, including any known or 
expected inconvenience, risk, discomfort or potential side effect and of their implications 
as far as they are currently known by the researchers. 
 
• I freely choose to participate in this study and understand that I can withdraw at any time. 
 
• I also understand that this research study is strictly confidential. 
 
• I hereby agree to participate in this research study. 
 
 
Name (Please Print): ..................................................................................................................................... . 
 
Signature: ........................................................................  Date: ...............................................................  
 
 
 
Name of Person who conducted informed consent discussion (Please Print): 
 
Signature: ........................................................................  Date: ...............................................................  
of Person who conducted informed consent discussion 
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8.9 Participant Information Sheet (PIS) 
   
Faculty of Pharmacy   Pharmacy Aged Care Research Lab 
The University of Sydney                             Concord Repatriation General Hospital 
Broccoli and drug metabolism 
INFORMATION FOR PARTICIPANTS 
You are invited to take part in a research study in healthy volunteers that will investigate the 
impact of eating broccoli on the activity of five enzymes that ‘break down’ (metabolise) 
medicines in the body. 
What is this study about?  
The aim of this study is to investigate the effect that eating broccoli can have on five 
enzymes that metabolise medicines in the body. Previous studies suggest that materials 
found in broccoli may increase or decrease the ability of the body to break down some 
medicines. This study aims to understand how this can happen and what it might mean for 
people taking these medicines. You are being asked to take part because you are healthy, 
male, aged between 18 and 55 years and of either South Asian (based on the information 
that both sets of grandparents have South Asian ancestry) or European ancestry (both sets 
of grandparents have European ancestry).  
The study is being conducted by Mr Shane Eagles (PhD Student), Adjunct Associate 
Professor Annette Gross and Professor Andrew McLachlan from the University of Sydney 
and Concord Hospital. 
Who can enter this study (inclusion and exclusion criteria)? 
Inclusion: Men who are of European and South Asian ancestry between the ages of 18 and 
55 years who are healthy (i.e. no current short-term or long-term health problems). 
Exclusion: People who are suffering from any current illness or long-term illness or are 
taking prescription medication, over-the-counter medicines or herbal/complementary 
medicines. People who are current cigarette smokers or ex-smokers who have quit smoking 
in the last 6 months. People with a known allergy or previous reaction to any of the 
following medications: caffeine, omeprazole, losartan, dextromethorphan and midazolam. 
What does this study involve?  
If you agree to participate in this study, you will be required to have a face-to-face interview 
(approx. 20 minutes duration) with the researchers at a time and place that suits you.  
In this study you will be asked to participate in four main activities: 
232 
 
1. Record the type and amount of all foods/beverages consumed completing a 
summary sheet leading up to your first visit and by completing a food diary for 
the last three days of the study; 
2. Add 200 g (approximately 2 cups) of broccoli twice daily (with lunch and dinner) 
to your usual diet for six days; 
3. Provide a blood sample (10 mL) to allow for the collection of your DNA, which 
will be used to study the genes that influence drug metabolising activity in your 
body; 
4. Come to Concord Hospital on three separate occasions. On each occasion you 
will take a dose of five medications and provide venous blood samples (five x 10 
mL samples) which will be used to measure the concentration of the medicines 
and their breakdown products in your blood over a 6-hour period. This 
information tells us the activity of the enzymes in the body. Each visit will take 
approximately 8 hours. 
Throughout the duration of the study you will be asked to follow your normal diet and 
broccoli will be eaten in addition to this for lunch and dinner. You are encouraged not to 
make any major changes to your diet whilst participating in this study. 
 
Please note that food and beverages will be provided during your visits to Concord Hospital. 
 
The diagram below summarises the timeline of the study, outlining the order in which you 
will be asked undertake each activity: 
 
Day 1: arrive at Concord Hospital by 8 am following an overnight fast (don't 
consume anything after 10 pm the night before except for water) for 
administration of the five medicines and then provide five x 10 mL blood 
samples over 6 hours. 
Day 2: wake up and eat 200 g of broccoli for breakfast at 6:30 am (consume 
nothing else except water) and return to Concord Hospital by 8 am, then 
take the five medicines and provide five x 10 mL blood samples over 6 hours
Days 3-8: eat 200 g broccoli with lunch and 200 g broccoli with dinner in 
addition to your normal diet. Starting on Day 6, you will record all food and 
drink consumed in a food diary for the next 3 days
Day 9: return to Concord Hospital by 8 am following an overnight fast (don't 
consume anything after 10 pm except for water) for final administration of the 
five medicines and then provide five x 10 mL blood samples over 6 hours. 
Bring your completed food diary with you
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Why do I have to provide a list of food and drink I consume? 
In the same way that broccoli can affect drug-metabolising enzyme activity in our bodies, 
most of what we eat and drink on a daily basis can have a similar effect on the way our body 
responds to medicines. The food diary will assist the investigators in explaining the different 
responses to eating broccoli amongst the participants, as certain foods and beverages have 
been shown to directly affect the enzymes being investigated in this study. 
 
What foods and beverages should I avoid while participating in this study? 
Grapefruit and grapefruit juice are known to affect the activity of some drug-metabolising 
enzymes being investigated in this study. Consuming grapefruit products during the study 
may change the results and participants are required to avoid them until after the study is 
complete. Also, you are required to avoid drinking any caffeinated beverages such as coffee 
(all types), tea (all types), Coke/Pepsi (all types) and energy drinks (all types) after 6 pm the 
night before coming to Concord on study days, and to avoid these beverages on the study 
days also. You may however consume caffeinated beverages during the 6 days of broccoli 
consumption. 
 
Why will I be asked to take five medicines on three separate occasions? 
Each of the five medicines used in this study are selectively broken down by one of the five 
enzymes being investigated in the study. The amount of the medicines and their metabolism 
by-products in your blood allows the researchers to measure the activity of the enzymes 
involved. These medicines have been chosen because they are specific for the breakdown 
pathway of interest, they have been proven to be safe, commonly used and have been 
shown not to interact or affect each other. 
 
The administration of the five medications and collection of blood samples needs to take 
place on three separate occasions so that the effect of eating broccoli on enzyme activity 
can be measured. The first occasion will be a ‘baseline’ measurement, the second occasion 
will also involve you eating 200 g of broccoli just before taking the medicines (to measure 
the short-term effects of eating broccoli) and the third occasion will be after six days of 
broccoli consumption (to measure the medium-term effects of eating broccoli). 
 
How safe are the medicines in this study? 
These medicines have been selected because they have been widely used and much is 
known about their effects on the body. All medicines have some risk of unwanted effects 
but in this study the chances of experiencing these effects are low because only a single 
dose is taken on each occasion. The medicines and their possible effects are summarized in 
the table below.  
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Medicine 
Usual use in 
humans 
Usual dose 
range 
Dose 
used in 
this 
study 
Possible side effects 
(occur in between 1% 
to 10% of people) 
Caffeine 
Stimulant present 
in beverages (e.g. 
tea, coffee, 
energy drinks) 
Varies 
greatly—as a 
guide, an 
average cup 
of coffee 
contains 80-
150 mg of 
caffeine 
100 mg 
Stomach upset, 
sleeplessness, 
restlessness, 
nervousness, shakes, 
headache and 
lightheadedness  
Omeprazole 
Treatment of 
‘heartburn’ or 
acid reflux from 
the stomach 
10-40 mg per 
day  
20 mg 
Stomach upset, 
headache, dizziness, 
mild tingling or ‘pins-
&-needles’ in 
arms/legs, 
mild skin rash 
Losartan 
Treatment of high 
blood pressure 
(hypertension) 
50-100 mg 
per day 
25 mg 
Dizziness, muscle 
cramps, leg pain, 
nasal congestion 
 
Dextromethorphan 
Over-the-counter 
cough 
suppressant (e.g. 
Bisolvon, 
Benadryl) 
30–120 mg 
per day 
30 mg 
Diarrhoea, sedation 
Midazolam 
Sedative usually 
used in the 
hospital setting 
during short 
surgical 
procedures 
1-3.5 mg as a 
single dose 
2 mg 
oral 
liquid 
which 
you will 
drink 
Drowsiness, altered 
alertness, slowed 
breathing rate, short-
term changes in blood 
pressure and heart 
rate, headache 
 
What is involved with providing blood samples? 
To measure the amount of the medicines and their by-products in your blood we will need 
you to provide blood samples. This will take place at Concord Hospital following an 
overnight fast (no food/drink besides water after 10 pm the night before) immediately 
before and over the six hours after you take the five medicines (at 0, 1, 2, 4 and 6 hours 
post-dose for a total of five samples taken on each occasion). 2 hours after the medicines 
are administered you will be provided with a muffin and water to break your fast, and a 
light lunch (sandwich/roll) will be provided later in the day. Samples will be taken via an 
intravenous cannula, which is a small tube that is inserted inside the vein or intravenous 
needle by trained nursing and/or pathology staff under the supervision of a medical doctor. 
The same research team will be with you at all times over this six-hour period and will 
answer and address any concerns you have whilst providing the blood samples. 
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Two of the medicines, midazolam and dextromethorphan, can cause mild sedation and 
drowsiness so driving is not recommended to and from the hospital on the days you take 
these medicines. We suggest that a friend/family member drop you off and pick you up. If 
this is not possible then a taxi can be provided to take you to and from the hospital. While 
under the sedative effects of midazolam you are advised to avoid operating machinery and 
catching public transport. 
 
How will my blood samples be used? 
Blood samples will only be used to measure the amounts of the five medicines and their 
respective by-products to determine the activity of the enzymes that they are involved 
with.  
 
A sample of your blood (approximately 10 mL) will be collected for DNA testing. Everyone’s 
DNA is different to some degree. The purpose of this testing is to investigate the genes that 
control the ability of your body to breakdown the medicines in this study.  
How will my DNA sample be used? 
Your DNA sample will ONLY be used to analyse the genes that can influence the activity of 
the drug-metabolising enzymes of interest in this study. Certain variations in these genes 
can influence the activity of the drug-metabolising enzymes. The researchers will be 
attempting to match any increases/decreases in enzyme activity with the presence of these 
particular gene variants. Your DNA sample will NOT be used for any other purpose.  
How do I store and eat the broccoli? 
After your second visit to Concord Hospital (after the second occasion of taking the five 
medicines and providing blood samples) the investigators will provide you with sealed, pre-
weighed “snap-lock” labeled bags containing 200 g (approximately 2 cups) of broccoli. You 
will be given 13 bags—enough to eat 200 g at lunch and 200 g at dinner for the next six days 
and one bag for breakfast on Day 2 of the study. These bags need to be kept in a refrigerator 
until use. If you are taking the broccoli to work with you only take the relevant portion 
needed for that day and ensure it is kept refrigerated until use; use a cooler bag with an ice 
pack when travelling. 
All participants are required to microwave one 200 g bag of broccoli in the microwave-safe 
container provided. Add a small amount of water underneath the white steaming tray, but 
ensure the water level stays below the tray, as nutrients can leak from the broccoli if it is 
touching water. Microwave for a time based on your microwave’s power settings (see table 
below). Take care in removing the broccoli from the microwave and when eating as the 
contents of the container may be hot. Proceed to eat the ENTIRE contents. All broccoli must 
be consumed. The broccoli is to be eaten in addition to your normal diet (continue 
eating/drinking what you normally would). 
Broccoli is a rich source of dietary fibre, and a sudden increase of fibre in your diet can slow 
down the movement of material through your gastrointestinal tract and in some cases 
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cause constipation. You are advised to drink plenty of water for the duration of the study to 
reduce the chance of this occurring. 
Table 8.1: Recommended cooking times based on microwave wattages. 
Microwave power (watts) Recommended cooking time (seconds) 
700 150 (2 min 30 s) 
800 135 (2 min 15 s) 
900 130 (2 min 10 s) 
1000 
1200 
120 (2 min) 
110 (1 min 50 s) 
Healthy volunteer statement 
People often volunteer to take part in medical research because they have a medical 
condition and the research may offer a chance of improving their health. Your role in this 
study is different. You are a healthy volunteer. As such, you need to carefully consider the 
risks associated with the research before you consent to take part. There is no expected 
benefit to your health from participation in this study. 
Will I be reimbursed for my time? 
You will be compensated for your time and inconvenience with a $500 payment on the 
provision that the study is completed in full.  
 
What are the risks associated with this study? 
Possible side effects that can arise from taking the five medications used in this study are 
listed above in this information sheet. None of these are considered serious or life-
threatening and will pass after the medicines are cleared from your body. While at Concord 
Hospital for the administration of these medicines/to provide blood samples, you will be 
monitored by the researchers and will be cared for should anything unexpected occur. 
 
Risks associated with intravenous blood sampling are usually limited to mild redness, 
swelling, and/or bruising around the site where the needle breaks the skin. Infection of the 
puncture site and/or associated veins is possible but is an extremely unlikely complication 
associated with this procedure. All blood samples will be taken under standard hospital 
conditions according to NSW Health guidelines to ensure your safety in this regard. 
 
There are no known risks associated with eating 400 g of broccoli daily for six days, however 
this dietary intake of broccoli may cause flatulence and constipation in some people.  
What are the benefits of this study? 
While we intend that this research study furthers medical knowledge, it may not be of direct 
benefit to you. 
237 
 
 
Who owns my samples?  
By signing the attached consent form, you relinquish all rights to ownership of your samples. 
Can I obtain the results of tests on my sample?  
The results of any tests done on your sample will not be made known to you, your family 
members or any other person. The results of these tests will not affect any present or future 
insurance policies, or your ability to get or keep a job. 
Can I withdraw from the study? 
Participation in this study is entirely voluntary. You are in no way obliged to participate and - 
if you do participate - you can withdraw at any time.  Whatever your decision, please be 
assured that it will not affect your relationship with medical or research staff. 
Confidentiality 
All details obtained from participants will remain confidential.  A report of this study may be 
submitted for publication, but individual participants will not be identifiable in such a report. 
Compensation 
Every reasonable precaution will be taken to ensure your safety during the course of the 
study. In the event that you suffer any injury as a result of participating in this research 
project, hospital care and treatment will be provided at no extra cost to you. 
Further Information 
When you have read this information, Mr Shane Eagles will discuss it with you further and 
answer any questions you may have.  If you would like to know more at any stage, please 
feel free to contact Professor Andrew McLachlan, on 9767 7373 or Mr Shane Eagles from 
the University of Sydney on 0431 635 958. This information sheet is for you to keep. 
 
This study has been approved by the Human Research Ethics Committee - CRGH of the Sydney Local 
Health District. If you have any concerns or complaints about the conduct of the research study, you 
may contact the Secretary of the Concord Hospital Human Research Ethics Committee, on (02) 9767 
5622. Alternatively, if you wish to speak with an independent person within the Hospital about any 
problems or queries about the way in which the study was conducted, you may contact the Patient 
Representative on (02) 9767 7488. 
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8.10 Approved clinical study advertisement 
   
Faculty of Pharmacy   Pharmacy Aged Care Research Lab 
The University of Sydney              Concord Repatriation General Hospital 
 
AN INVITATION TO PARTICIPATE 
 
Are you interested in taking part in a clinical study 
investigating the effect of broccoli on drug 
metabolism? 
We are looking for healthy MALE volunteers aged between 
18 to 55 years of European or South Asian geographic 
ancestry (ethnicity or origin): 
• European Ancestry (all countries of Europe including the UK and Ireland) 
• South Asian Ancestry (India, Pakistan and Sri Lanka) 
If you are interested please contact either: 
(Eligible participants will be reimbursed for their time on 
completion of the study) 
 
A project conducted by researchers at the Faculty of Pharmacy, University of 
Sydney in collaboration with Concord Repatriation General Hospital 
  
Mr Shane Eagles 
seag2551@uni.sydney.edu.au 
(phone 0431 635 958) 
Professor Andrew McLachlan 
andrew.mclachlan@sydney.edu.au 
(phone 9767 7373) 
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8.11 First participant 3-day food diary  
   
Faculty of Pharmacy                                                                            Pharmacy Aged Care 
Research Lab 
The University of Sydney              Concord Repatriation General Hospital 
 
Broccoli and Drug Metabolism 
3-day diet summary sheet 
 
Over the next three days, please fill out the following diet summary sheet. 
To the best of your ability, accurately record what you eat/drink for breakfast, lunch and 
dinner for the three days leading up to your first Concord visit. 
Write the name/type of the food or drink on the lines provided along with the 
amount/quantity consumed. If you are unsure of the amount in grams or mL/L, try to 
estimate or describe the amount, e.g. one can of… one tin of… 6 slices of… and so on. Please 
describe the items in as much detail as possible. For example, instead of “ham sandwich” 
write “ham, lettuce, tomato and cheese sandwich with butter (white bread)”. 
The researchers need this information to identify other items in your everyday diet that may 
affect the study’s results in a similar way to the broccoli.  
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Breakfast Day 1 
 
 
 
 
 
 
 
 
 
 
 
Breakfast Day 2 
 
Breakfast Day 3 
 
Lunch Day 1 
 
 
 
 
 
 
 
 
 
 
 
 
Lunch Day 2 Lunch Day 3 
Dinner Day 1 
 
 
 
 
 
 
 
 
 
 
 
 
Dinner Day 2 Dinner Day 3 
Snacks & Drinks 
 
 
 
 
 
 
 
 
 
Snacks & Drinks Snacks & Drinks 
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8.12 Second 3-day food diary (D6-D8) 
   
Faculty of Pharmacy                                                                    Pharmacy Aged Care Research Lab 
The University of Sydney              Concord Repatriation General Hospital 
 
Broccoli and Drug Metabolism 
FOOD DIARY 
 
Participant instructions: 
From days 6-8 of the study you will be required to accurately record of all of the food and 
drinks you consume in this diary. The researchers need this information to identify other 
items in your everyday diet that may affect the study’s results in a similar way to the 
broccoli. 
Write the name/type of the food or drink on the lines provided along with the 
amount/quantity consumed. If you are unsure of the amount in grams or mL/L, try to 
estimate or describe the amount, e.g. one can of… one tin of… 6 slices of… and so on. Please 
describe the items in as much detail as possible. For example, instead of “ham sandwich” 
write “ham, lettuce, tomato and cheese sandwich with butter (white bread)”. 
Each page is divided into easy to manage sections based around the three main meals of the 
day: breakfast, lunch and dinner.  
It is recommended that you record an entry in the diary IMMEDIATELY AFTER eating or 
drinking something to maximise the accuracy of the entries. 
There is a section for snacks in between each meal of the day—all food and drinks, no 
matter how small a serving should be recorded. 
There is also a broccoli check-box to help you to remember if you have eaten your broccoli 
portions. Please initial these sections as you microwave and eat each 200 g serving. 
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Breakfast Day 6 
 
 
 
 
 
 
 
 
 
 
 
Breakfast Day 7 
 
Breakfast Day 8 
 
Lunch Day 6 
 
 
 
 
 
 
 
 
 
 
Broccoli eaten?  Y     N     
Lunch Day 7 
 
 
 
 
 
 
 
 
 
 
Broccoli eaten?  Y     N     
Lunch Day 8 
 
 
 
 
 
 
 
 
 
 
Broccoli eaten?  Y     N     
Dinner Day 6 
 
 
 
 
 
 
 
 
 
 
Broccoli eaten?  Y     N     
 
Dinner Day 7 
 
 
 
 
 
 
 
 
 
 
Broccoli eaten?  Y     N     
Dinner Day 8 
 
 
 
 
 
 
 
 
 
 
Broccoli eaten?  Y     N     
Snacks & Drinks 
 
 
 
 
 
 
 
 
 
Snacks & Drinks Snacks & Drinks 
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8.13 Study day medical support protocol 
Responsibilities of medical staff in preparation for study days: 
- Write a clinical trials prescription for all participants 
- Arrange for the on-call clinician to be available to come to Andrology and assess any 
participants presenting with mild ADRs/medical complaints 
Responsibilities of medical staff on the day: 
- Insert/withdraw cannula 
- Check on any participants presenting with mild ADRs/medical complaints 
Responsibilities of researchers on the day: 
- Welcome participants and assess eligibility to participate on the day (i.e. not recently 
unwell, not currently unwell, successfully fasted since 10 pm the night before, 
baseline BP > 80/60 mmHg) 
- Drawing blood via cannula/handing of samples 
- Recording onto the data recording sheet 
- Monitoring clinical signs/symptoms of hypotension and sedation every hour 
- Monitoring clinical signs/symptoms of ADRs 
- Ensuring participants receive morning snack and lunch 
- Escorting participants to their means of transportation 
IF 
Mild drop in BP/HR accompanied by clinical signs of an ADR (light headedness, dizziness, 
sweaty/clammy/pale complexion) and/or increase in sedation score 
THEN 
Contact on-call clinician to assess participant in Andrology 
 
IF 
Moderate to severe as above or presents with nausea/vomiting 
THEN 
Arrange for participant to go to ED 
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IF 
Severe ADR/medical emergency (anaphylaxis, extreme sedation, extremely low BP/HR) 
THEN 
Call 222 and report Code Blue 
Assessing sedation: 
Use the Sedation Score for opioid use as per the Australian Medicines Handbook (AMH) 
2013, page 46. 
Sedation score: 
  0 – wide awake 
  1 – easy to rouse 
  2 – easy to rouse, but cannot stay awake 
  3 – difficult to rouse. 
Aim to keep the sedation score < 2; a score of 2 represents early respiratory depression. 
If any participant persistently has a sedation score of 2 or more the on-call clinician will be 
contacted to assess the participant in Andrology.  
Assessing BP: 
As there is no universal ‘cut-off’ value for determining when clinical hypotension is present, 
this will be assessed primarily by the presence of the clinical signs of hypotension: dizziness, 
light headedness, sweating/clammy with pale pallor and in extreme circumstances fainting. 
A drop in systolic BP of >30 will be used as a guide however the clinical signs will determine 
the course of action taken. 
BP drop > 30 and/or participant complains of dizziness, light headedness or presents as 
clammy, pale, etc. then contact the on-call clinician to assess the participant in Andrology. 
Assessing HR: 
A HR persistently below 50 bpm will be considered as a warning sign of bradycardia (BMJ 
Best Practice Guidelines – Bradycardia). Clinical signs of bradycardia such as dizziness/light 
headedness fainting or shortness of breath accompanied with a HR close to or below 50 will 
be considered criteria to contact the on-call clinician to assess the participant in Andrology. 
Assessing a medical emergency: 
If signs of anaphylaxis (shortness of breath, hives/acute rash, etc.) or extreme medical 
dysfunction/distress are observed in a participant, the researchers will transport the 
participant to the ED. If immediate assistance is required 222 will be called to report a Code 
Blue emergency.  
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8.14 Participant broccoli hand-out 
Broccoli handling/cooking instructions 
Each bag contains 200 g of washed and prepared broccoli. You must eat one WHOLE bag 
with lunch and dinner for 6 days as directed. ALL broccoli must be consumed. If you are full 
try spreading the two bags out over the whole day rather than with lunch and dinner. 
Broccoli must be kept at 4-6˚C at ALL times unless microwave cooking. If taking it to 
work/school/university etc., use the eski and cooler brick provided as a means of 
transporting the broccoli. 
If, for some reason, a portion of the broccoli is not consumed, record this in as much detail 
as possible (e.g. how much eaten, amount lost or forgotten, etc.) in the second food diary at 
the bottom. 
Please note: we will be analysing your blood samples for broccoli constituent levels, and 
will be able to determine if broccoli is not being eaten. If the investigators have sufficient 
reason to believe the broccoli has not been consumed as agreed to, the participant will be 
deemed to have not completed the study in full – thus not receive payment for their 
participation.  
 
Microwaving the broccoli 
1. Ensure the white tray is in the bottom of the container, and add a small amount of 
tap water up to just below the line of the tray – ensure the broccoli is not touching 
the water 
2. Secure the lid tightly and close the steam hole, then microwave at the specified time 
as per the wattage of your microwave as below: 
Microwave power (watts) Recommended cooking time (seconds) 
700 150 (2 min 30 s) 
800 135 (2 min 15 s) 
900 130 (2 min 10 s) 
1000 
1200 
120 (2 min) 
110 (1 min 50 s) 
 
3. The broccoli will be hot so be careful in removing it from the container. 
4. Eat the broccoli – if it is really unpalatable you may add a small amount (< 10 mL) of 
salad dressing to add flavour 
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8.15 DNA purification and extraction 
Pages 17-19 of “Genomic DNA from blood: User manual” (Macherey-Nagel, Dec. 
2015/Rev. 15). Provided by Trent Peters courtesy of the Australian Genome Research 
Facility Ltd 
 
Genomic DNA purification with NucleoSpin® Blood L 
 
Before starting the preparation: 
• Check if Buffer BQ2 and Proteinase K were prepared according to section 3. 
• Set an incubator or water bath to 56 °C. 
• Preheat Elution Buffer BE to 70 °C. 
• For centrifugation, a centrifuge with a swing-out rotor and appropriate buckets 
• capable of reaching 4,000–4,500 x g is required. 
 
1. Lyse blood sample 
Pipette up to 2 mL blood (or body fluid) sample (equilibrated to room temperature) and 150 
μL Proteinase K into a 15-mL tube (not provided). 
 
If processing buffy coat, do not use more than 1 mL and add PBS to adjust the volume to 2 
mL. 
 
If cultured cells are used, resuspend up to 2 x 107 cells in a final volume of 2 mL PBS. 
 
If old or clotted blood samples are processed, see section 6.1 for recommendations. 
 
Add 2 mL Buffer BQ1 (if processing less than 2 mL blood, add one volume of Buffer BQ1) to 
the samples and vortex the mixture vigorously for 10 s. 
 
Note: Vigorous mixing is important to obtain high yield and purity of DNA. 
 
Incubate samples at 56 °C for 15 min. 
 
Let the samples cool down to room temperature before proceeding with addition of 
ethanol. 
 
The lysate should become brownish during incubation with Buffer BQ1. Increase incubation 
time with Proteinase K (up to 20 min) and vortex once or twice during incubation if 
processing older or clotted blood samples. 
 
2. Adjust DNA binding conditions 
Add 2 mL ethanol (96–100 %) (if processing less than 2 mL blood, add 1 volume of ethanol) 
to each sample and mix by inverting the tube 10 times. 
 
Note: High local ethanol concentration must be avoided by immediate mixing after addition. 
Be sure that the lysate has cooled down to room temperature before loading it onto the 
column. Loading of hot lysate may lead to diminished yields. 
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3. Bind DNA 
For each preparation, take one NucleoSpin® Blood L Column placed in a Collection Tube and 
load 3 mL of lysate. Do not moisten the rims of the columns. Close the tubes with screw 
caps and centrifuge 3 min at 4,500 x g. 
 
Usually the lysate will start to flow-through the columns even before centrifugation. This will 
not adversely affect DNA yield or purity. Keep NucleoSpin® Blood L Column in an upright 
position as liquid may pass through the ventilation slots on the rim of the column even if the 
caps are closed. 
 
Load all of the remaining lysate in a second step to the respective NucleoSpin® Blood L 
Column, avoiding moistening the rim. Centrifuge 5 min at 4,500 x g. Discard the flow-
through and place the column back into the Collection Tube. 
 
Remove the Collection Tube with the column carefully from the rotor to avoid that the flow-
through comes in contact with the column outlet. Be sure to wipe off any spilled lysate from 
the Collection Tube before placing the column back. 
 
4. Wash silica membrane 
Add 2 mL Buffer BQ2. Centrifuge 2 min at 4,500 x g.  
 
It is not necessary to discard the flow-through after the first washing step. 
2nd wash 
Add 2 mL Buffer BQ2. Centrifuge 10 min at 4,500 x g. Remove the column carefully from the 
rotor in order to avoid that the flow-through comes in contact with the column outlet. 
 
By prolonged centrifugation during this second washing step, residual ethanolic washing 
Buffer BQ2 is removed from the silica membrane of the NucleoSpin® Blood L Column. 
 
5. Dry silica membrane 
The drying of the NucleoSpin® Blood L Column is performed by prolonged centrifugation 
time (10 min) in the 2nd wash step.  
 
6. Elute highly pure DNA 
Insert the column into a new Collection Tube (15 mL) and apply 200 μL preheated Buffer BE 
(70 °C) directly to the center of the silica membrane. Incubate at room temperature for 2 
min. Centrifuge at 4,500 x g for 2 min. 
 
For alternative elution procedures see section 2.4. 
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8.16 List of ADME iPLEX gene variants 
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8.17 SPSS mixed-effects model syntaxes 
 
CYP1A2 
MIXED LnCYP1A2 BY Day Ethnicity rs2069514a rs762551a 
  /CRITERIA=CIN(90) MXITER(150) MXSTEP(10000) SCORING(1) 
SINGULAR(0.000000000001) HCONVERGE(0, 
    ABSOLUTE) LCONVERGE(0, ABSOLUTE) PCONVERGE(0.000001, ABSOLUTE) 
  /FIXED=Day Ethnicity rs2069514a rs762551a Day*Ethnicity 
Ethnicity*rs2069514a Ethnicity*rs762551a | 
    SSTYPE(3) 
  /METHOD=ML 
  /PRINT=SOLUTION 
  /RANDOM=INTERCEPT | SUBJECT(ID) COVTYPE(ID) 
  /REPEATED=Day | SUBJECT(ID) COVTYPE(CSR) 
  /EMMEANS=TABLES(Day) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(rs2069514a) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(rs762551a) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(Day*Ethnicity) COMPARE(Day) ADJ(LSD) 
  /EMMEANS=TABLES(Day*Ethnicity) COMPARE(Ethnicity) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*rs2069514a) COMPARE(Ethnicity) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*rs2069514a) COMPARE(rs2069514a) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*rs762551a) COMPARE(Ethnicity) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*rs762551a) COMPARE(rs762551a) ADJ(LSD). 
   
CYP2C19 
MIXED LnCYP2C191 BY Day Ethnicity rs12248560a rs3758581a rs4244285a 
  /CRITERIA=CIN(90) MXITER(150) MXSTEP(10000) SCORING(1) 
SINGULAR(0.000000000001) HCONVERGE(0, 
    ABSOLUTE) LCONVERGE(0, ABSOLUTE) PCONVERGE(0.000001, ABSOLUTE) 
  /FIXED=Day Ethnicity rs12248560a rs3758581a rs4244285a Day*Ethnicity 
Ethnicity*rs12248560a Ethnicity*rs3758581a Ethnicity*rs4244285a | 
    SSTYPE(3) 
  /METHOD=ML 
  /PRINT=SOLUTION 
  /RANDOM=INTERCEPT | SUBJECT(ID) COVTYPE(ID) 
  /REPEATED=Day | SUBJECT(ID) COVTYPE(CSR) 
  /EMMEANS=TABLES(Day) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(rs12248560a) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(rs3758581a) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(rs4244285a) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(Day*Ethnicity) COMPARE(Day) ADJ(LSD) 
  /EMMEANS=TABLES(Day*Ethnicity) COMPARE(Ethnicity) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*rs12248560a) COMPARE(Ethnicity) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*rs12248560a) COMPARE(rs12248560a) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*rs3758581a) COMPARE(Ethnicity) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*rs3758581a) COMPARE(rs3758581a) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*rs4244285a) COMPARE(Ethnicity) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*rs4244285a) COMPARE(rs4244285a) ADJ(LSD). 
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CYP2C9 
MIXED LnCYP2C9 BY Day Ethnicity rs1057910a rs1799853a 
  /CRITERIA=CIN(90) MXITER(150) MXSTEP(10000) SCORING(1) 
SINGULAR(0.000000000001) HCONVERGE(0, 
    ABSOLUTE) LCONVERGE(0, ABSOLUTE) PCONVERGE(0.000001, ABSOLUTE) 
  /FIXED=Day Ethnicity rs1057910a rs1799853a Day*Ethnicity 
Ethnicity*rs1057910a Ethnicity*rs1799853a | 
    SSTYPE(3) 
  /METHOD=ML 
  /PRINT=SOLUTION 
  /RANDOM=INTERCEPT | SUBJECT(ID) COVTYPE(ID) 
  /REPEATED=Day | SUBJECT(ID) COVTYPE(CSR) 
  /EMMEANS=TABLES(Day) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(rs1057910a) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(rs1799853a) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(Day*Ethnicity) COMPARE(Day) ADJ(LSD) 
  /EMMEANS=TABLES(Day*Ethnicity) COMPARE(Ethnicity) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*rs1057910a) COMPARE(Ethnicity) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*rs1057910a) COMPARE(rs1057910a) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*rs1799853a) COMPARE(Ethnicity) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*rs1799853a) COMPARE(rs1799853a) ADJ(LSD). 
   
CYP2D6 
MIXED LnCYP2D6 BY Day Ethnicity rs1065852a rs1080985a rs28371725a 
  /CRITERIA=CIN(90) MXITER(150) MXSTEP(10000) SCORING(1) 
SINGULAR(0.000000000001) HCONVERGE(0, 
    ABSOLUTE) LCONVERGE(0, ABSOLUTE) PCONVERGE(0.000001, ABSOLUTE) 
  /FIXED=Day Ethnicity rs1065852a rs1080985a rs28371725a Day*Ethnicity 
Ethnicity*rs1065852a Ethnicity*rs1080985a Ethnicity*rs28371725a | 
    SSTYPE(3) 
  /METHOD=REML 
  /PRINT=SOLUTION 
  /RANDOM=INTERCEPT | SUBJECT(ID) COVTYPE(ID) 
  /REPEATED=Day | SUBJECT(ID) COVTYPE(CSR) 
  /EMMEANS=TABLES(Day) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(rs1065852a) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(rs1080985a) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(rs28371725a) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(Day*Ethnicity) COMPARE(Day) ADJ(LSD) 
  /EMMEANS=TABLES(Day*Ethnicity) COMPARE(Ethnicity) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*rs1065852a) COMPARE(Ethnicity) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*rs1065852a) COMPARE(rs1065852a) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*rs1080985a) COMPARE(Ethnicity) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*rs1080985a) COMPARE(rs1080985a) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*rs28371725a) COMPARE(Ethnicity) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*rs28371725a) COMPARE(rs28371725a) ADJ(LSD). 
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MIXED LnCYP2D6 BY Day Ethnicity rs3892097a 
  /CRITERIA=CIN(90) MXITER(150) MXSTEP(10000) SCORING(1) 
SINGULAR(0.000000000001) HCONVERGE(0, 
    ABSOLUTE) LCONVERGE(0, ABSOLUTE) PCONVERGE(0.000001, ABSOLUTE) 
  /FIXED=Day Ethnicity rs3892097a Day*Ethnicity Ethnicity*rs3892097a| 
    SSTYPE(3) 
  /METHOD=REML 
  /PRINT=SOLUTION 
  /RANDOM=INTERCEPT | SUBJECT(ID) COVTYPE(ID) 
  /REPEATED=Day | SUBJECT(ID) COVTYPE(CSR) 
  /EMMEANS=TABLES(Day) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(rs3892097a) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(Day*Ethnicity) COMPARE(Day) ADJ(LSD) 
  /EMMEANS=TABLES(Day*Ethnicity) COMPARE(Ethnicity) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*rs3892097a) COMPARE(Ethnicity) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*rs3892097a) COMPARE(rs3892097a) ADJ(LSD). 
   
MIXED LnCYP2D6 BY Day Ethnicity CYP2D6copies 
  /CRITERIA=CIN(90) MXITER(150) MXSTEP(10000) SCORING(1) 
SINGULAR(0.000000000001) HCONVERGE(0, 
    ABSOLUTE) LCONVERGE(0, ABSOLUTE) PCONVERGE(0.000001, ABSOLUTE) 
  /FIXED=Day Ethnicity CYP2D6copies Day*Ethnicity Ethnicity*CYP2D6copies| 
    SSTYPE(3) 
  /METHOD=REML 
  /PRINT=SOLUTION 
  /RANDOM=INTERCEPT | SUBJECT(ID) COVTYPE(ID) 
  /REPEATED=Day | SUBJECT(ID) COVTYPE(CSR) 
  /EMMEANS=TABLES(Day) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(CYP2D6copies) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(Day*Ethnicity) COMPARE(Day) ADJ(LSD) 
  /EMMEANS=TABLES(Day*Ethnicity) COMPARE(Ethnicity) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*CYP2D6copies) COMPARE(Ethnicity) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*CYP2D6copies) COMPARE(rs3892097a) ADJ(LSD). 
   
CYP3A4 
MIXED LnCYP3A4 BY Day Ethnicity rs35599367a 
  /CRITERIA=CIN(90) MXITER(150) MXSTEP(10000) SCORING(1) 
SINGULAR(0.000000000001) HCONVERGE(0, 
    ABSOLUTE) LCONVERGE(0, ABSOLUTE) PCONVERGE(0.000001, ABSOLUTE) 
  /FIXED=Day Ethnicity rs35599367a Day*Ethnicity Ethnicity*rs35599367a| 
    SSTYPE(3) 
  /METHOD=REML 
  /PRINT=SOLUTION 
  /RANDOM=INTERCEPT | SUBJECT(ID) COVTYPE(ID) 
  /REPEATED=Day | SUBJECT(ID) COVTYPE(CSR) 
  /EMMEANS=TABLES(Day) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(rs35599367a) COMPARE ADJ(LSD) 
  /EMMEANS=TABLES(Day*Ethnicity) COMPARE(Day) ADJ(LSD) 
  /EMMEANS=TABLES(Day*Ethnicity) COMPARE(Ethnicity) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*rs35599367a) COMPARE(Ethnicity) ADJ(LSD) 
  /EMMEANS=TABLES(Ethnicity*rs35599367a) COMPARE(rs35599367a) ADJ(LSD). 
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8.18 Dextromethorphan and dextrorphan AUC data and CYP2D6 activity by genotype 
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8.19 Allele frequencies by ancestry 
CYP1A2 genotype CYP1A2*1C * Geographic ancestry Crosstabulation 
 
Geographic ancestry 
Total European South Asian 
CYP1A2 genotype rs2069514 GA Count 0 3 3 
% within CYP1A2 genotype rs2069514 0.0% 100.0% 100.0% 
% within Geographic ancestry 0.0% 30.0% 15.0% 
% of Total 0.0% 15.0% 15.0% 
GG Count 10 7 17 
% within CYP1A2 genotype rs2069514 58.8% 41.2% 100.0% 
% within Geographic ancestry 100.0% 70.0% 85.0% 
% of Total 50.0% 35.0% 85.0% 
Total Count 10 10 20 
% within CYP1A2 genotype rs2069514 50.0% 50.0% 100.0% 
% within Geographic ancestry 100.0% 100.0% 100.0% 
% of Total 50.0% 50.0% 100.0% 
 
CYP1A2 genotype CYP1A2*1F * Geographic ancestry Crosstabulation 
 
Geographic ancestry 
Total European South Asian 
CYP1A2 genotype rs762551 AA Count 5 4 9 
% within CYP1A2 genotype rs762551 55.6% 44.4% 100.0% 
% within Geographic ancestry 45.5% 40.0% 42.9% 
% of Total 23.8% 19.0% 42.9% 
CA Count 5 4 9 
% within CYP1A2 genotype rs762551 55.6% 44.4% 100.0% 
% within Geographic ancestry 45.5% 40.0% 42.9% 
% of Total 23.8% 19.0% 42.9% 
CC Count 1 2 3 
% within CYP1A2 genotype rs762551 33.3% 66.7% 100.0% 
% within Geographic ancestry 9.1% 20.0% 14.3% 
% of Total 4.8% 9.5% 14.3% 
Total Count 11 10 21 
% within CYP1A2 genotype rs762551 52.4% 47.6% 100.0% 
% within Geographic ancestry 100.0% 100.0% 100.0% 
% of Total 52.4% 47.6% 100.0% 
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CYP2C19 genotype CYP2C19*1C * Geographic ancestry Crosstabulation 
 
Geographic ancestry 
Total European 
South 
Asian 
CYP2C19 genotype 
rs3758581 
GA Count 2 1 3 
% within CYP2C19 genotype 
rs3758581 
66.7% 33.3% 100.0% 
% within Geographic ancestry 18.2% 10.0% 14.3% 
% of Total 9.5% 4.8% 14.3% 
GG Count 9 9 18 
% within CYP2C19 genotype 
rs3758581 
50.0% 50.0% 100.0% 
% within Geographic ancestry 81.8% 90.0% 85.7% 
% of Total 42.9% 42.9% 85.7% 
Total Count 11 10 21 
% within CYP2C19 genotype 
rs3758581 
52.4% 47.6% 100.0% 
% within Geographic ancestry 100.0% 100.0% 100.0% 
% of Total 52.4% 47.6% 100.0% 
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CYP2C19 genotype CYP2C19*2 * Geographic ancestry Crosstabulation 
 
Geographic ancestry 
Total European 
South 
Asian 
CYP2C19 genotype 
rs4244285 
AA Count 0 1 1 
% within CYP2C19 genotype 
rs4244285 
0.0% 100.0% 100.0% 
% within Geographic ancestry 0.0% 10.0% 4.8% 
% of Total 0.0% 4.8% 4.8% 
GA Count 3 5 8 
% within CYP2C19 genotype 
rs4244285 
37.5% 62.5% 100.0% 
% within Geographic ancestry 27.3% 50.0% 38.1% 
% of Total 14.3% 23.8% 38.1% 
GG Count 8 4 12 
% within CYP2C19 genotype 
rs4244285 
66.7% 33.3% 100.0% 
% within Geographic ancestry 72.7% 40.0% 57.1% 
% of Total 38.1% 19.0% 57.1% 
Total Count 11 10 21 
% within CYP2C19 genotype 
rs4244285 
52.4% 47.6% 100.0% 
% within Geographic ancestry 100.0% 100.0% 100.0% 
% of Total 52.4% 47.6% 100.0% 
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CYP2C19 genotype CYP2C19*17 * Geographic ancestry Crosstabulation 
 
Geographic ancestry 
Total European 
South 
Asian 
CYP2C19 genotype 
rs12248560 
CC Count 8 7 15 
% within CYP2C19 genotype 
rs12248560 
53.3% 46.7% 100.0% 
% within Geographic ancestry 72.7% 70.0% 71.4% 
% of Total 38.1% 33.3% 71.4% 
CT Count 2 3 5 
% within CYP2C19 genotype 
rs12248560 
40.0% 60.0% 100.0% 
% within Geographic ancestry 18.2% 30.0% 23.8% 
% of Total 9.5% 14.3% 23.8% 
TT Count 1 0 1 
% within CYP2C19 genotype 
rs12248560 
100.0% 0.0% 100.0% 
% within Geographic ancestry 9.1% 0.0% 4.8% 
% of Total 4.8% 0.0% 4.8% 
Total Count 11 10 21 
% within CYP2C19 genotype 
rs12248560 
52.4% 47.6% 100.0% 
% within Geographic ancestry 100.0% 100.0% 100.0% 
% of Total 52.4% 47.6% 100.0% 
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CYP2D6 genotype CYP2D6*10 * Geographic ancestry Crosstabulation 
 
Geographic ancestry 
Total European South Asian 
CYP2D6 genotype rs1065852 CC Count 7 9 16 
% within CYP2D6 genotype rs1065852 43.8% 56.3% 100.0% 
% within Geographic ancestry 63.6% 90.0% 76.2% 
% of Total 33.3% 42.9% 76.2% 
CT Count 4 1 5 
% within CYP2D6 genotype rs1065852 80.0% 20.0% 100.0% 
% within Geographic ancestry 36.4% 10.0% 23.8% 
% of Total 19.0% 4.8% 23.8% 
Total Count 11 10 21 
% within CYP2D6 genotype rs1065852 52.4% 47.6% 100.0% 
% within Geographic ancestry 100.0% 100.0% 100.0% 
% of Total 52.4% 47.6% 100.0% 
 
 
 
 
 
 
CYP2C9 genotype CYP2C9*3 * Geographic ancestry Crosstabulation 
 
Geographic ancestry 
Total European South Asian 
CYP2C9 genotype rs1057910 AA Count 9 9 18 
% within CYP2C9 genotype rs1057910 50.0% 50.0% 100.0% 
% within Geographic ancestry 81.8% 90.0% 85.7% 
% of Total 42.9% 42.9% 85.7% 
CA Count 2 1 3 
% within CYP2C9 genotype rs1057910 66.7% 33.3% 100.0% 
% within Geographic ancestry 18.2% 10.0% 14.3% 
% of Total 9.5% 4.8% 14.3% 
Total Count 11 10 21 
% within CYP2C9 genotype rs1057910 52.4% 47.6% 100.0% 
% within Geographic ancestry 100.0% 100.0% 100.0% 
% of Total 52.4% 47.6% 100.0% 
CYP2C9 genotype CYP2C9*2 * Geographic ancestry Crosstabulation 
 
Geographic ancestry 
Total European South Asian 
CYP2C9 genotype rs1799853 CC Count 8 10 18 
% within CYP2C9 genotype rs1799853 44.4% 55.6% 100.0% 
% within Geographic ancestry 72.7% 100.0% 85.7% 
% of Total 38.1% 47.6% 85.7% 
CT Count 3 0 3 
% within CYP2C9 genotype rs1799853 100.0% 0.0% 100.0% 
% within Geographic ancestry 27.3% 0.0% 14.3% 
% of Total 14.3% 0.0% 14.3% 
Total Count 11 10 21 
% within CYP2C9 genotype rs1799853 52.4% 47.6% 100.0% 
% within Geographic ancestry 100.0% 100.0% 100.0% 
% of Total 
52.4% 47.6% 100.0% 
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CYP2D6 genotype CYP2D6*2A * Geographic ancestry Crosstabulation 
 
Geographic ancestry 
Total European South Asian 
CYP2D6 genotype rs1080985 CC Count 5 5 10 
% within CYP2D6 genotype rs1080985 50.0% 50.0% 100.0% 
% within Geographic ancestry 45.5% 50.0% 47.6% 
% of Total 23.8% 23.8% 47.6% 
GC Count 6 5 11 
% within CYP2D6 genotype rs1080985 54.5% 45.5% 100.0% 
% within Geographic ancestry 54.5% 50.0% 52.4% 
% of Total 28.6% 23.8% 52.4% 
Total Count 11 10 21 
% within CYP2D6 genotype rs1080985 52.4% 47.6% 100.0% 
% within Geographic ancestry 100.0% 100.0% 100.0% 
% of Total 52.4% 47.6% 100.0% 
 
CYP2D6 genotype CYP2D6*41 * Geographic ancestry Crosstabulation 
 
Geographic ancestry 
Total European 
South 
Asian 
CYP2D6 genotype 
rs28371725 
AG Count 2 3 5 
% within CYP2D6 genotype 
rs28371725 
40.0% 60.0% 100.0% 
% within Geographic ancestry 18.2% 30.0% 23.8% 
% of Total 9.5% 14.3% 23.8% 
GG Count 9 7 16 
% within CYP2D6 genotype 
rs28371725 
56.3% 43.8% 100.0% 
% within Geographic ancestry 81.8% 70.0% 76.2% 
% of Total 42.9% 33.3% 76.2% 
Total Count 11 10 21 
% within CYP2D6 genotype 
rs28371725 
52.4% 47.6% 100.0% 
% within Geographic ancestry 100.0% 100.0% 100.0% 
% of Total 52.4% 47.6% 100.0% 
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CYP2D6 genotype CYP2D6*4 * Geographic ancestry Crosstabulation 
 
Geographic ancestry 
Total European South Asian 
CYP2D6 genotype rs3892097 AG Count 4 1 5 
% within CYP2D6 genotype rs3892097 80.0% 20.0% 100.0% 
% within Geographic ancestry 36.4% 10.0% 23.8% 
% of Total 19.0% 4.8% 23.8% 
GG Count 7 9 16 
% within CYP2D6 genotype rs3892097 43.8% 56.3% 100.0% 
% within Geographic ancestry 63.6% 90.0% 76.2% 
% of Total 33.3% 42.9% 76.2% 
Total Count 11 10 21 
% within CYP2D6 genotype rs3892097 52.4% 47.6% 100.0% 
% within Geographic ancestry 100.0% 100.0% 100.0% 
% of Total 52.4% 47.6% 100.0% 
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CYP2D6 gene copy number * Geographic ancestry Crosstabulation 
 
Geographic ancestry 
Total European South Asian 
CYP2D6 copy number 1 copy Count 2 3 5 
% within CYP2D6 copy 
number 
40.0% 60.0% 100.0% 
% within Geographic 
ancestry 
18.2% 30.0% 23.8% 
% of Total 9.5% 14.3% 23.8% 
2 copies Count 3 1 4 
% within CYP2D6 copy 
number 
75.0% 25.0% 100.0% 
% within Geographic 
ancestry 
27.3% 10.0% 19.0% 
% of Total 14.3% 4.8% 19.0% 
More than 2 copies Count 6 6 12 
% within CYP2D6 copy 
number 
50.0% 50.0% 100.0% 
% within Geographic 
ancestry 
54.5% 60.0% 57.1% 
% of Total 28.6% 28.6% 57.1% 
Total Count 11 10 21 
% within CYP2D6 copy 
number 
52.4% 47.6% 100.0% 
% within Geographic 
ancestry 
100.0% 100.0% 100.0% 
% of Total 52.4% 47.6% 100.0% 
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 CYP3A4 genotype CYP3A4*22 * Geographic ancestry Crosstabulation 
 
Geographic ancestry 
Total European 
South 
Asian 
CYP3A4 genotype 
rs35599367 
CC Count 10 10 20 
% within CYP3A4 genotype 
rs35599367 
50.0% 50.0% 100.0% 
% within Geographic ancestry 90.9% 100.0% 95.2% 
% of Total 47.6% 47.6% 95.2% 
CT Count 1 0 1 
% within CYP3A4 genotype 
rs35599367 
100.0% 0.0% 100.0% 
% within Geographic ancestry 9.1% 0.0% 4.8% 
% of Total 4.8% 0.0% 4.8% 
Total Count 11 10 21 
% within CYP3A4 genotype 
rs35599367 
52.4% 47.6% 100.0% 
% within Geographic ancestry 100.0% 100.0% 100.0% 
% of Total 52.4% 47.6% 100.0% 
 
GSTM1 rs1065411 * Geographic ancestry Crosstabulation 
 
Geographic ancestry 
Total European South Asian 
GSTM1 rs1065411 CC Count 4 4 8 
% within GSTM1 rs1065411 50.0% 50.0% 100.0% 
% within Geographic ancestry 36.4% 40.0% 38.1% 
% of Total 19.0% 19.0% 38.1% 
CG Count 1 1 2 
% within GSTM1 rs1065411 50.0% 50.0% 100.0% 
% within Geographic ancestry 9.1% 10.0% 9.5% 
% of Total 4.8% 4.8% 9.5% 
GG Count 6 5 11 
% within GSTM1 rs1065411 54.5% 45.5% 100.0% 
% within Geographic ancestry 54.5% 50.0% 52.4% 
% of Total 28.6% 23.8% 52.4% 
Total Count 11 10 21 
% within GSTM1 rs1065411 52.4% 47.6% 100.0% 
% within Geographic ancestry 100.0% 100.0% 100.0% 
% of Total 52.4% 47.6% 100.0% 
269 
 
 
GSTP1 rs1695 * Geographic ancestry Crosstabulation 
 
Geographic ancestry 
Total European South Asian 
GSTP1 rs1695 AA Count 8 6 14 
% within GSTP1 rs1695 57.1% 42.9% 100.0% 
% within Geographic ancestry 72.7% 60.0% 66.7% 
% of Total 38.1% 28.6% 66.7% 
AG Count 3 3 6 
% within GSTP1 rs1695 50.0% 50.0% 100.0% 
% within Geographic ancestry 27.3% 30.0% 28.6% 
% of Total 14.3% 14.3% 28.6% 
GG Count 0 1 1 
% within GSTP1 rs1695 0.0% 100.0% 100.0% 
% within Geographic ancestry 0.0% 10.0% 4.8% 
% of Total 0.0% 4.8% 4.8% 
Total Count 11 10 21 
% within GSTP1 rs1695 52.4% 47.6% 100.0% 
% within Geographic ancestry 100.0% 100.0% 100.0% 
% of Total 52.4% 47.6% 100.0% 
 
 
 
 
  
